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Pulmonary emphysema is a serious worldwide illness, causing progressive and 
irreversible alveolar wall loss and difficulty in breathing. It is caused mostly by cigarette 
smoking. However, its unresolved complex and multiple pathogenic mechanisms have left this 
disease without effective pharmacotherapy. This project hypothesized that cinnamic acid-based 
dehydropolymers (DHPs), originally discovered as novel anti-coagulants, protect against 
emphysema through their potent triple inhibitory actions against oxidative stress, inflammation 
and elastase, some of the pathogenic mechanisms associated with this disease. 
xxi 
 
 
 
Three in vitro inhibitory activity assays for oxidative stress, lung inflammation and 
neutrophil elastase (NE) were developed and used to identify the most potent triple inhibitor 
DHP. These activities were determined by chromogenic free radical generation in chemical 
oxidation, lung epithelial (Calu-3) repression of pro-inflammatory nuclear factor κB (NFκB) 
upon its plasmid transfection and chromogenic substrate NE hydrolysis, respectively. The 
sulfated caffeic acid DHP, CDS was shown to be the most potent in all three assessments, 
yielding the half-maximal inhibitory concentrations of 3.52, ~10 and 0.43 µM, respectively. 
CDS was tested with pulmonary delivery in an in vivo rat model of emphysema induced 
by elastase and cigarette smoke extract (HSE/CSE). CDS at 5 and 30 µg/kg was instilled into the 
lung at 2 h prior to HSE/CSE instillation. The lung tissues and bronchoalveolar lavage fluids 
(BALFs) were taken 1 or 48 h post-HSE/CSE instillation to determine the tissue reduced 
glutathione (rGSH), airway infiltration of inflammatory neutrophils and airway luminal elastase 
alongside lung hemorrhage. The HSE/CSE instillation significantly caused 43.0 % decrease in 
rGSH, 104.8-fold greater neutrophil infiltration, 2.8-fold higher elastase activity and 9.3-fold 
increased lung hemorrhage, compared to the saline (negative) control. However, all these 
inductions were significantly protected by CDS at 30 µg/kg, exhibiting 92.9, 76.6, 59.7 and 70.4 
% inhibition, respectively; reduced effects were seen at 5 µg/kg, showing its dose-related 
responses. As a result, the HSE/CSE-induced airspace enlargement assessed on 28
th
 day was also 
prevented by CDS at 30 µg/kg, yet not at 5 µg/kg. In conclusion, this study has demonstrated the 
in vitro and in vivo effectiveness of CDS for its possible use in the protection against 
emphysema development, specifically via inhalation.   
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CHAPTER 1 
 
 
BACKGROUND AND SIGNIFICANCE 
 
 
 
 
Pulmonary emphysema is characterized by the destruction of the alveolar septa, resulting 
in abnormal and irreversible enlargement of the airspaces [Snider, 1985]. It primarily causes 
moderate-to-severe dyspnea as a clinical manifestation due to the physical and functional lung 
tissue damage [Kinsman et al, 1983]. This disease, along with chronic bronchitis, is a component 
of chronic obstructive pulmonary disease (COPD), which is currently the fourth leading cause of 
death in the United States, where over 12 million people are currently diagnosed, costing 
approximately a total of $32.1 billion in its management [NHLBI, 2010]. Correspondingly, the 
World Health Organization (WHO) has predicted continuously increased prevalence of this 
emphysema and COPD worldwide, so that it would soon become the fifth most common cause of 
morbidity and the third most common chronic disease [Lopez & Murray, 1998; WHO, 2007]. 
Clearly, it is indispensable to reduce the trend and occurrence of this worldwide ill health by any 
means including novel effective pharmacotherapies for its prevention, treatment and cure. 
2 
 
The development of emphysema has been highly associated with chronic cigarette 
smoking, although certain genetic factors, such as α1-antitrypsin (α1AT) deficiency, have also 
been demonstrated to cause this disease [Larsson, 1978]. Chronic cigarette smoking is 
responsible for 80-90 % of all cases of emphysema [Thun et al, 1997; Fletcher & Peto, 1977]. In 
addition, the WHO has reported that passive smoking is also associated with 10-43 % increased 
risk of emphysema and COPD [WHO, 2007]. Hence, quitting smoking and avoiding second-
hand smoke could logically prevent the occurrence of emphysema. However, the success rate for 
smoking cessation is as low as 15 % in emphysema [Caverley et al, 2008]. In addition, in some 
patients, it has been reported that slow and progressive destruction of lung parenchyma still 
occurs even after smoking cessation, for which the reason remains completely uncertain [Hogg, 
2006]. Hence, at present, the pathogenic mechanisms and cascades, by which chronic cigarette 
smoking causes emphysema have not yet been fully clarified. Even so, it has been repeatedly 
suggested that alveolar macrophages, neutrophils and epithelium participate in the pathogenesis 
of emphysema, as a result of elevated oxidative stress [Mak, 2008], increased inflammation 
[Roth, 2008] and/or elastolytic enzyme release and tissue degradation [Abboud & Vimalanathan, 
2008]. The destruction of the alveolar walls is believed to be mediated primarily through the 
elastolytic tissue degradation, yet recently, apoptosis has been proposed as a mechanism causing 
progressive loss of both capillary endothelial and lung epithelial cells [Kasahara et al, 2002]. 
Accordingly, the modern concept of lung destruction and airspace enlargement in emphysema 
should integrate all four mechanisms that are intricately tied together as shown in Figure 1.1 
[Voelkel et al, 2004]. Nevertheless, apoptosis is still believed to occur in a secondary fashion, 
subsequent to the primary mechanisms centered on oxidative stress, inflammation and 
elastolysis. 
3 
 
 
 
 
 
 
 
Figure 1.1: The modern concept of emphysematous lung destruction
proposed by Voelkel et al [2004]. Cigarette smoking initially causes oxidative
stress, inf lammation and increased elastolytic activity in the lung. Impaired
vascular endothelial growth factor (VEGF) and oxidative stress trigger
apoptosis, which contribute to the loss of the alveolar walls and septa.
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Oxidative stress has been associated with pathogenesis of many diseases such as 
atherosclerosis [Singh & Jialal, 2006], myocardial infarction [Serdar et al, 2007] and more 
importantly, emphysema and COPD [Mak, 2008]. In emphysema and COPD patients, increased 
levels of oxidative stress indicators, e.g., 8-isoprostone and hydrogen peroxide (H2O2), have been 
demonstrated in their exhaled breath condensates [Kharitonov et al, 2002]. As cigarette smoke 
contains many reactive oxygen species at a concentration of >1015 free radicals per puff 
including long-lived tar semiquinone [Pryor et al, 1993], it becomes logical to hypothesize that 
such cigarette smoke exposure, especially in a chronic fashion, causes continuous oxidative 
burden to the lung tissues to trigger the pathogenic cascade leading to emphysema. In addition, 
cigarette smoke has been shown to activate resident alveolar macrophages and luminally 
recruited neutrophils to release endogenous reactive oxygen species, such as highly reactive 
superoxide anions [Hoidal et al, 1981; Bridges et al, 1985]. These exogenously- and 
endogenously-derived oxidative stresses have been shown to participate in several pathogenic 
mechanisms leading to emphysema. Smoking surely causes homeostatic imbalance between 
endogenous oxidants and anti-oxidants, such as glutathione and membrane phospholipids (lipid 
peroxidation) [Cross et al, 1994; Lannan et al, 1994; Li et al, 1994]. It inactivates certain anti-
proteases like α1AT, leading to increased elastin breakdown in the lung parenchyma [Bowler et 
al, 2004], while directly damaging elastin and collagen in the lung [Cantin et al, 1985]. 
Moreover, it has been suggested to decrease deformability and increase endothelial adhesion of 
circulating neutrophils to facilitate their recruitment into the airways [Drost et al,1993]. It can 
also activate certain pro-inflammatory transcription factors, such as nuclear factor kappa B 
(NFκB), activator protein-1 (AP-1) and cAMP-responsive element-binding protein (CREB), 
thereby stimulating several inflammatory genes to amplify the inflammatory response [Barnes et 
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al, 1997]. In this context, it has been recently shown that oxidative stress activated the histone 
acetyltransferase activity, associated with increased transcription of multiple inflammatory genes 
[Tomita et al, 2003; Rahman, 2003]. Finally, it can activate the mitogen-activated protein (MAP) 
kinase pathways that regulate many inflammatory gene expressions [Ogura et al, 1998]. 
Accordingly, many approaches to boost anti-oxidative defenses in patients with 
emphysema and COPD have been attempted previously. Among them, natural anti-oxidant 
radical scavengers, such as vitamins C and E, have been repeatedly tested in emphysema and 
COPD patients, yet the results have been rather disappointing [Steinberg & Chait, 1998; Smit et 
al, 1999; Daga et al, 2003]. Moreover, several drug entities, such as N-acetylcysteine (NAC) and 
superoxide dismutase (SOD), have also been tested in animal models, without reaching clinic 
[Dekhuijzen, 2004; Smith et al, 2002]. Hence, these single anti-oxidant therapies are insufficient 
to modulate the multiple pathogenic processes of emphysema and COPD as shown in Figure 1.1; 
though the anti-oxidation should remain as a part of rational therapeutic approach. 
 
Inflammation has also been associated with pathogenesis of emphysema and COPD. 
Chronic cigarette smokers typically exhibit massive infiltration of inflammatory cells, such as 
macrophages and neutrophils, into the lung tissues and luminal airways, often accompanied with 
alveolar wall destruction [Niewoehner et al, 1974; Merchant et al, 1992; Finkelstein et al, 1995]. 
It is believed that resident alveolar macrophages are initially stimulated to release potent 
chemotactic factors, such as interleukin-8 (IL-8), which somehow preferentially recruit 
neutrophils into the lung [Hunninghake et al, 1983; Kunkel et al, 1991; Peleman et al, 1993; 
Rutgers et al, 2000; Tanino et al, 2002; Traves et al, 2002]; though its cellular mechanisms 
remain unresolved. However, in a recent study [Churg et al, 2004], it was advocated that the pro-
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inflammatory mediator, tumor necrosis factor α (TNFα), primarily released from the alveolar 
macrophages, is critical to cause inflammatory cell infiltration in cigarette smoke-induced 
emphysema. In this study, TNFα released from the alveolar macrophages in response to cigarette 
smoke exposure was shown to directly activate the pro-inflammatory transcription factors like 
NFκB and AP-1, which led to increased gene transcription of the inflammatory cytokines 
including IL-1, IL-6 and IL-8 [Rahman et al, 1998]. Thus, the development of such chronic and 
persistent inflammation is now thought to be responsible, at least in part, for the alveolar 
destruction, which could potentially persist even after smoking cessation in some patient 
populations [Hogg, 2006]. 
As this inflammation primarily occurs within the lung, it should be beneficial to use local 
anti-inflammation therapy with inhaled corticosteroids (ICSs). This has been a premise for the 
use of ICSs in emphysema and COPD, yet efficient symptomatic relief has mostly required 
combination use of either short- or long-acting bronchodilators [Calverly et al, 2003; Szafranski 
et al, 2003]. However, these ICSs, even for a prolonged period of combined therapy, have not 
yet been successful in modifying the underlying disease condition [Vestbo et al, 1999; Dahl et 
al, 2001; Calverley et al, 2003; Cazzola et al, 2004; Niewoehner et al, 2005; Leigh et al, 2006]. 
These disappointing results have now triggered the efforts to discover novel effective anti-
inflammatory entities for this disease. Such approaches include drugs to neutralize TNFα and 
inhibit IL-8 and NFκB; these are currently under pre-clinical development according to 
Fitzgerald & Fox [2007]. 
 
The protease-antiprotease imbalance has been a long-standing hypothesis as a pathogenic 
mechanism in the development of emphysema. It was shown in 1965 that lung instillation of a 
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proteolytic enzyme caused emphysema [Gross et al, 1965]. Subsequently, the deficiency of the 
endogenous neutrophil elastase inhibitor, α1AT, was verified to cause the α1AT-related genetic 
emphysema [Niewoehner, 1988]. Correspondingly, cigarette smoke has been reported to activate 
both macrophages and neutrophils to release proteases, which breakdown pulmonary connective 
tissues. However, the major elastolytic enzyme in this protease-antiprotease hypothesis has yet to 
be confirmed. In response to cigarette smoke, the airway neutrophils secrete a variety of 
proteases, such as neutrophil elastase (NE), cathepsin G and proteinase-3 [Churg & Wright, 
2005], while the alveolar macrophages release elastolytic matrix metalloproteinases (MMPs), 
e.g., MMP-9 and MMP-12 [Churg et al, 2007]. Among them, NE is a major constituent of lung 
elastolytic activity, cleaving most of the components of the pulmonary extracellular matrix, such 
as type I-IV collagens, proteoglycan fibronectin, laminin and highly resistant elastin [Ginzberg et 
al, 2001]. It was also reported to have various biologic activities, such as inflammatory IL-8 
release from the epithelium [Nakamura et al, 1992]. In contrast, MMPs were also shown to be 
capable of degrading the extracellular matrix components of lung parenchyma [Finlay et al, 
1997; Ohnishi et al, 1998].  
As NE and MMPs have exhibited many detrimental effects potentially relevant to 
emphysema, many inhibitors of NE and/or MMPs (i.e., MMP-9 and MMP-12) have been 
developed and tested [Obhayashi, 2002; Norman, 2009]. Nevertheless, most of the NE inhibitors 
have been discontinued in their development primarily due to a lack of promising clinical 
outcomes. For instance, a potent NE inhibitor MR889 failed to reduce the biochemical markers 
of lung destruction even following 4 weeks of administration in emphysema patients [Luisetti et 
al, 1996]. Meanwhile, MMP inhibitors are still at early pre-clinical stages of development. 
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Hence, this has again raised a question concerning the effectiveness of this single mechanism 
inhibition in emphysema treatment. 
 
As described above, attempts to inhibit one of the multiple pathogenic mechanisms 
shown in Figure 1.1 have so far been unsuccessful for prevention, treatment or cure of 
emphysema. As a result, pharmacological approach is currently limited to control symptoms and 
reduce the frequency and severity of acute exacerbations, i.e., symptomatic relief without cure, 
using bronchodilators like β2 receptor agonists and anticholinergics, often combined with anti-
inflammatory ICSs. As a result, none of the existing medications has been shown to halt the 
progressive damage of the lung parenchyma and the relentless decline in lung function [Barnes, 
2002]. Clearly, therefore, there is a strong need to discover novel effective therapeutic entities 
for its prevention, treatment and cure. In this consideration, it has now been hypothesized that the 
multiple pathogenic mechanisms require their simultaneous inhibitions to provide a major 
benefit on this disease. Note however that completely different approaches have also been 
pursued such as inhibitors of phosphodiesterase-4, p38 MAP kinase, phosphoinositide-3 kinase-γ 
and nitric oxide synthase [Barnes, 2005].  
 
It is intriguing that this complex involvement of oxidative stress, inflammation and 
elastase in the pathogenesis of emphysema and COPD somewhat resembles that seen in 
pathogenic blood coagulation that leads to atherothrombosis. In chronic cigarette smokers, blood 
viscosity has been reported to be often elevated, which is blamed to lead to an increased risk of 
atherothrombosis [Yanbaeva et al, 2007]. This pro-coagulant condition appears to be caused by 
higher levels of thrombin and fibrinogen alongside lower levels of anti-factor Xa, all of which 
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are attributed to systemic oxidative stress from chronic cigarette smoke exposure [Hioki et al, 
2001; Wannamethee et al, 2005; Yanbaeva et al, 2007]. Meanwhile, the processes of blood 
coagulation and inflammation have been reported to be associated whereby inflammation leads 
to activation of coagulation, and vice versa [Levi et al, 2004]. Coagulation proteases such as 
thrombin have been shown to activate specific cell receptors known as the protease-activated 
receptors on the epithelial, mononuclear and endothelial cells, thereby mediating inflammatory 
responses including cytokine production and inflammatory cell apoptosis. In fact, anti-coagulants 
like heparin and factor Xa inhibitors have been demonstrated to hamper this coagulation-
associated inflammation, typically concurrent with NFκB modulation [Thourani et al, 2000; 
Matsushita et al, 2006]. On the flip side, inflammatory cells may initiate activation of 
coagulation by expression of pro-coagulant materials leading to platelet activation resulting in 
the formation of platelet-fibrin thrombus [Levi et al, 2004]. In fact, in line with this cascade, the 
anti-inflammatory phytosterol guggulsterone has been reported to inhibit thrombus formation 
[Gebhard et al, 2009]. Meanwhile, most of coagulation factors such as thrombin and factors IXa, 
Xa, XIa and XIIa belong to the serine protease class of enzymes, like NE [Prezelj et al, 2007]. 
Hence, certain anti-coagulants, such as heparin and anti-thrombin, function as serine protease 
inhibitors and thus, inhibit NE [Gilles et al, 1997; Spencer et al, 2006].   
 
Recently, unique dehydropolymers (DHPs) of several 4-hydroxy cinnamic acids have 
been discovered as a novel class of anti-coagulants, which were shown to act via direct dual 
inhibition of thrombin and factor Xa [Monien et al, 2006]. These DHPs were chemo-
enzymatically synthesized as either unsulfated or sulfated oligomers composed of caffeic acid 
(CA), ferulic acid (FA) or sinapic acid (SA), in two steps, as described in Figure 1.2 [Monien et 
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al, 2006; Henry et al, 2007]. Briefly, the monomers were coupled via oxidation under the 
catalysis of horseradish peroxidase (HRP) in the presence of H2O2, generating radical 
intermediates, I1 and I2. These underwent chain extension, primarily with β-5 and β-O-4 inter-
monomer linkages to result in 4-15 units oligomerization to CA-, FA- or SA-based DHPs, i.e., 
unsulfated DHPs referred to as CD, FD and SD, respectively. These unsulfated DHPs were then 
reacted with triethylamine-sulfur trioxide (Et3N/SO3) complex, which yielded sulfated DHPs as 
CDS, FDS and SDS, respectively [Monien et al, 2006; Henry et al, 2007]. Their averaged 
molecular weights determined by size exclusion chromatography using their acetylated 
counterparts ranged from 2800 to 4120 Da, as shown in Table 1.1. Their elemental analysis 
found that sulfation was added as 0.30-0.40 mole per monomer unit for CDS, FDS and SDS 
(Table 1.1). Finally, their in vitro inhibitory binding activities to factor Xa and thrombin were 
shown to differ substantially, yielding the half-maximal inhibitory concentration (IC50) values 
ranging from 0.02 to 0.94 µM [Monien et al, 2006; Henry et al, 2007]. Among them, the caffeic 
acid-based DHP referred to as CD and CDS appear to be structurally the most potent, while 
sulfation led to a substantial improvement in the IC50 values by 3.5- or 4.7-fold, such that CDS 
was the most potent anti-coagulant [Monien et al, 2006; Henry et al, 2007]. These DHPs were 
further evaluated for their anti-coagulant activities by the determinations of the prothrombin and 
activated partial thromboplastin times (PT and APTT, respectively). CDS was again shown to be 
the most potent, yielding 42.1 and 13.0 µg/ml (12.7 and 3.9 µM), respectively, of concentrations 
doubling the normal human plasma clotting time [Monien et al, 2006].    
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Figure 1.2: Synthetic scheme of the unsulfated and sulfated 4-hydroxy
cinnamic acid-based dehydropolymers (DHPs) [Monien et al, 2006].
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CD 2,800 0.14
FD
SD
CDS
FDS
SDS
MW1
[Da]
3,650
2,990
3,320
4,120
3,550
Sulfates
per unit2
0.40
0.30
0.38
—
—
—
IC50
3
Factor Xa Thrombin
[µM]
0.74
0.94
0.03
0.08
0.24
0.07
0.32
0.33
0.02
0.03
0.09
Oligomer
1Weight-averaged molecular weight; 2 Averaged number of sulfates per monomeric
unit, derived from elemental sulfur composition analysis and averaged oligomer
size; and 3The half-maximal inhibitory concentration (IC50) obtained the from
chromogenic substrate hydrolysis assays for each enzyme.
Table 1.1: Unsulfated and sulfated dehydropolymers (DHPs) of caffeic acid, ferulic
acid and sinapic acid alongside their physicochemical and in vitro inhibitory
activities to coagulation enzymes [Monien et al, 2006; Henry et al, 2007].
13 
 
Because factor Xa and thrombin both belong to serine protease enzyme family, like NE 
[Prezelj et al, 2007], the inhibitory activities of the cinnamic acid-based DHPs on these enzymes 
(Table 1.1) implied their prospective inhibitory activities upon NE. Moreover, their monomers 
were all shown to be potent anti-oxidants by virtue of their radical scavenging activity [Natella et 
al, 1999; Neudorffer et al, 2004], while the monomer, CA, was reported to weakly inhibit human 
sputum elastase with an IC50 value of 93 µM [Löser et al, 2000]. Finally, phenethyl ester 
derivative of CA has been recently found to be anti-inflammatory, by virtue of a structural 
relative of flavonoids [Natarajan et al, 1996]. Integrating all these findings, it became logical to 
hypothesize that these cinnamic acid-based DHPs are equipped with triple inhibitory activities to 
oxidative stress, inflammation and NE. Nevertheless, the cinnamic acid-based DHPs are 
comprised mostly of 3-4 kDa macromolecules, which would not be expected to be absorbed 
following oral administration; making injection the only viable option. Because emphysema and 
COPD locally affect the lung, however, DHPs could likely benefit from delivery via inhalation. 
In this sense, non-peptidic nature of the DHP molecules could add a further benefit, by virtue of 
a reduced likelihood to local metabolic degradation by the lung’s enzymes. These factors may 
permit a much lower dose to be effective, in comparison to systemic administration like 
injection.  
 
Accordingly, this dissertation project was aimed to demonstrate the therapeutic potential 
of the cinnamic acid-based DHPs as novel macromolecular entities for pulmonary delivery in the 
treatment of emphysema and COPD. The unsulfated or sulfated DHPs composed of CA, FA or 
SA were first assessed in three in vitro systems to identify and characterize the most potent 
“triple inhibitor” of oxidative stress, lung inflammation and neutrophil elastase. The most potent 
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candidate was then further tested after pulmonary administration to determine its effects to 
prevent the airspace enlargement in an in vivo rat model of experimental pulmonary emphysema. 
Direct local lung delivery of DHPs was hypothesized to enable a much lower effective dose to 
combat emphysema, without causing significant adverse effects due to their previously 
demonstrated effects as anti-coagulants in the systemic circulation (notably, their systemic 
absorption via the lung should be retarded due to their molecular size). 
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CHAPTER 2 
 
 
HYPOTHESES 
 
 
 
 
 
The goal of this dissertation project was to demonstrate the therapeutic potential of 
cinnamic acid-based dehydropolymers (DHPs) as novel macromolecular entities for pulmonary 
delivery, as agents for use in the treatment of emphysema and chronic obstructive pulmonary 
disease (COPD). Overall, it was hypothesized that the DHPs originally designed as novel anti-
coagulants are equipped with potent inhibitory activities against oxidative stress, inflammation 
and neutrophil elastase, the pathogenic mechanisms believed to cause airspace enlargement in 
this disease. Specifically, the project is first aimed to identify the most potent triple inhibitor 
among the unsulfated or sulfated DHPs through in vitro assessments. The project then proceeds 
to test the most potent triple inhibitor DHP in vivo in a rat model of experimental pulmonary 
emphysema, in order to establish its “prophylactic” effects following pulmonary delivery. The 
project is designed to test the following 5 hypotheses: 
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a. In vitro molar potency assessments can be established to determine inhibitory activities to 
oxidative stress, inflammation and neutrophil elastase, in order to identify the most potent 
triple inhibitor. 
 
b. All the unsulfated and sulfated DHPs exhibit potent yet different in vitro anti-oxidative, anti-
inflammatory and anti-elastase activities. 
 
c. A new in vivo rat model of experimental pulmonary emphysema caused by induced 
oxidative stress, inflammation and elastase can be developed with a combination instillation 
of human sputum elastase and cigarette smoke extract (HSE/CSE), leading to the airspace 
enlargement. 
 
d. Pulmonary delivery of the most potent triple inhibitor DHP exhibits dose-dependent 
“prophylactic” effects to the HSE/CSE-induced oxidative stress, inflammation and elastase in 
the emphysema rat model, determined by reduced glutathione (rGSH) level, inflammatory 
neutrophil cell infiltration, and airway luminal elastase activity, respectively. 
 
e. Pulmonary delivery of the most potent triple inhibitor DHP exhibits dose-dependent 
“prophylactic” effects to the HSE/CSE-induced airspace enlargement. 
 
In Chapter 3, the unsulfated and sulfated DHPs will be tested in three in vitro systems to 
assess the molar inhibitory activities to oxidative stress, inflammation and elastase. The most 
potent triple inhibitor will be identified as a DHP yielding the lowest half-maximal inhibitory 
concentrations, while the inhibitory mechanisms and specificities will also be explored and 
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discussed through additional experiments including the assessment of the monomer and 
reference molecules. This will then lead to Chapter 4 where the DHP identified as the most 
potent triple inhibitor in Chapter 3 is tested with pulmonary delivery in the in vivo rat model of 
HSE/CSE-induced emphysema. The protective effects of in vivo lung anti-oxidative stress, anti-
inflammation and anti-elastase activities will be assessed following pulmonary delivery of DHP 
at two different doses via the measurements of the lung tissue rGSH, airway luminal neutrophil 
infiltration and elastase activity, respectively. Most importantly, the DHP effect on the induced 
airspace enlargement will then be assessed, while that on the lung hemorrhage will be as an 
additional lung injury marker. Finally, Chapter 5 will summarize all of the findings of this 
dissertation project and provide overall conclusions.    
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CHAPTER 3 
 
 
IN VITRO TRIPLE INHIBITORY POTENCY ASSESSMENTS OF 
CINNAMIC ACID-BASED DEHYDROPOLYMERS AGAINST 
OXIDATIVE STRESS, INFLAMMATION AND ELASTASE 
 
 
 
 
 
3.1 INTRODUCTION 
 
The currently accepted pathogenic mechanisms of emphysema and its airspace 
enlargement complexly involve, at least, oxidative stress, inflammation and induced elastase 
activity within the lung, as described in Figure 1.1 in Chapter 1. It is therefore logically ideal to 
inhibit all of these pathogenic mechanisms simultaneously, yet such a versatile single chemical 
entity is yet to be identified, leaving the disease manageable only for symptomatic relief by 
inhaled bronchodilators and corticosteroids [Barnes & Hansel, 2004]. In line with this logical 
ideality, the dual inhibitory activities have been recently shown for curcumin and N-
acetylcysteine (NAC), which are now considered to be more promising therapeutic molecules for 
this disease application [Bridgeman et al, 1991; Motterlini et al, 2000]. Accordingly, it was 
hypothesized through Chapters 1 and 2 that the non-peptidic cinnamic acid-based 2.8-4.1 kDa 
dehydropolymers (DHPs) originally synthesized as novel anti-coagulants [Monien et al, 2006; 
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Henry et al, 2007] were triple inhibitors of these three pathogenic mechanisms. Clearly however, 
it was essential that their triple inhibitory potencies were first to be determined among different 
monomer unit (i.e., caffeic, ferulic or sinapic acid) structures with or without sulfation. Hence, 
this chapter was designed to identify and characterize the most potent triple inhibitor using three 
different in vitro assessments systems for subsequent testing in the animal model of emphysema 
in Chapter 4. 
As the formation of reactive oxygen species (ROS) is primarily responsible for elevated 
oxidative stress, the in vitro scavenging capacity assay to stable, non-biological radicals was 
chosen to determine the anti-oxidative potency and activity of the test molecules. In contrast, the 
in vitro anti-inflammatory potency and activity was assessed via trans-repression of the cellular 
inflammatory transcription factor, nuclear factor ĸB (NFĸB), in non-confluent lung epithelial 
(Calu-3) cells following tumor necrosis factor α (TNFα) stimulation [Jafuel et al, 2000; 
Roumestan et al, 2003; Arora, 2008]. Finally, the anti-elastase potency and activity, especially to 
human neutrophil elastase (HNE), was determined using the chromogenic substrate hydrolysis 
assay. In each study, the unsulfated or sulfated DHPs were tested, alongside reference molecules, 
to determine and rank the molar inhibitory potencies, after which the inhibitory kinetics, 
mechanisms and/or specificity were also explored.   
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3.2 MATERIALS AND METHODS  
 
3.2.1 TEST MOLECULES 
The unsulfated or sulfated DHPs composed of caffeic, ferulic or sinapic acid were 
chemoenzymatically synthesized at Dr. Desai’s laboratory and received as 5 mM phosphate-
buffered saline (PBS) solutions following characterization, as described in Table 1.1 in Chapter 
1. The average molecular weights, elemental compositions and sulfate per unit monomer for the 
DHPs tested in this chapter are described in detail in Table 3.1. These were stored at -20 oC prior 
to use. One of the monomers, caffeic acid (CA) was also supplied by Dr Desai’s laboratory. 
Trolox® (6-hydroxyl-2,5,7,8-tertamethylchroman-2-carboxylic acid) and fluticasone propionate 
(FP) were purchased from Cayman Chemical Company (Ann Arbor, MI) and Sigma-Aldrich (St. 
Louis, MO), respectively.  
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3.2.2 IN VITRO ANTI-OXIDATIVE ACTIVITY ASSESSMENT 
In vitro anti-oxidative activities of the DHPs and CA were determined using a chemical 
anti-oxidation assay kit (Cayman Chemical Company) in a 96-well plate format. It was carried 
out in accordance with the manufacturer’s protocol. The assay employs formation of a stable 
chromogenic radical cation, ABTS.+ from 2,2'-azinobis(3-ethyl-benzothiazoline-6-sulphonic 
acid) (ABTS) during incubation with metmyoglobin and hydrogen peroxide (H2O2). ABTS
·+ 
interacts with ferryl myoglobin and thereby produces a relatively stable blue-green color, which 
is measured at 750 nm. Anti-oxidants in the assay mixture suppress this color production, in 
proportion to their potencies or concentrations. In the kit, a water soluble tocopherol analogue, 
Trolox®, was used as a reference anti-oxidant. The anti-oxidative activity for a given test 
molecule could be described, relative to that for Trolox® tested at 0, 0.09, 0.43, 0.86, 2.14, 4.27, 
6.43, 8.57, 10.71, 13.90 and 17.38 µM.  
In each well, the test molecules or Trolox® (0.01 ml) at different concentrations was 
mixed with metmyoglobin (0.01 ml) and ABTS (0.15 ml) and then, 441 µM H2O2 (0.04 ml) was 
added to initiate ABTS oxidation to its radical cation ABTS·+ at room temperature. The 
absorbance at 750 nm was monitored spectrophotometrically for 15 min using a multi-mode 
microplate reader, SynergyTM 2 (BioTek Instruments, Inc., Winooski, VT). The DHP or CA 
concentrations were varied, ranging from 0 to 100 µM. The initial rate of ABTS·+ production (Y) 
was assessed from the absorbance change (∆Abs) in the first 5 min, as recommended by the 
manufacturer, which was then plotted as a function of logarithmic concentrations (C) of the test 
or reference molecules, Trolox®, DHPs and CA. The half-maximal (50 %) anti-oxidative 
concentration (AOC50) values were derived from these concentration-response curves through 
curve-fitting to the following 4-parameter logistic function equation: 
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Y= Ymin + (Y0-Ymin) / [1+(C/AOC50)
HS] 
where Y0 is the ∆Abs value in the absence of the test molecules, Ymin is the lowest asymptotic 
∆Abs value seen at the highest concentration (i.e., 100 µM), and HS is the Hill slope. The 
nonlinear regression curve-fitting employed Scientist software (Version 2.0; MicroMath, St 
Louis, MO), where the AOC50 and HS values were floated for determination, while the Y0 and 
Ymin values were fixed. The coefficient of determination (COD) and Model Selection Criterion 
(MSC) were used to assess “goodness-of-fit” of the curve-fitting, in addition to visual inspection 
of residuals.    
 
3.2.3 IN VITRO ANTI-INFLAMMATORY ACTIVITY ASSESSMENT 
In vitro anti-inflammatory activities of the DHPs and CA were determined with the lung 
epithelial trans-repression of the pro-inflammatory transcription factor, NFκB, using the 
transfected Calu-3 human bronchial epithelial cells in a 12-well plate format. The Calu-3 cells 
were obtained at passage 19 from the American Type Culture Collection (ATCC; Rockville, 
MD) and propagated in the 25 or 75 cm2 culture flasks (Corning Costar; Cambridge, MA), 
according to the ATCC’s protocol [Product Information Sheet, ATCC]. Briefly, the cells were 
seeded in the flasks at a density of 0.1 x 106 cells/cm2 and cultured in 10 or 20 ml of the Eagles 
Minimum Essential Medium (EMEM; ATCC) supplemented with 10 % (v/v) fetal bovine serum 
(Invitrogen, Carlsbad, CA) and 1 % (v/v) penicillin-streptomycin (Sigma-Aldrich). They were 
maintained under the humidified 95 % (v/v) air and 5 % (v/v) CO2 at 37 °C in the incubator 
(Model 5410, NAPCO, Milliville, NJ) connected to a CO2 gas cylinder (National Welders, 
Richmond, VA). The culture media was changed every other day, during which cell growth was 
monitored under the microscope (Nikon-TMS phase contrast microscope, Image Systems Inc., 
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Columbia, MD). Typically, the cells reached confluence by 5-7 days, such that they were 
passaged into well plates for experiments and/or new flasks for further propagation, and 
otherwise, frozen for cell bank storage following trypsin-EDTA (Sigma-Aldrich) treatment. 
For experiments, on day 1, the Calu-3 cells were seeded at a density of 0.5 x 106 
cells/well in 12-well plates and cultured in the culture media for 24 h. On day 2, the non-
confluent yet adherent cells were transfected with the custom-made plasmid NFκB tagged with 
luciferase enzyme gene, pNFκB-Luc (VCU Molecular Biology Core Facility, Richmond, VA), 
using the Effectene® transfection kit (Qiagen, Valencia, CA) and its reagents (Effectene, 
Enhancer and Buffer EC) under the protocol slightly modified from that developed previously 
[Arora, 2008]. Initially, the master-mix transfection solution was prepared by 10 min incubation 
of 0.6 µg pNFκB-Luc in 0.075 ml Buffer EC and 0.0048 ml Enhancer, followed by another 10 
min incubation with 0.0048 ml Effectene. This master-mix solution was diluted to 1 ml with the 
culture media and then added to each well for 24 h transfection. On day 3, the transfected Calu-3 
cells were stimulated for 6 h with 30 ng/ml of human tumor necrosis factor α (hTNFα; BD 
Biosciences, San Jose, CA) in the presence of DHPs, CA or FP at 0-100 µM; the plates were 
maintained in the incubator. At 6 h, the cells were thoroughly rinsed with PBS (Invitrogen) and 
harvested with 0.1 ml of the lysis reagent (Promega, Madison, WI). The lysed cell samples were 
centrifuged at 12,000 g for 5 min (Eppendorf centrifuge 5810R; Westbury, NY), and their 
supernatants were subjected to luminescence measurement and protein assay. The 0.02 ml 
samples were used to determine the luminescence signals as the Luc activities in relative light 
unit (RLU) using the 20/20n luminometer (Turner Biosystems, Sunnyvale, VA), while 0.025 ml 
samples were used for the total protein content assay using the bicinchoninic assay (BCA) kit 
(Pierce Biotechnology, Thermo Scientific, Rockford, IL). The NFκB-Luc activity of the Calu-3 
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cell lysates was normalized and expressed as RLU per mg protein, and such normalized NFκB-
Luc activities in each treatment group were further processed to derive a fold-induction relative 
to the transfection control, in order to accommodate for inter-transfection efficiency differences.   
 
3.2.4 IN VITRO ANTI-ELASTASE ACTIVITY ASSESSMENT 
In vitro anti-elastase activities of the DHPs and CA were determined, first using human 
neutrophil elastase (HNE), via enzymatic hydrolysis of a chromogenic substrate, N-
methoxysuccinyl Ala-Ala-Pro-Val p-nitroanilide (MeOSuc-AAPV-pNA; Sigma-Aldrich) at 37º 
C in a 96-well plate format. HNE (salt-free, lyophilized; Athens Research and Technology, Inc., 
Athens, GA) was reconstituted in 50 mM acetate buffer (pH 5.5) and aliquoted at 8 mU/µl in 
polypropylene tubes for storage at -80 °C. The substrate, MeOSuc-AAPV-pNA was prepared as 
a fresh stock for each experiment at 8.7 mM in dimethyl sulfoxide (DMSO).  
For experiments, 0.02 ml of the enzyme (HNE) stock solution was first diluted with 
0.488 ml of the assay buffer, i.e., 0.1 M sodium phosphate buffer (pH 7.6) and 0.25 M sodium 
chloride (NaCl), to yield a concentration of 0.315 U/ml. The substrate stock solution (8.7 mM) 
was also diluted with the assay buffer by 10-fold to 0.87 mM. In each well, each of the DHPs or 
CA at different concentrations was placed as 0.18 ml solution of the assay buffer. Then, 0.02 ml 
of the HNE solution prepared above and containing 6.3 mU HNE was added to each well, 
followed by addition of 0.06 ml of the 0.87 mM substrate solution; this enabled the final 
substrate concentration at 0.2 mM. The progress of the hydrolysis at 37° C was monitored 
spectrophotometrically with the microplate reader (SynergyTM 2) for 2 h as absorbance increase 
at 405 nm originating from p-nitroaniline (pNA) generation. In parallel, the absorbance was also 
monitored for the test molecules (DHPs or CA) without HNE for the use in correction, due to 
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their inherent absorbance; this was subtracted from the observed absorbance at each of the given 
times. The initial linear rate (Y) of pNA production represented by the absorbance increase in the 
first 10 min (∆Abs) was plotted as a function of logarithmic concentrations of the DHPs and CA 
(C). The half-maximal (50 %) inhibitory concentration (IC50) values were derived from the 
concentration-response curves by curve-fitting to the following 4-parameter logistic function 
equation: 
Y= Ymin + (Y0-Ymin) / [1+(C/IC50)
HS] 
where Y0 is the ∆Abs value in the absence of the test molecules, Ymin is the lowest asymptotic 
∆Abs value seen at the highest concentration (i.e., 100 µM), and HS is the Hill slope. The 
nonlinear regression curve-fitting employed Scientist software (Version 2.0; MicroMath), where 
the IC50 and HS values were floated for determination, while the Y0 and Ymin values were fixed. 
The COD and MSC values were used for the “goodness-of-fit” assessment. 
The most potent DHP against HNE identified above was further tested for enzyme 
specificity to human sputum elastase (HSE; 875 U/mg; Elastin Products and Co., Inc.) and 
porcine pancreatic elastase (PPE; 82 U/mg; Elastin Products Co., Inc.) under the same protocol, 
yet adding 1000 mU and 91 mU to each well, respectively; the substrate (MeOSuc-AAPV-pNA) 
concentration remained consistent at 0.87 mM. The IC50 values were similarly derived from the 
concentration-response curves though curve-fitting, as described above.  
Furthermore, the most potent DHP identified above was also tested with respect to its 
time-dependent HNE inhibition. HNE (6.3 mU in each well) was first incubated with the DHP at 
0, 0.3, 0.7 and 1 µM for varying 0, 1, 5, 7, 10, 30 and 90 min at 37° C. The probe substrate, 
MeOSuc-AAPV-pNA was then added at a final concentration of 0.2 mM, like the inhibition 
studies described above. While the progress of the hydrolysis was monitored at 405 nm for 1 h as 
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the absorbance increase (∆Abs) in the microplate reader, the ∆Abs values for the first 10 min 
(∆Abs10) were used to determine the remaining fractional enzyme activity with respect to the 
controls using the following equation:  
                          
 
                      ∆Abs10 in the presence of CDS 
Remaining fractional enzyme activity =  
                      ∆Abs10 in the absence of CDS 
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3.3 RESULTS  
 
3.3.1 IN VITRO ANTI-OXIDATIVE  ACTIVITY ASSESSMENT 
Figure 3.1 shows the time-course profiles of the absorbance increase at 750 nm due to 
ABTS.+ generation and thus, ABTS oxidation in the absence or presence of CDS at 1, 3, 5 and 10 
µM in the chemical anti-oxidation assay. CDS at 0.0001, 0.001, 0.01, 0.1, 7 and 100 µM was 
also tested to determine the AOC50 value accurately in Figure 3.3, yet the profiles are not shown 
for a clarity reason. Likewise, the time-course profiles of the 750 nm absorbance increase for 
CA, CD, FDS and SDS at different concentrations are shown in Figure 3.2. For all the test 
molecules, the absorbance increase (∆Abs) was suppressed with increasing concentrations, 
demonstrating their anti-oxidative activities. While most of the profiles in Figures 3.1 and 3.2 
were apparent first-order, the initial oxidative rate was assessed at 5 min, as recommended by the 
manufacturer. Accordingly, Figure 3.3 shows such initial oxidative rates as a function of (A) 
CDS, CD and CA and (B) CDS, FDS and SDS concentrations. It was clear that all the test 
molecules exhibited reverse-logistic profiles and thus, concentration-dependent anti-oxidative 
activities, while their molar potencies varied substantially. In Figure 3.3(A), the sulfated caffeic 
acid DHP, CDS was clearly shown to be the most potent over the unsulfated DHP, CD, and the 
monomer, CA. In Figure 3.3(B), CDS was again shown to be the most potent over the sulfated 
DHPs of other monomer units, ferulic and sinapic acid (i.e., FDS and SDS, respectively). In each 
case, the curve-fitting was successful in Figure 3.3 (>3.4 of MSC; >0.992 of COD), which 
appropriately yielded the AOC50 and HS values, as described in Table 3.1. CDS yielded the 
lowest AOC50 value of 3.52±0.14 µM, which was 1.8-fold less than unsulfated DHP, CD 
(6.15±0.33 µM) and 4.8-fold less than the monomer, CA (16.82±1.16 µM). It was likely 
29 
 
therefore that, while the sulfation of CD only slightly improved the potency, the unit structure 
(i.e., CA) was a primary pharmacophore for this anti-oxidative activity, yet its 5-13 unit repeated 
structure didn’t simply add the potency in a proportional fashion. In contrast, as suggested in the 
profiles in Figure 3.3(B), the other two sulfated DHPs, FDS and SDS, resulted in a slightly 
higher AOC50 values of 5.05±0.34 and 5.53±0.34 µM, respectively (Table 3.2). Even so, these 
anti-oxidative potencies of the sulfated DHPs (AOC50 = 3.52-5.53 µM) were shown to be 
equivalent to 9.4 µM of Trolox, the tocopherol analogue known as an intermediate anti-oxidant 
ranked between vitamins C and E [Cayman’s user protocol]. Hence, these sulfated DHPs were 
more potent anti-oxidants than these natural vitamins, among which CDS was identified to be the 
most potent. Meanwhile, as shown in Table 3.2, the Hill slopes (HS) values were nearly 
comparable among the caffeic acid-based molecules (CA, CD and CDS), while substantially 
differing between the unit structures. This suggested by definition that the cooperativity in the 
free radical scavenging action was dependent upon the unit structure, rather than the repeated 
structure or sulfation, although such a deduction should be hardly conclusive, especially for the 
DHPs due to the heterogeneity of the oligomers.  
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Figure 3.1: Time-course profiles of the absorbance increase (∆Abs) at 750 nm due to
ABTS oxidation in the absence or presence of the sulfated caffeic acid DHP, CDS at
different concentrations. Data represent mean from duplicate measurements: each data
set exhibited effectively no variability.
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Figure 3.2: Time-course profiles of the absorbance increase (∆Abs) at 750 nm due to
ABTS oxidation in the absence or presence of the caffeic acid monomer, CA, the
unsulfated caffeic acid DHP, CD, the sulfated ferulic and sinapic acid DHPs, FDS and
SDS, respectively. Data represent mean from duplicate measurements: each data set
exhibited effectively no variability.
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Figure 3.3 (A): The absorbance increase (∆Abs) at 750 nm for 5 min as a function of
concentration of the sulfated caffeic acid DHP, CDS, the unsulfated caffeic acid DHP, CD
and the caffeic acid monomer, CA in the chemical anti-oxidation assay, derived from the
time-course profiles in Figures 3.1 and 3.2. Data represent mean from duplicate or
triplicate measurements. The solid lines are the result of the curve-fitting.
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Figure 3.3 (B): The absorbance increase (∆Abs) at 750 nm for 5 min as a function of
concentration of the sulfated caffeic, ferulic and sinapic acid DHPs, CDS, FDS and SDS,
respectively, derived from the time-course profiles in Figures 3.1 and 3.2. Data represent
mean from duplicate or triplicate measurements. The solid lines are the result of the
curve-fitting.
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3.3.2 IN VITRO ANTI-INFLAMMATORY ACTIVITY ASSESSMENT 
Figure 3.4 shows the hTNFα-dependent NFκB luciferase (Luc) activities of the 
transfected Calu-3 epithelial cells in various treatment groups testing anti-inflammatory activities 
of the DHPs and CA alongside FP. As were the cases with the confluent Calu-3 cells previously 
[Arora, 2008], the luminescence signals, i.e., the RLU values per mg protein, were substantially 
different in each experiment, presumably due to different transfection efficiencies. Nevertheless, 
their induction by hTNFα relative to the transfection and vehicle control (without hTNFα 
induction) was consistent 1.9±0.4-fold and thus, such fold-induction values were used in Figure 
3.4. In Figure 3.4(A), the anti-inflammatory activity of CDS against hTNFα-dependent 
inflammation is shown. CDS itself at 10 µM was first confirmed to have no effect on the basal 
NFκB-Luc level in the cells, equivalent to the transfection control. As described above, hTNFα 
was shown to induce cellular inflammation (i.e., NFκB-Luc level) by 1.9±0.4-fold (Figure 3.4). 
However, this hTNFα-dependent NFκB-Luc induction was repressed by CDS in a concentration-
dependent manner; 1 µM CDS was ineffective, 10 µM CDS exhibited significant 47.7 % 
repression, and 50 µM CDS enabled near complete 98.4 % repression (Figure 3.4(A)). This 
clearly demonstrated that CDS was equipped with the anti-inflammatory activity, and its half-
maximal effective concentration was approximated to be ~10 µM. In contrast, as shown in 
Figure 3.4(B), when compared at 50 µM, CD and FDS were unable to achieve near complete 
repression unlike CDS, even though their effects were significant; % repression were lower 56.8 
and 64.8 %, respectively. Hence, it was demonstrated that CDS was again the most potent among 
these DHPs in this anti-inflammatory activity, like the anti-oxidative activity. Notably, the 
monomer, CA failed to repress the induced NFκB-Luc level, even at a higher 100 µM (Figure 
3.4(B)). Therefore, the repeated structure was likely the pharmacophore for this anti-
36 
 
inflammation, and sulfation potentiated the activity considerably. Meanwhile, in this system, FP, 
one of the most potent inhaled corticosteroids used in the treatment of asthma, was capable of 
100 % repression at a lower 5 µM, as shown in Figure 3.4(B). This supported a notion that CDS 
was not as potent as FP with respect to this anti-inflammatory effect. 
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Figure 3.4 (A): hTNFα-dependent NFκB luciferase activities of the transfected Calu-3 cells in
the absence or presence of 1, 10 or 50 µM sulfated caffeic acid DHP, CDS. Vhcl: Vehicle.
Data represent mean±standard error (SE) from n≥3. #p<0.05, compared to the vehicle-
treated and -stimulated cells, *p<0.05, compared to the vehicle-treated and hTNFα-stimulated
cells.
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Figure 3.4 (B): hTNFα-dependent NFκB luciferase activities of the transfected Calu-3 cells in
the absence or presence of various test molecules including fluticasone propionate (FP).
Vhcl: Vehicle. Data represent mean±standard error (SE) from n≥3. #p<0.05, compared to the
vehicle-treated and -stimulated cells, *p<0.05, compared to the vehicle-treated and hTNFα-
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3.3.3 IN VITRO ANTI-ELASTASE ACTIVITY ASSESSMENT 
Figure 3.5 shows the time-course profiles of pNA generation converted from the 
absorbance increase at 405 nm in the absence or presence of CDS at 0.1, 1, 10 and 100 µM in the 
MeOSuc-AAPV-pNA hydrolysis assay for HNE; CDS at 0.01, 0.3, 5 and 50 µM was also tested 
to determine the IC50 value accurately in Figure 3.7, yet the profiles are not shown for a clarity 
reason. Likewise, the time-course profiles of pNA generation for CA, CD, FDS and SDS at 
different concentrations are shown in Figure 3.6. All the DHPs were shown to suppress the pNA 
generation in a concentration-dependent manner, which demonstrated their anti-HNE (elastase) 
activities. In contrast, the monomer, CA failed to show suppression, resulting in the effectively 
overlaid profiles by 100 µM (Figure 3.6). While these profiles in Figure 3.5 and 3.6 were 
apparent first-order, the initial hydrolysis rates were assessed at 10 min, where the linear profiles 
were best demonstrated. Accordingly, Figure 3.7 shows the initial hydrolysis rates as a function 
of (A) CDS, CD and CA and (B) CDS, FDS and SDS concentrations. It was clear that all DHPs 
exhibited reverse-logistic function profiles and thus, concentration-dependent anti-HNE 
(elastase) activities, while their molar potencies were substantially varied. In Figure 3.7(A), CDS 
was shown to be more potent than CD, while the monomer, CA did not inhibit HNE even by 1 
mM (CA exhibited ~20 % of the anti-HNE activity at 10 mM; data not shown). In Figure 3.7(B), 
CDS was again shown to be the most potent among the sulfated DHPs, although their differences 
were relatively small. The curve-fitting was successful in Figure 3.7 (>4.0 of MSC; >0.993 of 
COD), which appropriately yielded the IC50 and HS values, as described in Table 3.2. CDS 
yielded the lowest IC50 value of 0.43±0.04 µM, which was 6.6-fold less than the unsulfated 
DHP, CD (2.82±0.20 µM); the IC50 value for the monomer CA couldn’t be determined. Hence, 
like the anti-inflammation activity, it appeared that the repeated structure was the pharmacophore 
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for this anti-HNE (elastase) activity that was considerably potentiated by sulfation. In contrast, 
the other two sulfated DHPs, FDS and SDS, resulted in only slightly higher IC50 values of 
0.55±0.04 and 0.72±0.07 µM, respectively (Table 3.3). This suggested that the most potent unit 
structure was caffeic acid, even though the difference in the activity was relatively small. 
Meanwhile, as shown in Table 3.3, the Hill slopes (HS) were comparable among the sulfated 
DHP molecules (CDS, FDS and SDS), while substantially differing from the unsulfated CD. 
This suggested by definition that the cooperativity in the elastase inhibition was dependent upon 
sulfation, rather than the unit structure, although such a deduction should be inconclusive, 
especially for the DHPs due to the heterogeneity of the oligomers.  
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Figure 3.5: Time-course profiles of p-nitroaniline (pNA) generation from MeOSuc-AAPV-
pNA by human neutrophil elastase (HNE) in the absence or presence of the sulfated
caffeic acid DHP, CDS at different concentrations. Data represent mean±standard
deviation (SD) from n≥3.
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Figure 3.6: Time-course profiles of p-nitroaniline (pNA) generation from MeOSuc-AAPV-
pNA by human neutrophil elastase (HNE) in the absence or presence of the caffeic acid
monomer, CA, the unsulfated caffeic acid DHP, CD and the sulfated ferulic and sinapic
acid DHPs, FDS and SDS, respectively. Data represent mean±standard deviation (SD)
from n≥3.
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Figure 3.7 (A): Mass of p-nitroaniline (pNA) generated for 10 min as a function of
concentration of the sulfated caffeic acid DHP, CDS, the unsulfated caffeic acid DHP, CD
and the caffeic acid monomer, CA in the in vitro human neutrophil elastase (HNE)-
induced chromogenic substrate hydrolysis assay, derived from the time-course profiles
in Figures 3.5 and 3.6. Data represent mean±standard deviation (SD) from n=3. The
solid lines are the result of the curve-fitting.
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Figure 3.7 (B): Mass of p-nitroaniline (pNA) generated for 10 min as a function of
concentration of the sulfated caffeic, ferulic and sinapic acid DHPs, CDS, FDS and SDS,
respectively, in the in vitro human neutrophil elastase (HNE)-induced chromogenic
substrate hydrolysis assay, derived from the time-course profiles in Figures 3.5 and 3.6.
Data represent mean±standard deviation (SD) from n=3. The solid lines are the result of
the curve-fitting.
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Figure 3.8 shows the time-course profiles of pNA generation for the most potent HNE 
inhibitor, CDS at 0.1, 1 and 10 µM, yet against other elastases, (A) human sputum elastase 
(HSE) and (B) porcine pancreatic elastase (PPE). Other concentrations, e.g., 0.01, 0.3, 0.5, 5, 10, 
20 and 100 µM for HSE and 100 µM for PPE, were also tested, yet are not shown for a clarity 
reason. With increasing concentrations from 0.1 to 10 µM, CDS suppressed the pNA generation 
by HSE, while no suppression was observed against PPE even at 10 µM, suggesting no or 
insignificant anti-PPE activity of CDS. As the initial hydrolysis rates assessed at 10 min were 
different in different enzymes, Figure 3.9 shows the remaining fractional enzyme activity of 
HNE, HSE and PPE as a function of CDS concentration. CDS clearly exhibited reverse-logistic 
function profiles for HNE and HSE, yet no inhibition for PPE. The curve-fitting was successful 
(Figure 3.9), yielding the IC50 values of 0.43±0.04 and 0.11±0.02 µM for HNE and HSE, 
respectively; the profile and IC50 value for HNE had also been shown in Figure 3.7 and Table 
3.2, respectively.  
Meanwhile, Figure 3.10 shows the remaining fractional HNE activity, compared to the 
control, after 0-90 min pre-incubation with 0, 0.3, 0.7 and 1 µM CDS. At a given CDS 
concentration, the remaining fractional HNE activity decreased with increasing the pre-
incubation periods by 30 min. This suggested that the anti-HNE activity of CDS was time-
dependent, reaching the maximum after 30 min of pre-incubation. 
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Figure 3.8: Time-course profiles of p-nitroaniline (pNA) generation from MeOSuc-AAPV-
pNA by (A) human sputum elastase (HSE) and (B) porcine pancreatic elastase (PPE) in
the absence or presence of the sulfated caffeic acid DHP, CDS at different
concentrations. Data represent mean±standard deviation (SD) from n≥3.
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Figure 3.9: Remaining fractional enzyme activity of human neutrophil elastase (HNE),
human sputum elastase (HSE) and porcine pancreatic elastase (PPE) as a function of
CDS concentration. Data represent mean±standard deviation (SD) from n=3. The solid
lines are the result of the curve-fitting.
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Figure 3.10: Effect of pre-incubation period of CDS and HNE on remaining fractional
enzyme activity. CDS at 0, 0.3, 0.7 and 1 µM was pre-incubated with HNE for 0, 1, 5, 7,
10, 30 and 90 min, followed by the chromogenic substrate hydrolysis assay. Data
represent mean±standard deviation (SD) from n≥3.
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3.4 DISCUSSION 
 
In this chapter, three relatively simple yet sensitive in vitro methods have been developed 
to assess the triple inhibitory activities of the cinnamic acid-based DHPs to oxidative stress, 
inflammation and neutrophil elastase. All DHPs were shown to be potent triple inhibitors, yet 
their molar potencies were different due to their monomer structures, oligomerization and/or the 
absence or presence of sulfation. Among them, the sulfated caffeic acid DHP, CDS was the most 
potent in all three inhibitory activities, yielding the half-maximal effective concentrations of 
3.52, ~10 and 0.43 µM, respectively. These molar potencies were relatively weaker than those 
for thrombin and factor Xa (In vitro IC50 = 0.02 and 0.03 µM, respectively; Table 1.1), yet 
effectively equivalent to 3.9 and 12.7 µM of their anti-coagulation potencies [Monien et al, 
2006]. Thus, with a premise that CDS was to be locally administered to the lung in order to 
maintain its low systemic levels, these findings of the triple inhibitory actions are considered to 
be quite promising for the use in the treatment of emphysema.  
   
3.4.1  CDS AS AN ANTI-OXIDATIVE DRUG 
By virtue of the suggested mechanisms of radical scavenging activities for the cinnamic 
acid monomers, i.e., CA, FA and SA [Natella et al, 1999; Neudorffer et al, 2004], their DHPs 
were tested by determining the total anti-oxidative capacity during certain chemical oxidative 
reaction, rather than determining the relatively complex cell oxidative markers. As summarized 
in Table 3.1, CDS was shown to be the most potent anti-oxidant among the tested molecules 
including the monomer CA. Its half-maximal anti-oxidative (AOC50) concentration was 3.52 
µM, which was ranked higher than anti-oxidative potencies of vitamins C and E [Cayman’s user 
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protocol]. The rank order among the sulfated DHPs (from the most to least potent) was 
CDS>FDS>SDS, which was consistent with that of their monomers (CA>FA>SA) [Natella et al, 
1999; Neudorffer et al, 2004]. In addition, for a given unit structure (e.g., caffeic acid), the Hill 
slopes (Table 3.1) derived from the inhibitory response-concentration curves were comparable, 
suggesting that the cooperativity in the free radical scavenging depended on the unit structure. It 
was likely therefore, that the anti-oxidative mechanisms of these DHPs were consistent with 
those of the monomers, which were either trapping the free radicals directly or scavenging them 
through a series of coupled reactions with anti-oxidant enzymes [Rao et al, 1996]. Even so, its 5-
13 unit repeated structure didn’t simply add the potency in a proportional fashion, and the 
sulfation only slightly improved the potency.  
 Various small molecule radical scavengers have been tested for their use in emphysema 
and COPD. N-acetylcysteine (NAC) has been tested as a congener of the key lung anti-oxidant 
glutathione (GSH) in an attempt to enhance the GSH levels in the lungs of patients with 
emphysema and COPD, which has resulted in varying and inconclusive success [Bridgeman et 
al, 1991; Bridgeman et al, 1994]. In contrast, natural anti-oxidative vitamins C and E have also 
been tested to reduce the oxidative stress in cigarette smokers [Smit et al, 1999; Romieu & 
Trenga, 2001; Daga et al, 2003], however, the results have been rather disappointing. Recently, a 
polyphenol anti-oxidant from red wine, resveratrol (3,5,4’-trihydroxy-trans-stilbene) has been 
shown to protect against lung’s oxidative stress through direct scavenging of the reactive oxygen 
species [Lorenz et al, 2003; Kode et al, 2008]. Finally, curcumin, the active molecule of a 
rhizomatous herbaceous perennial plant, turmeric (Curcuma longa) was shown to act as oxygen 
radical and thus hydroxyl radical scavenger, thereby increasing the anti-oxidative GSH levels 
and exhibiting protective effects in cigarette- and elastase-induced experimental emphysema in 
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vivo [Suzuki et al, 2009]. Compared to all these small molecule radical scavengers, CDS and 
other DHPs are 2.8-4.1 kDa macromolecules uniquely exhibiting potent anti-oxidative activities 
ranked between vitamins C and E, as described above. Thus, these potencies should justify their 
test in the in vivo emphysema model, and their local pulmonary delivery would potentially 
provide the longevity of anti-oxidative action in the lung by virtue of longer local residence time 
as a result of lesser systemic absorption.     
 
3.4.2  CDS AS AN ANTI-INFLAMMATORY DRUG 
As described in Chapter 1, in emphysema, a pro-inflammatory cytokine, TNFα primarily 
released from alveolar macrophages has been suggested to trigger the cellular inflammatory 
cascade leading to activation of inflammatory transcription factor, NFκB. Thus, TNFα-induced 
NFκB activation in the Calu-3 lung epithelial cells was used to assess the anti-inflammatory 
activities of the cinnamic acid-based DHPs. As decsribed in Figure 3.11, mediated via the TNF 
receptor (TNFR), TNFα has been shown to activate and translocate NFκB into the nucleus where 
certain inflammatory cytokines are synthesized and released. It is these cytokines that lead to 
increased sequestration and infiltration of inflammatory cells like macrophages and neutrophils 
to the lung. Therefore, the TNFα-induced cellular NFκB activation was closely relevant as an in 
vitro lung inflammation seen in lung diseases including emphysema. Among the tested 
molecules, CDS was shown to be the most potent with a half-maximal effective concentration of 
~10 µM, while achieving complete NFĸB repression at 50 µM. This anti-inflammatory effect 
was not observed for the monomer CA, but was potently for its methyl or phenylmethyl esters 
(CAME and CAPE, respectively) [Chung et al, 2004; Shin et al, 2004]. Hence, it was likely that 
these anti-inflammatory effects emerged due to these repeated structures, and if so, their 
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mechanisms would involve inhibition of inhibitory ĸB (IĸB) degradation (Figure 3.11) and/ or 
suppression of NFĸB interaction with DNA [Natarajan et al, 1996]. However, this mechanistic 
clarification remains to be inconclusive, as the DHPs were macromolecules which are 
conventionally believed not to enter the cells. Note, however, that this deduction was also 
applied to FA and SA analogues that exhibited potent anti-inflammatory activities via NFĸB 
inhibition [Nagasaka et al, 2007; Yun et al, 2008].  
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Figure 3.11: Mechanisms of tumor necrosis factor α (TNFα)-induced activation of
nuclear factor kappa B (NFκB) leading to synthesis of a variety of inflammatory
cytokines.
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Recently, similar NFκB inhibitory activities have been identified for phenolic molecules 
like resveratrol, silymarin and curcumin [Jobin et al, 1999; Manna et al, 1999; Donelly et al, 
2005; Biswas et al, 2005]. Resveratrol was shown to block the TNFα-induced NFκB-mediated 
gene transcription in alveolar epithelial A549 cells with an IC50 value of 21 µM [Donelly et al, 
2005]. The flavonoid, silymarin also exhibited NFκB repression, yet with a much higher IC50 
value and cytotoxicity [Manna et al, 2000; Polyak et al, 2010]. Finally, curcumin at 40 µM was 
shown to inhibit the TNFα-induced NFκB activation by 90 % through suppression of IκB 
phosphorylation and degradation. Hence, the anti-inflammatory activity of CDS was effectively 
equivalent to these other phenolic molecules, even though being less potent than FP, as shown in 
Figure 3.4(B). Meanwhile, certain marcolide antibiotics such as erythromycin and its derivatives, 
azithromycin and clarithromycin, have also been shown to be anti-inflammatory [Kikuchi et al, 
2002; Desaki et al, 2004; Kanai et al, 2004], yielding the IC50 values of ~56 µM. Hence, CDS 
was ranked more potent than these antibiotics [Cheung et al, 2010].  
 The mechanism by which CDS causes NFκB repression as the anti-inflammatory effect, 
is presently not fully clarified, yet likely different from that of ICSs, i.e., histone deacetylase 
(HDAC) recruitment to the site of active inflammatory gene transcription and subsequent 
inhibition of core histone acetylation as necessary for inflammatory gene transcription [Ito et al, 
2000]. This is primarily due to uncertainties associated with cellular disposition and signal 
interactions of CDS. CDS could directly act on TNFα and/or TNFα receptor (TNFR) outside the 
cells, scavenging to trigger their inflammatory cascades. Otherwise, CDS could directly affect 
intracellular inflammatory cascades following cellular internalization like CAME and CAPE. 
While this mechanistic clarification should be a subject of next pursuit, inactivated HDAC in 
emphysema and COPD, presumably caused by increased oxidative stress, has left a question as 
56 
 
to the anti-inflammatory activity of CDS under that condition. In fact, resistance or reduced 
response of ICSs in emphysema and COPD during chronic administration has been implicated 
with these impaired HDACs [Barnes, 2004]. Thus, it would be still important to prove the anti-
inflammatory activity of CDS in the emphysematous inflammation.    
 
3.4.3  CDS AS A NEUTROPHIL ELASTASE INHIBITOR  
Neutrophil elastase (NE) has been implicated in the pathogenesis of emphysema and 
COPD due to a variety of its actions, particularly towards lung tissue degradation [Ginzberg et 
al, 2001]. Such degradation occurs by this enzyme released from neutrophils in the lung lining 
fluid, and therefore, a simple in vitro NE-induced hydrolysis assay of a substrate like that 
developed in this study was relevant and sufficient to determine the anti-NE activity. As 
summarized in Table 3.2, CDS was found to be the most potent human NE inhibitor, yielding the 
IC50 value of 0.43 µM. Notably, sulfation led to a 6.6-fold increase in the anti-elastase activity. 
This sulfation effect appeared to be in line with a reduced anti-elastase activity of chemically 
modified heparin with fewer sulfate groups, compared to unmodified heparin [Spencer et al, 
2006]. The interaction between heparin and NE has been shown to be strongly electrostatic, 
which involved positively charged arginine residues on NE disposed in a ''cluster shoe'' 
arrangement on the surface of the enzyme with negatively charged sulfate groups of heparin 
[Redini et al, 1988]. As these positively charged “clamps” tightly bind the negatively charged 
sulfate groups of heparin, the intervening chain extends across the active site leading to its 
bridging between the two clamps, thereby sterically hindering the substrate binding [Baici et al, 
1993; Hornebeck et al, 1994; Volpi et al, 1996]. It seems likely that the inhibition of NE by CDS 
may result partly due to such electrostatic interactions. Intriguingly, the monomer CA was shown 
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to be ineffective by 100 µM, which differed from its reported weak inhibitory activity with the 
IC50 value of 93 µM [Löser et al, 2000]. However, it is clear that the anti-HNE activities of CD 
and CDS resulted from the repeated (5-13 units) structure rather than monomer unit. Among the 
sulfated DHPs, the rank order (from the most to least potent) was CDS>FDS>SDS, which was 
consistent with that of the inhibitory potencies to other serine proteases, thrombin and factor Xa, 
as described in Table 1.1 [Monien et al, 2006; Henry et al, 2007]. 
By now, many synthetic neutrophil elastase (NE) inhibitors have been discovered, which 
are broadly classified into three classes: peptide-based inhibitors, heterocyclic inhibitors and 
acylating/alkylating agents [Ohbayashi, 2002]. The peptide-based inhibitors require a short 
peptide sequence to interact with the enzyme, although their additional non-peptidic structures 
are also highly associated with the activity. In contrast, heterocyclic inhibitors inhibit the enzyme 
by covalent binding of their heterocyclic ring with the active site of the enzyme, whereas the 
acylating/alkylating agents owe their inhibitory activity to the presence of a highly reactive 
functional group which forms a stable and usually non-hydrolyzable covalent bond to the active 
site of the enzyme [Edwards & Bernstein; 1994]. Table 3.4 summarizes some of these synthetic 
small molecule NE inhibitors. It is unfortunate that, regardless of their potencies, all these NE 
inhibitors have shown limited and otherwise no success in clinical emphysema and COPD trials. 
This may be attributed to relatively rapid clearance of these inhibitors from the lungs, as similar 
observations were seen in the HNE-induced emphysema in animal models [Stone, 1990]. Hence, 
although CDS was less potent, compared to these molecules, with respect to the IC50 values, its 
high molecular weight of 3.3 kDa may provide rather potent efficacy in vivo by virtue of longer 
residence time in the lung. 
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 Interestingly, CDS exhibited inhibitory selectivity to HNE and HSE, with more potent 
activity to HSE, while failing to inhibit PPE (Figure 3.9). This can be explained, at least in part, 
by electrostatic interactions between the negatively charged CDS and positively charged 
enzymes. At a physiological pH, both HNE (PI > 10) and HSE (PI = 11) are highly positively 
charged [Sullivan et al, 2008], compared to PPE (PI = 8-8.5). Hence, CDS would have weaker 
electrostatic interactions with PPE, compared to HNE or HSE. Finally, this inhibitory activity of 
CDS was shown to be time-dependent, which likely suggested irreversible covalent binding as its 
mechanism [Waley, 1985]. 
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Ki [µM]
Table 3.4: In vitro half-maximal inhibitory concentration (IC50) and inhibitory constant (Ki)
for various neutrophil elastase inhibitors.
a. Sato et al, 2001; b. Bialecki, 1998; c. Veale et al, 1997; d. Mitsuhashi et al, 1999; e.
William et al, 1991b; f. Shinguh et al, 1997; g. Nakao et al, 1997; h. William et al, 1991a;
i. Miyazaki et al, 1998; j. Baici et al, 1990.
Molecule IC50 [µM]
MR 889j - 1.38
AE-3793a 0.19x10-2 0.32x10-4
TEI-8362d 0.72 1.38x10-3
ONO-5046i 0.44x10-1 0.20
ONO-6818g - 1.28x10-2
CE-1037b - 0.45x10-3
FK706f 0.83x10-1 0.42x10-2
ICI-200880h - 0.05x10-2
0.05x10-2ICI-200355h -
ICI-186756e - 0.36x10-2
ZD 8321c - 0.13x10-1
ZD 0892c - 0.67x10-3
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3.5 CONCLUSIONS 
 
Three in vitro methods were developed to assess the inhibitory activities of DHPs and the 
monomers to oxidative stress, lung inflammation and neutrophil elastase. The anti-oxidative 
activity of the test molecules was determined by chromogenic free radical generation from 
ABTS by metmyoglobin and H2O2. Initial oxidation rate of free radical generation was assessed 
at 5 min, monitored at 750 nm, and the AOC50 values were derived by nonlinear regression 
curve-fitting. Both DHPs and monomers exhibited anti-oxidative activities with CDS being the 
most potent with the AOC50 value of 3.52±0.14 µM. Indeed, CDS was more potent than a water 
soluble analogue of vitamin E, Trolox®. In contrast, the anti-inflammatory activity was 
determined via lung epithelial repression of TNFα-induced NFκB activation in Calu-3 human 
bronchial epithelial cells. TNFα induced an increased NFκB activity by 1.9-fold, relative to the 
transfection control. CDS was again shown to be the most potent, which repressed the 1.9-fold 
induced NFκB activity in a concentration-related manner between 1 and 50 µM. Finally, the anti-
elastase activity, specifically to HNE, was determined by enzymatic hydrolysis of its 
chromogenic substrate at 37° C. Initial rate of pNA production was assessed at 10 min, 
monitored at 405 nm, and the IC50 values were derived by nonlinear regression curve-fitting. All 
DHPs demonstrated potent HNE inhibition, with CDS, once again, being the most potent with 
the IC50 value of 0.43±0.04 µM. In addition, CDS inhibited HSE, but not PPE, while exhibiting 
time-dependent inhibition.  
In conclusion, these in vitro potency assessment studies have clearly demonstrated that 
the sulfated caffeic acid DHP, CDS was the most potent triple inhibitor of oxidation, lung 
epithelial inflammation and elastase over its unsulfated DHP, CD, and the sulfated DHPs of 
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other two cinnamic acids, FDS and SDS. CDS is a new chemical and non-peptidic 
macromolecular entity with a uniquely distinct pharmacophore, that exhibited, for the first time, 
potent triple inhibitory actions to the mechanisms suggested to be critically involved in the 
emphysema pathogenesis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
62 
 
CHAPTER 4 
 
 
TRIPLE INHIBITORY ACTIVITIES AND PREVENTION OF AIRSPACE 
ENLARGEMENT BY SULFATED CAFFEIC ACID DEHYDROPOLYMER 
IN THE EMPHYSEMA RAT MODEL FOLLOWING PULMONARY 
DELIVERY 
 
 
 
 
 
4.1. INTRODUCTION 
 
Novel cinnamic acid-based dehydropolymers (DHPs) originally synthesized as new and 
potent anti-coagulants were hypothesized to exert triple inhibitory activities to oxidative stress, 
inflammation and neutrophil elastase, the critical mechanisms believed to cause pulmonary 
emphysema. Accordingly, in Chapter 3, three in vitro potency assessment studies were carried 
out, successfully identifying the sulfated caffeic acid DHP, CDS, as the most potent triple 
inhibitor with the half-maximal effective concentrations of 3.51, ~10 and 0.40 µM, respectively. 
Because this 3.3 kDa non-peptidic macromolecule could potentially offer an additional 
advantage of longer lung residence without causing much of the systemic exposure, pulmonary 
delivery was a logically preferable route of administration to treat this lung disease. However, it 
was uncertain whether the triple inhibitory activities shown in vitro in Chapter 3 could be also 
seen in vivo, especially in the animal model of emphysema. More importantly, it also remained 
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uncertain if these triple inhibitory activities led to inhibition or reduction of the most relevant 
pathogenic manifestation of emphysema, airspace enlargement. Hence, this chapter was designed 
to test CDS in an in vivo rat model of experimental emphysema induced by a combination of 
human sputum elastase and cigarette smoke extract (HSE/CSE). It was aimed to establish 
protective effects of CDS with pulmonary delivery, against induced oxidative stress, 
inflammation, elastase activity, and importantly, airspace enlargement. The in vivo anti-oxidative 
activity was assessed by the lung tissue levels of reduced glutathione (rGSH), while the in vivo 
anti-inflammatory activity was assessed by inflammatory cell counts in the bronchoalveolar 
lavage fluid (BALF). The in vivo anti-elastase activity was assessed by the BALF elastase 
activity using a chromogenic substrate hydrolysis assay; the airway luminal hemorrhage was also 
assessed by the BALF absorbance at 541 nm. Lastly, the airspace enlargement was quantified by 
determination of mean linear intercept (MLI) of the alveolar airspaces.   
 
 
 
 
 
 
 
 
 
   
 
64 
 
4.2. MATERIALS AND METHODS 
 
4.2.1 MATERIALS 
CDS was obtained from Dr. Desai’s laboratory as a 5 mM phosphate-buffered saline 
(PBS) solution and stored at -20 °C prior to use. Human sputum elastase (HSE) was purchased 
from Elastin Products Company (Owensville, MO) as lyophilized powder certified to be 875 
U/mg protein with 100 % protein and > 95.0 % purity; these values were used to prepare HSE 
instillation solutions accurately from powder weight. The HSE stock solution was prepared at 
8750 U/ml (10 mg/ml) in 50 % glycerol and 50 % 0.02 M sodium acetate (NaOAc; pH 5) and 
stored in 50 µl aliquots at -20 °C, as recommended by the manufacturer for a stability reason. 
Research-grade cigarettes, 1R3F, were obtained from the Kentucky Tobacco Research and 
Development Center (University of Kentucky, Lexington, KY); this product had been 
characterized exhaustively for research use, e.g., total particulate and aerosol matter and contents 
of carbon monoxide, nitrogen oxides, nicotine and water in their brochure.  
 
4.2.2 ANIMALS 
This research adhered to the NIH Principles of Laboratory Animal Care (NIH publication 
#85-23, revised in 1985) under the protocol approved by the Institutional Animal Care and Use 
Committee at Virginia Commonwealth University (VCU; Protocol AM20086). Sprague-Dawley 
rats (male; specific-pathogen-free), 8-9 weeks of age, weighing 250-275 g, were received from 
Hilltop Lab Animals, Inc. (Scottsdale, PA) or Harlan Laboratories, Inc. (Indianapolis, IN). 
Animals were housed individually in the accredited animal care facility, where temperature (20-
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23° C), relative humidity (40-70 %) and light-dark cycling (12-12 h; the light cycle was between 
6 am and 6 pm) were tightly controlled. They were acclimatized for ≥ 3 days prior to use. 
 
4.2.3 EXPERIMENTAL PROTOCOL 
Figure 4.1 describes the overall experimental protocol to assess the in vivo protective 
effects of CDS administered to the lung in the rat model of pulmonary emphysema. A total of 60 
animals were divided into the following 4 groups: 1) the negative control (receiving PBS twice 
instead of CDS and HSE/CSE), 2) the positive control (receiving PBS instead of CDS, followed 
by HSE/CSE for emphysema induction), 3) the test of CDS at 5 µg/kg (receiving CDS at 5 
µg/kg, followed by HSE/CSE), and 4) the test of CDS at 30 µg/kg (receiving CDS at 30 µg/kg, 
followed by HSE/CSE). In some experiments, a group of animals were added to receive CDS at 
30 µg/kg, followed by PBS, in order to ensure unaltered biomarkers by CDS itself. On Day 1, 
PBS or CDS was first orotracheally instilled into the lung. At 2 h later, PBS or HSE/CSE was 
then orotracheally instilled into the lung in order to induce experimental pulmonary emphysema. 
The method of these orotracheal instillations is described in detail below. At 1 h (on Day 1), 48 h 
(on Day 3) or 28 days (on Day 29) following PBS or HSE/CSE instillation, animals were 
sacrificed under the pentobarbital anesthesia induced by an intraperitoneal injection at 50 mg/kg, 
in order to determine several lung markers in this experimental emphysema, as described in 
detail below.  
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4.2.4 HSE/CSE SOLUTION PREPARATION 
The CSE solution was freshly prepared in each experiment by bubbling mainstream 
smoke from one 1R3F into 3 ml of cold PBS under ice at a rate of 1 cigarette/8-9 min using a 
smoke machine kindly provided from Dr. Chu of the Hunter Holmes McGuire Richmond VA 
Medical Center. Subsequently, 0.05 ml of the HSE stock solution (8750 U/ml; 10 mg/ml) 
prepared above was added to 0.825 ml of the CSE solution to prepare the HSE/CSE instillation 
solution under ice prior to instillation. 
 
4.2.5 OROTRACHEAL PULMONARY INSTILLATION 
Each of the CDS (or PBS) and HSE/CSE (or PBS) solutions was administered to the lung 
by orotracheal instillation under the short anesthesia of isoflurane (Webster Veterinary Supply, 
Inc., Sterling, MA). Each rat was anesthetized in a chamber box with 4 % (v/v) isoflurane vapors 
generated from a vaporizer (Ohmeda Tech 4 Surgivet®, Smiths Medical North America, 
Waukesha, WN) in 95 % oxygen and 5 % air as a carrier gas (National Welders, Richmond, VA) 
at 3.5 l/min. Sufficient depth of anesthesia was typically attained in 5 min, ensured by the 
absence of corneal and pedal reflexes. Subsequently, the animal was placed in a supine position 
on a surgical board inclined at 60° under the heat lamp. The tracheal entry lumen was visually 
confirmed through the oral cavity using a small animal fiber-optic laryngoscope (Welch Allyn, 
Skaneateles Falls, NY), and then, 0.1 ml of CDS at 5 or 30 µg/kg body weight or PBS was 
directly instilled into the lung using a PennCentury Microsprayer (Wyndmoor, PA); the tip of the 
Microsprayer was positioned just before the tracheal bifurcation. The animals were held in an 
upright position for 1 min to avoid cough reflexes before returning to the cages. The entire 
instillation operation was typically completed within 6 min of the isoflurane anesthesia, after 
which the animals regained consciousness in 4 min. At 2 h following this CDS or PBS 
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instillation, animals were again anesthetized with isoflurane, and subjected to the similar 
procedure for 0.2 ml instillation of HSE/CSE or PBS to the lungs using the PennCentury 
Microsprayer for emphysema induction. Upon complete recovery from the anesthesia, e.g., in 4 
min following instillation, the animals were returned to the animal care facility. 
 
4.2.6 IN VIVO ANTI-OXIDATIVE ACTIVITY: LUNG TISSUE GSH AND GSSG  
Each group was comprised of 5 animals. At 1 h following HSE/CSE or PBS instillation, 
each rat was anesthetized with an intraperitoneal injection of 50 mg/kg sodium pentobarbital 
(Ovation Pharmaceuticals, Inc., Deerfield, IL). The trachea was exposed and cannulated through 
an incision made in the trachea; a tight ligature secured its position. The chest cavity was opened, 
and the pulmonary circulation was then perfused with 30-40 ml of saline at 15 ml/min 
(Masterflex Pump Systems, Vernon Hills, IL) for blood removal. The bronchoalveolar lavage 
(BAL) was performed for the whole lung with 8 ml of ice-cold saline repeatedly washing the 
lung lumen for 3 times; the volume of ~6 ml was typically recovered. The lung tissue was 
immediately removed from the body, washed and cleaned with distilled deionized water (DDW). 
It was then divided into two parts, each of which was weighed. One part was used to determine 
the GSH and GSSG levels as described below, while the other part was frozen at -70 °C for 
future analysis. 
The lung tissue levels of GSG and GSSG were determined by the method developed by 
Rahman et al [2007]. Immediately following removal, the weighed lung tissue was homogenized 
with a 10 times volume of ice-cold 5 % sulfosalicylic acid (SSA, Sigma-Aldrich) using a tissue 
homogenizer (Biospec Products Inc., Bartlesville, OK). The homogenate was centrifuged at 3500 
rpm for 10 min at 25 oC (Marathon®, Fisher Scientific, Pittsburg, PA), and 1 ml of the 
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supernatant was then diluted with 9 ml of the KPE buffer comprised of 0.1 M potassium 
phosphate buffer and 5 mM ethylene diamine tetraacetic acid (EDTA, Sigma-Aldrich) as the 
total GSH (tGSH) samples. Separately, for GSSG determination, 0.1 ml of the supernatant was 
first mixed with 0.002 ml of 2-vinyl pyridine (2-VP, Sigma-Aldrich) for derivatization of 
reduced GSH (rGSH) and left for 1 h at room temperature to complete the reaction. The 
unreacted excess 2-VP was then neutralized by adding 0.006 ml of triethanolamine (TE, Sigma-
Aldrich); the solution was mixed thoroughly by vortexing and then, allowed to stand for 10 min 
at room temperature to complete the neutralization, i.e., the GSSG samples. In a 96-well plate, 
0.02 ml of the tGSH and GSSG samples alongside their standards at 26.4, 13.2, 6.6, 3.3 and 1.65 
nmoles/ml in the KPE buffer (and the blank KPE buffer) were added to each well. Subsequently, 
0.12 ml of freshly prepared 1:1 mixture of 1.7 mM 5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB; 
Ellman’s reagent, Sigma-Aldrich) and 3.3 mU/ml glutathione reductase enzyme (GR, Sigma-
Aldrich) was further added to the wells. At 30 s following DTNB/GR addition, 0.06 ml of 0.8 
mM β-nicotinamide adenine dinucleotide 2′-phosphate (βNADPH, Sigma-Aldrich) was added, 
and the absorbance at 412 nm was determined every 35 s for 3 min using the microplate reader 
(SynergyTM 2). The rates of the absorbance increase (i.e., absorbance/min) due to formation of 2-
nitro-5-benzoic acid (TNB) were calculated from the linear portions of the absorbance vs. time 
profiles. The tGSH and GSSG concentrations in each sample was multiplied by the volumes, i.e., 
10X SSA volume and SSA volume, respectively, to convert to the tGSH and GSSG amounts, 
which were further normalized by the sample tissue weight to be expressed as nmoles/g lung 
tissue. The rGSH amounts were then calculated using the following equation:  
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rGSH = tGSH – [2 x GSSG] 
 
4.2.7 IN VIVO ANTI-INFLAMMATORY ACTIVITY: AIRWAY NEUTROPHIL 
INFILTRATION 
Each group was comprised of 5 animals. At 48 h following HSE/CSE or PBS instillation, 
each rat anesthetized with an intraperitoneal injection of 50 mg/kg sodium pentobarbital was 
subjected to the BAL, as described above. While 0.5 ml of the BAL fluid (BALF) was taken for 
determination of lung hemorrhage, as described in section 4.2.9, the rest of the BALF was 
centrifuged at 3,500 rpm for 5 min at 4 ºC. The supernatant was separated for determination of 
the airway luminal elastase activity, as described in section 4.2.8. Meanwhile, the cell pellets 
were resuspended in 1 ml of ice-cold saline, and their aliquots (0.04 ml) were used to determine 
the total cell count using a hemocytometer (Fisher Scientific). The differential cell count of 
neutrophils, macrophages and other cells was performed under the microscope with the BALF 
cell smears prepared from cytocentrifuge of 0.1 ml of 0.4 x 106 cell suspensions at 1500 rpm for 
2 min (Thermo Electron Corporation, Waltham, MA), followed by slide fixation with a few 
drops of 100 % methanol for 2 min and Wright stain (EMD Chemicals, Gibbstown, NJ) in a 
coplin jar for 5 min. The excess stain was rinsed by dipping the slides in tap water 5-6 times, and 
the slides were thoroughly air-dried. A drop of cytoseal mounting media (Thermo Scientific) was 
applied on each of the cell smears placed with cover-slips. The transparent nail polish was finally 
applied around the cover-slips for air-tight seal. Using a BX40 microscope (Olympus Imaging 
America Inc., Center Valley, PA) under a magnification of 10X, a total of 300 cells were counted 
to determine the fractions of neutrophils, macrophages and other cells. These fraction values 
were used with the total cell counts to calculate the absolute number of each cell type. 
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4.2.8 IN VIVO ANTI-ELASTASE ACTIVITY: AIRWAY LUMINAL ELASTASE  
The BALF supernatant taken at 48 h following HSE/CSE or PBS instillation, as 
described in section 4.2.7, was used to determine the airway luminal elastase activity by the 
substrate hydrolysis assay in a 96-well plate format. The solution of a substrate, N-
benzyloxycarbonyl-Ala-Pro-norvaline p-choloro thiobenzyl ester (Boc-Ala-Pro-Nva-SBzl(Cl), 
Bachem, Torrance, CA) was first prepared at 10 mg/ml in DMSO as a stock solution; it was 
stored in 25 µl aliquots at -20° C, as recommended by the manufacturer for a 6 month stable 
storage. In each assay, the substrate stock solution was thawed and diluted to 0.5 mg/ml with the 
assay buffer, 0.1 M N-(2-hydroxyethyl)piperazine-N'-2-ethanesulfonic acid (HEPES, Fisher 
Scientific) buffer (pH 7.5) containing 0.5 M sodium hydrochloride (NaCl, Fisher Scientific); 
complete substrate dissolution was ensured via vortexing. In each well, 0.05 ml of this 0.5 mg/ml 
substrate solution was pre-equilibrated with 0.05 ml of the assay buffer, followed by addition of 
0.05 ml of the BALF samples. The hydrolytic reaction was then initiated by addition of 0.05 ml 
of 0.143 mg/ml DTNB, which resulted in TNB generation upon reaction of p-chlorothiobenzyl 
group released from the substrate with the enzymes in the BALF samples. Such a TNB 
production was monitored at 412 nm using the microplate reader (SynergyTM 2) for 60 min. The 
blank samples (without the substrate) were also determined for each BALF sample to correct for 
their non-specific absorbance. The absorbance increase (∆Abs) at 60 min was used to represent 
the airway luminal elastase activity.  
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4.2.9 IN VIVO LUNG HEMORRHAGE  
The BALF supernatant taken at 48 h following HSE/CSE or PBS instillation, as 
described in section 4.2.7, was used to determine the lung hemorrhage by the method described 
by Shinguh et al [1999]. In a 96-well plate, 0.25 ml of the BALF samples were added to each 
well, and their absorbance at 541 nm was measured using the microplate reader (SynergyTM 2). 
The absorbance values were directly used as a measure of lung hemorrhage, which represented 
the hemoglobin content of the BALF samples.  
 
4.2.10 AIRSPACE ENLARGEMENT 
Each group was comprised of 5 animals. At 28 days following HSE/CSE or PBS 
instillation, each rat was anesthetized with an intraperitoneal injection of 50 mg/kg sodium 
pentobarbital. Its trachea was exposed and cannulated through an incision made on the trachea. 
After the chest cavity was opened, the animal was sacrificed by cutting the abdominal aorta. The 
lung was carefully removed from the body and then, inflated with 0.5 % agarose solution at 45° 
C, introduced through the tracheal cannula at a pressure of 20 cm H2O. This 0.5 % agarose 
solution was prepared by slowly adding agarose (Invitrogen, Carlsbad, CA) into warm DDW in a 
beaker on a magnetic hotplate stirrer; its complete dissolution was ensured. The fully inflated 
lungs were placed on ice for ≥ 5 min to solidify the luminal agarose, followed by fixation in 10 
% buffered formalin (Fisher Scientific) at 4 oC for 24 h. The fixed lung tissues were sent to the 
VCU Anatomical Pathology Laboratory for their paraffin block preparations, followed by 
hematoxylin-eosin (HE) staining of their 4 µm-thick sections.  
The airspace enlargement was quantified with the MLI values determined with the lung 
sections, according to the method originally described by Robbesom et al [2003] with slight 
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modifications. Each slide was coded, yet measured in a random order. In each lung section, 3 
microscopic field images (3450 µm x 2585 µm) under 25X magnification were randomly 
selected, photographed using the Axiovision software (Allied High Tech Products, Rancho 
Dominguez, CA) and printed out on a letter size paper. A transparent sheet with horizontal lines 
drawn with 4 cm intervals was placed on the printed images, where the intercepts of the alveolar 
walls with each of 5 horizontal lines were counted manually. Thus, in each of the field images, 5 
MLI values were obtained by dividing the horizontal length of the image (3450 µm) by the 
number of the alveolar wall intercepts. A total of 15 MLI values from 3 field images were 
obtained in each animal, and the mean value was used to represent such an animal. 
 
4.2.11 DATA ANALYSIS 
All the data for each of the treatment groups were expressed as mean ± standard error 
(SE). Individual values were used for testing statistical difference using analyses of variance 
(ANOVA). In the event of significant difference in the ANOVA, the Tukey-Kramer multiple 
comparison test was carried out to identify the groups showing the statistical differences. In both 
ANOVA and Tukey-Kramer multiple comparison test, p<0.05 was considered to be significant. 
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4.3 RESULTS 
 
All animals appeared to tolerate CDS administered to the lung by 30 µg/kg, evidenced by 
no abnormality in appearance, posture, mobility, appetite and body weight gain during the study 
period. All animals also survived from the HSE/CSE instillation during the study periods, even 
though several emphysematous features were observed, as described in detail below.  
 
4.3.1 IN VIVO ANTI-OXIDATIVE STRESS: LUNG TISSUE GSH AND GSSG  
Figure 4.2 shows the lung tissue levels of tGSH, GSSG and rGSH in nmoles/g lung tissue 
at 1 h following HSE/CSE or PBS instillation in different treatment groups. These are also 
shown in Table 4.1 alongside % inhibition relative to the induced changes in the tGSH and rGSH 
levels (the differences between the negative and positive controls). In the negative control 
animals who received PBS twice, the tGSH, GSSG and rGSH levels in the lung tissues were 
944.8±34.5, 213.7±22.5 and 517.4±29.6 nmoles/g lung tissue, respectively. However, in the 
positive control animals who received no CDS, the HSE/CSE instillation was shown to decrease 
the tGSH level significantly by 25.3±2.8 % (i.e., 705.8±30.0 nmoles/g lung tissue) and the rGSH 
level by 43.0±3.3 % (i.e., 294.8±19.1 nmoles/g lung tissue). This decreased rGSH level 
suggested the elevated oxidative stress in the lung tissues by the HSE/CSE instillation, while the 
GSSG level remained unaltered, presumably due to negligible direct oxidation from rGSH to 
GSSG; in turn, this speculated rGSH oxidation to GSH-conjugate, as discussed later in this 
chapter. When CDS at 5 µg/kg was administered to the lung at 2 h before the HSE/CSE 
instillation, the induced decrease in the rGSH level was significantly prevented by 87.0±3.8 % 
(p<0.05; Figure 4.2; Table 4.1), even though the decrease in the tGSH levels was statistically 
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insignificant. In contrast, CDS at the higher dose of 30 µg/kg was capable of preventing such 
decreases in both the tGSH and rGSH levels by 78.5±3.7 and 92.9±2.5 % (p<0.05), respectively, 
resulting in near normal 893.3±34.4 and 501.5±23.5 nmoles/g lung tissue, respectively. It was 
clear therefore that CDS at 30 µg/kg was effective with its pulmonary delivery in this 
emphysema model, exhibiting in vivo tissue anti-oxidative stress activity.  
  
76 
 
 
 
 
 
 
 
 
 
 
0
200
400
600
800
1000
PBS+PBS
PBS+HSE/CSE
5 µg/kg CDS+HSE/CSE
30 µg/kg CDS+HSE/CSE
n
m
o
le
s
/g
 L
u
n
g
 T
is
s
u
e
Figure 4.2: Total GSH (tGSH), GSSG and reduced GSH (rGSH) levels in the lung
tissues taken at 1 h following instillation of phosphate-buffered saline (PBS) or human
sputum elastase (HSE)/cigarette smoke extract (CSE) in the rat model of emphysema in
different treatment groups. At 2 h prior to the HSE/CSE instillation, PBS or CDS at 5 or
30 µg/kg was instilled to the lung. Data represent mean±standard error (SE) from n=5.
*p<0.05, compared to the negative control where PBS was administered twice instead of
CDS and HSE/CSE, #p<0.05, compared to the positive control where PBS was
administered instead of CDS, followed by HSE/CSE instillation.
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4.3.2 IN VIVO ANTI-INFLAMMATION: AIRWAY NEUTROPHIL INFILTRATION 
Figure 4.3 shows the total and differential cell counts in the BALF at 48 h following 
HSE/CSE or PBS instillation in different treatment groups; these are also summarized in Table 
4.2. In the negative control animals, the total BALF cell count was 76.4±4.2 x 104 cells, which 
was dominantly comprised of macrophages by 98.2 % along with 1.1 % of neutrophils. CDS at 
30 µg/kg alone (without HSE/CSE instillation) was confirmed to have insignificant effect on 
these total and differential cell counts in BALF (p>0.05). In contrast, in the positive control 
animals, the HSE/CSE instillation caused a significant increase in the total cell counts by 2.9-
fold (p<0.05), primarily due to 104.8-fold increase of neutrophils, in addition to 1.8-fold increase 
of macrophages. This demonstrated successful development of neutrophilic inflammation in the 
lung, relevant to emphysema pathogenic features [Kuraki et al, 2002]. When CDS at 5 µg/kg 
was administered to the lung at 2 h before the HSE/CSE instillation, these increased total and 
differential cell counts were effectively unaltered (Figure 4.3; Table 4.2). However, CDS at the 
higher dose of 30 µg/kg was capable of preventing the HSE/CSE-induced airway luminal cell 
infiltration significantly, specifically in the neutrophil counts by 76.6±6.9 % (p<0.05); the 
decrease in the BALF macrophage counts by 47.4 % was also significant. It was clear therefore 
that CDS at 30 µg/kg was effective with its pulmonary delivery in this emphysema model, 
exhibiting in vivo anti-inflammatory activity against the airway luminal neutrophilia caused by 
the HSE/CSE instillation. 
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Figure 4.3: Total and differential cell counts in the bronchoalveolar lavage fluid (BALF)
taken at 48 h following instillation of phosphate buffered-saline (PBS) or human sputum
elastase (HSE)/cigarette smoke extract (CSE) in the rat model of emphysema in
different treatment groups. At 2 h prior to the HSE/CSE instillation, PBS or CDS at 5 or
30 µg/kg was instilled to the lung. Data represent mean±standard error (SE) from n=5.
*p<0.05, compared to the negative control where PBS was administered twice instead of
CDS and HSE/CSE, #p<0.05, compared to the positive control where PBS was
administered instead of CDS, followed by HSE/CSE instillation.
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4.3.3 IN VIVO ANTI-ELASTASE: AIRWAY LUMINAL ELASTASE ACTIVITY 
Figure 4.4 shows the time-course profiles of the absorbance increase (∆Abs) at 412 nm 
representing the elastase activity in the BALF samples taken at 48 h following PBS and 
HSE/CSE instillation in the negative and positive control animals (without CDS), respectively. 
All of the time-course profiles including those testing the CDS effects reached asymptotes within 
30 min, suggesting that the hydrolytic reaction was kinetically limited by the airway luminal 
elastase (enzyme activity) rather than the substrate. Accordingly, the asymptotic ∆Abs value at 
60 min was used to represent the elastase activity in each of the BALF samples in order to assess 
the airway luminal anti-elastase activity of CDS, as shown in Figure 4.5 and in Table 4.3. 
Despite relatively large variability within groups, the HSE/CSE instillation caused a significantly 
higher 2.8-fold ∆Abs value at 60 min in the positive control, compared to the negative control 
(p<0.05; 0.11±0.01 and 0.04±0.01, respectively). This clearly demonstrated that HSE/CSE 
induced elevated airway luminal elastase activity at 48 h in this animal model. In contrast, CDS 
at 5 and 30 µg/kg, when administered to the lung at 2 h before the HSE/CSE instillation, was 
able to prevent such an increase of the luminal elastase activity significantly by 50.3±3.9 and 
59.7±5.4 %, respectively (Figure 4.5; Table 4.3). Hence, it was clearly suggested that CDS at 30 
µg/kg was effective with its pulmonary delivery in this emphysema model, exhibiting the in vivo 
airway luminal anti-elastase activity.  It should be noted that, as shown in Figure 4.5, CDS at 30 
µg/kg alone did not alter the elastase activity in the airways.  
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Figure 4.4: Time-course profiles of the absorbance increase (∆Abs) at 412 nm
representing the elastase activity of the BALF taken at 48 h following instillation of
phosphate buffered-saline (PBS) and human sputum elastase (HSE)/cigarette smoke
extract (CSE) in the rat model of emphysema in the negative and positive control
animals, respectively. Data represent mean±standard error (SE) from n=5.
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Figure 4.5: Airway luminal elastase activity represented by ∆Abs at 60 min in the
bronchoalveolar lavage fluid (BALF) taken at 48 h following instillation of phosphate
buffered-saline (PBS) or human sputum elastase (HSE)/cigarette smoke extract (CSE)
in the rat model of emphysema in different treatment groups. At 2 h prior to the
HSE/CSE instillation, PBS or CDS at 5 or 30 µg/kg was instilled to the lung. Data
represent mean±standard error (SE) from n=5. *p<0.05, compared to the negative
control where PBS was administered twice instead of CDS and HSE/CSE, #p<0.05,
compared to the positive control where PBS was administered instead of CDS, followed
by HSE/CSE instillation.
*
# #
84 
 
 
 
 N
e
g
a
ti
v
e
 C
o
n
tr
o
l
T
re
a
tm
e
n
t
In
d
u
c
ti
o
n
B
A
L
F
 E
la
s
ta
s
e
A
c
ti
v
it
y
P
B
S
P
B
S
H
S
E
/C
S
E
H
S
E
/C
S
E
P
o
s
it
iv
e
 C
o
n
tr
o
l
T
e
s
t-
C
D
S
T
e
s
t-
C
D
S
P
B
S
C
D
S
 (
5
 µ
g
/k
g
)
C
D
S
 (
3
0
 µ
g
/k
g
)
H
S
E
/C
S
E
- -
G
ro
u
p
T
a
b
le
4
.3
:
A
ir
w
a
y
lu
m
in
a
l
e
la
s
ta
s
e
a
c
ti
v
it
y
re
p
re
s
e
n
te
d
a
s
∆
A
b
s
a
t
6
0
m
in
in
th
e
b
ro
n
c
h
o
a
lv
e
o
la
r
la
v
a
g
e
fl
u
id
(B
A
L
F
)
ta
k
e
n
a
t
4
8
h
fo
ll
o
w
in
g
in
s
ti
ll
a
ti
o
n
o
f
p
h
o
s
p
h
a
te
-
b
u
ff
e
re
d
s
a
lin
e
(P
B
S
)
o
r
h
u
m
a
n
s
p
u
tu
m
e
la
s
ta
s
e
(H
S
E
)/
c
ig
a
re
tt
e
s
m
o
k
e
e
x
tr
a
c
t
(C
S
E
)
in
th
e
ra
t
m
o
d
e
l
o
f
e
m
p
h
y
s
e
m
a
in
d
if
fe
re
n
t
tr
e
a
tm
e
n
t
g
ro
u
p
s
,
a
lo
n
g
s
id
e
%
in
h
ib
it
io
n
o
f
th
e
H
S
E
/C
S
E
-i
n
d
u
c
e
d
e
la
s
ta
s
e
a
c
ti
v
it
y
b
y
th
e
s
u
lf
a
te
d
c
a
ff
e
ic
a
c
id
D
H
P
,
C
D
S
.
%
 I
n
h
ib
it
io
n
 w
rt
p
o
s
it
iv
e
 c
o
n
tr
o
l
B
A
L
F
e
la
s
ta
s
e
a
c
ti
v
it
y
:
∆
A
b
s
o
rb
a
n
c
e
a
t
4
1
2
n
m
b
y
6
0
m
in
in
th
e
c
h
ro
m
o
g
e
n
ic
s
u
b
s
tr
a
te
h
y
d
ro
ly
s
is
a
s
s
a
y.
D
a
ta
re
p
re
s
e
n
t
m
e
a
n
±
s
ta
n
d
a
rd
e
rr
o
r
(S
E
)
fr
o
m
n
=
5
.
*p
<
0
.0
5
fr
o
m
th
e
n
e
g
a
ti
v
e
c
o
n
tr
o
l;
**
p
<
0
.0
5
fr
o
m
th
e
p
o
s
it
iv
e
c
o
n
tr
o
l.
* *
*
*
*
*
*
*
*
0
.0
4
±
0
.0
1
0
.1
1
±
0
.0
1
0
.0
7
±
0
.0
1
0
.0
8
±
0
.0
1
5
0
.3
±
3
.9
5
9
.7
±
5
.4
85 
 
4.3.4 LUNG HEMORRHAGE 
Figure 4.6 shows the lung hemorrhage represented by the absorbance at 541 nm for the 
BALF samples taken at 48 h following HSE/CSE or PBS instillation in different treatment 
groups; these are also summarized in Table 4.4. In the negative control animals, the BALF 
absorbance was effectively negligible 0.007±0.003, which remained unaltered by CDS 
administered alone at 30 µg/kg (without HSE/CSE instillation). However, the HSE/CSE 
instillation caused significant lung hemorrhage, resulting in a 9.3-fold ∆Abs increase in the 
BALF (0.065±0.014), compared to the negative control animals (p<0.05). Notably, this induced 
lung hemorrhage was significantly prevented by CDS at both 5 and 30 µg/kg, when administered 
at 2 h before the HSE/CSE instillation. In fact, the effects appeared to be dose-dependent, 
exhibiting 59.9±7.4 and 70.4±10.0 % inhibitions, respectively (p<0.05; Table 4.4). It was clear 
therefore that CDS at both 5 and 30 µg/kg was effective with its pulmonary delivery in this 
emphysema model to protect from this initial lung hemorrhage caused by the HSE/CSE 
instillation. 
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Figure 4.6: The absorbance at 541 nm representing lung hemorrhage in the
bronchoalveolar lavage fluid (BALF) taken at 48 h following instillation of phosphate
buffered-saline (PBS) or human sputum elastase (HSE)/cigarette smoke extract (CSE)
in the rat model of emphysema in different treatment groups. At 2 h prior to the
HSE/CSE instillation, PBS or CDS at 5 or 30 µg/kg was instilled to the lung. Data
represent mean±standard error (SE) from n=5. *p<0.05, compared to the negative
control where PBS was administered twice instead of CDS and HSE/CSE, #p<0.05,
compared to the positive control where PBS was administered instead of CDS, followed
by HSE/CSE instillation.
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4.3.5 PREVENTION OF THE AIRSPACE ENLARGEMENT 
Figure 4.7 shows the representative histological hematoxylin-eosin (HE)-stained 
micrographs of the left lung lobes taken on 28 days following HSE/CSE or PBS instillation in 
different treatment groups. The mean linear intercept (MLI) values for the alveolar airspace were 
determined from this type of micrographs and are thus shown in Figure 4.8. Compared to the 
negative control animals, the absence of the alveolar walls was visually apparent in the positive 
control animals, demonstrating substantial airspace enlargement caused by the HSE/CSE 
instillation. This HSE/CSE-induced airspace enlargement was quantified by a significant 1.5-fold 
increase in the MLI value (p<0.05; 53.0±1.4 → 79.1±1.9 µm), as shown in Figure 4.8. 
Unfortunately, the absence of the alveolar walls appeared to continue in the animals receiving 
CDS at 5 µg/kg at 2 h before the HSE/CSE instillation. Indeed, the MLI value was 85.5±2.7 µm, 
almost comparable to 79.1±1.9 µm seen in the positive control animals. In contrast, CDS at the 
higher dose of 30 µg/kg was shown to yield the near normal MLI value of 53.8±1.3 µm, being 
equivalent to the negative control. Hence, it was clear that CDS at 30 µg/kg was effective with 
its pulmonary delivery in this emphysema model to protect from the airspace enlargement caused 
by the HSE/CSE instillation. 
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Figure 4.7: Representative histological hematoxylin-eosin (HE)-stained micrographs of
the left lung lobes taken on 28 days following instillation of phosphate buffered-saline
(PBS) or human sputum elastase (HSE)/cigarette smoke extract (CSE) in the rat model
of emphysema in different treatment groups (25 X magnification).
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Figure 4.8: Mean linear intercept (MLI) values determined from the left lung lobes taken
on 28 days following instillation of phosphate buffered-saline (PBS) or human sputum
elastase (HSE)/cigarette smoke extract (CSE) in the rat model of emphysema in
different treatment groups. At 2 h prior to the HSE/CSE instillation, PBS or CDS at 5 or
30 µg/kg was instilled to the lung. Data represent mean±standard error (SE) from n=5.
*p<0.05, compared to the negative control where PBS was administered twice instead of
CDS and HSE/CSE, #p<0.05, compared to the positive control where PBS was
administered instead of CDS, followed by HSE/CSE instillation.
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4.4 DISCUSSION 
 
The in vivo animal studies of pulmonary emphysema in this chapter have successfully 
demonstrated that the sulfated caffeic acid DHP, CDS exerted significant triple inhibitory actions 
to lung tissue oxidative stress, inflammation and neutrophil elastase following 30 µg/kg 
pulmonary administration, thereby protecting from the airspace enlargement. The major findings 
in response to CDS at 30 µg/kg were as follows: (1) HSE/CSE-induced lung tissue rGSH 
decrease was prevented by 92.9±2.5 %; (2) HSE/CSE-induced airway infiltration of 
inflammatory neutrophils was prevented by 76.6±6.9 %; (3) HSE/CSE-induced elevation of 
airway luminal elastase activity was prevented by 59.7±5.4 %; (4) HSE/CSE-induced airway 
luminal hemorrhage was prevented by 70.4±10.0 %; and (5) HSE/CSE-induced airspace 
enlargement was prevented by 97.0±2.4 %. All of these preventive effects were statistically 
significant (p<0.05), yet obtained at different times, i.e., 1 or 48 h or 28 days, following 
HSE/CSE instillation. These different times were chosen through preliminary studies to best 
demonstrate each of the biomarker inductions by the HSE/CSE instillation.   
 
4.4.1. HSE/CSE-INDUCED EXPERIMENTAL PULMONARY EMPHYSEMA 
Two approaches have generally been taken to induce pulmonary emphysema in rats; 
chronic cigarette smoke exposure and single pulmonary instillation of the tissue-degrading 
enzyme, elastase [Janoff et al, 1977; Caverra et al, 2001a; Caverra et al, 2001b]. Among them, 
the use of chronic cigarette smoke exposure should be more relevant, but has been less popular, 
primarily as it requires special experimental (smoke generator and exposure) systems and more 
inconveniently, a long period of repeated exposure. Single exposure was shown to cause 
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pulmonary oxidative stress and inflammation for a short period, yet the airway neutrophilia and 
airspace enlargement were hardly induced [Caverra et al, 2001a; Caverra et al, 2001b]. As a 
result, repeated and chronic exposure becomes essential, and in fact, 5-6 months are required for 
developing the airspace enlargement [Churg et al, 2003a; Churg et al, 2003b; Churg et al, 2008; 
Fox & Fitzgerald, 2009]. In contrast, since the first finding in 1965 [Gross et al, 1965], single 
pulmonary instillation of the tissue degrading enzyme, elastase, has been used extensively as an 
experimental emphysema model. It initially leads to severe lung inflammation, thereby recruiting 
neutrophils into the airways, followed by significant alveolar wall loss and airspace enlargement 
[Janoff et al, 1977]. Intriguingly, this elastase-induced inflammation appears to be resistant to 
corticosteroid treatment, similar to some cases of human emphysema [Birell et al, 2005]. 
However, its pathogenic development is much rapid in response to this single insult, which is 
quite different from most of the human cases. Besides, it is primarily triggered by elastolytic 
burden, and therefore, oxidative stress may have played a minor or insignificant role in this 
animal model, unlike human emphysema which is mostly associated with chronic cigarette 
smoking; note that, cigarette smoke does not contain elastolytic burden but probably induces 
endogenous counterpart [Smith et al, 1988]. Due to this reason, this study employed CSE 
combined with HSE in order to assess the anti-oxidative effects of CDS, as identified in vitro in 
Chapter 3.  
At 1 h following HSE/CSE instillation, the lung tissue levels of tGSH and rGSH were 
both significantly decreased by 25.3±2.8 and 43.0±3.3 % (p<0.05), whereas the GSSG levels 
remained unchanged, compared to the negative control (Figure 4.2; Table 4.1). This implied that 
more general oxidative response of rGSH conversion to GSSG did not take place by this 
HSE/CSE instillation. Correspondingly, in vitro and in vivo lung cell studies in the literature 
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have demonstrated that cigarette smoke condensate caused dose- and time-dependent depletion 
of intracellular GSH without altering the GSSG levels [Rahman et al, 1995a; Rahman et al, 
1995b]. In turn, this can be explained by the formation of GSH-conjugate through reaction of 
electrophiles contained in the cigarette smoke, namely β-carbonyls, with highly reactive thiol of 
rGSH [Rahman et al, 1995a, van der Toorn et al, 2007]. Hence, such GSH-conjugate formation 
by cigarette smoke was tested in a satellite study, where tGSH and rGSH were determined at a 
150 nmoles/ml solution in PBS following direct bubbling of air or cigarette smoke. As shown in 
Figure 4.9, the cigarette smoke-bubbling resulted in under-estimation of both the tGSH and 
rGSH levels by 21.0±0.3 and 19.6±0.3 % (p<0.05), respectively, while the GSSG levels 
remained consistent, compared to the air-bubbling. This confirmed the GSH-conjugate formation 
as a result of oxidative stress caused by the HSE/CSE instillation in this animal model. 
Meanwhile, the HSE/CSE instillation also led to significant 2.9-fold (p<0.05) greater 
inflammatory cell infiltration into the lung at 48 h, which was predominantly by airway 
neutrophilia, i.e., 104.8-fold increase in the BALF neutrophils, compared to the negative control 
(Figure 4.3; Table 4.2). In addition, the BALF elastase activity at 48 h was also significantly 
elevated by 2.8-fold (p<0.05) post-HSE/CSE instillation (Figure 4.5; Table 4.3). This elevated 
elastase activity was likely due to increased appearance of endogenous elastase, rather than 
exogenously instilled HSE, as the latter was reported to be cleared by 48 h from the lung with a 
half-life of only 45 min [Stone et al, 1988]. The HSE/CSE instillation also led to a significant 
9.3-fold (p<0.05) increase in the lung hemorrhage by 48 h, compared to the negative control 
(Figure 4.6; Table 4.4). Lastly, the HSE/CSE instillation caused significant airspace enlargement 
by 28 days, quantified as a 1.5-fold increase (p<0.05) in the MLI value. All of these were 
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considered to be the relevant pathogenic biomarker changes, given the current mechanistic 
implications associated with pulmonary emphysema, e.g., Figure 1.1. 
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Figure 4.9: Total GSH (tGSH), GSSG and reduced GSH (rGSH) levels in a 150
mmoles/ml solution of GSH in phosphate-buffered saline (PBS) after bubbling of air or
cigarette smoke (CS) from one 1R3F cigarette generated with a smoking machine. The
tGSH, GSSG and rGSH levels were determined, as described in section 4.2.6. Data
represent mean±standard deviation (SD) from n=3. *p<0.05, compared to the air
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4.4.2.  CDS AS A TRIPLE INHIBITOR DRUG 
Pulmonary delivery of CDS was able to inhibit the HSE/CSE-induced oxidative stress in 
a dose-dependent manner, measured with the tissue rGSH levels. CDS at 30 µg/kg, but not at 5 
µg/kg, was shown to inhibit the decrease in the tissue rGSH level by 92.9 % (Figure 4.2; Table 
4.1). This near complete tissue anti-oxidative action at 30 µg/kg was remarkably potent, 
compared to other anti-oxidant molecules. The anti-oxidants, N-acetylcysteine (NAC) and 
silymarin, respectively, caused 93.8 and 81.3 % inhibitions to the decreased GSH levels, yet at 
much greater oral doses of 150 and 50 mg/kg [Bridgeman et al, 1991; Toklu et al, 2008]. A red 
wine-derived anti-oxidant, resveratrol, also caused similar 87.5 % inhibition to the decreased 
GSH levels, yet as a result of 14-day oral administration at 10 mg/kg/day [Sener et al, 2007]. As 
their in vitro anti-oxidative potencies were not as inferior as CDS, as discussed in Chapter 3, this 
remarkably potent anti-oxidative action for CDS in the lung must have been due to direct local 
administration by pulmonary delivery. Indeed, much potent anti-oxidant molecules have been 
recently tested, yet requiring higher doses than 30 µg/kg, when systemic delivery was employed 
like NAC and resveratrol, e.g., 82.6 % inhibition was observed at 0.2 mg/kg for vasicine 
[Srinivasarao et al, 2006]. 
Meanwhile, pulmonary delivery of CDS could inhibit the HSE/CSE-induced lung 
inflammation in a dose-dependent manner, measured with the airway infiltration of neutrophils. 
Again, CDS at 30 µg/kg, but not at 5 µg/kg, was shown to protect from such an airway luminal 
neutrophilia by 76.6 % (Figure 4.3; Table 4.2). In this context, it was intriguing that a small anti-
oxidative molecule, curcumin enabled 71.1 % inhibition against the airway luminal neutrophilia, 
when administered orally at 100 mg/kg in chronic cigarette smoke-induced emphysema [Suzuki 
et al, 2009]. The elastase inhibitor ONO-6818 caused 80.0 % inhibition, when administered 
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orally at 10 mg/kg in the elastase-induced emphysema [Kuraki et al, 2002]. Following 
intraperitoneal injection, another elastase inhibitor, ONO-5046 caused 99.5 % inhibition at 300 
mg/kg [Yasui et al, 1995]. Hence, again, these higher dose requirements for effective anti-
inflammation in the literature, compared to CDS, could be due to the route of administration, 
while also being due to their small molecules in size, which typically result in faster elimination, 
compared to the macromolecular CDS.   
Finally, pulmonary delivery of CDS was able to inhibit the HSE/CSE-induced airway 
luminal elastase activity, somewhat in a dose-related fashion. In this case however, CDS at both 
30 and 5 µg/kg was shown to cause significant 59.7 and 50.3 % (p<0.05) inhibitions, 
respectively, compared to the positive control (Figure 4.5; Table 4.3). For these figures, fair 
comparison was possible, as pulmonary delivery was tested for a neutrophil elastase inhibitor, 
TEI-8362, which caused 86.6 % inhibition at 100 µg/kg [Mitsuhashi et al, 1999]. When 
intraperitoneal injection was employed, however, a much higher dose, i.e., 300 mg/kg, was 
necessary to cause 97.4 % inhibition for another elastase inhibitor, ONO-5046 [Yasui et al, 
1995]. 
Because elastase (e.g., HSE) has been shown to trigger elastolytic breakdown in the lung, 
it was beneficial to monitor such barrier damage in the airway-to-blood interface using 
hemoglobin leakage into the airways, called hemorrhage. Pulmonary delivery of CDS could 
inhibit the HSE/CSE-induced lung hemorrhage in a dose-related manner. CDS at both 30 and 5 
µg/kg was shown to cause significant 70.4 and 59.9 % (p<0.05) inhibitions, respectively, 
compared to the positive control (Figure 4.6; Table 4.4). This clearly suggested that CDS could 
protect from the HSE/CSE-induced lung cell barrier damage, presumably caused by HSE. 
Indeed, several elastase inhibitors like FK706, TEI-8362 and FR901277 have been shown to be 
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effective in this elastase-induced lung hemorrhage, reporting the half-maximal effective lung 
doses (ED50) of 30, 45 and 19 µg/kg, respectively
 [Shinguh et al, 1997; Mitsuhashi et al, 1999; 
Fujie et al, 1999]. Although these ED50 values derived from different study protocols and 
conditions are not directly comparable, the ED50 value for CDS in this study was approximated 
to be estimated at < 5 µg/kg, given its 59.9 % inhibition (Figure 4.6; Table 4.4). Hence, CDS was 
considered to be a more potent inhibitor over these inhibitors. 
 
4.4.3. CDS AS AN INHIBITOR OF AIRSPACE ENLARGEMENT 
Pulmonary delivery of CDS was able to inhibit the HSE/CSE-induced airspace 
enlargement in a dose-dependent manner, quantified with the MLI values. Despite significant 
inhibitions of the airway luminal elastase and lung hemorrhage, CDS at 5 µg/kg was incapable of 
protecting from reducing the airspace enlargement (Figure 4.7). In contrast, however, CDS at 30 
µg/kg completely inhibited the airspace enlargement and maintained effectively normal MLI 
value, compared to the negative control (Figure 4.8). This could imply that controlling oxidative 
stress and inflammation is more critical than controlling elatase to prevent the airspace 
enlargement in emphysema. Indeed, the anti-oxidative and anti-inflammatory curcumin exhibited 
43.1 % inhibition in the cigarette smoke-induced airspace enlargement, when repeatedly 
administered orally at 100 mg/kg before every cigarette smoke exposure [Suzuki et al, 2009]. 
Nevertheless, a potent neutrophil elastase inhibitor ONO-6818 caused dose-dependent 76.9 and 
84.6 % inhibitions in the elastase-induced airspace enlargement at oral doses of 10 and 100 
mg/kg, respectively [Kuraki et al, 2002]. Hence, at present, this implication should remain 
inconclusive, as it is uncertain if ONO-6818 is also anti-oxidative and/or anti-inflammatory.  
 
99 
 
4.5 CONCLUSIONS 
 
Experimental pulmonary emphysema was induced in rats by a single orotracheal 
instillation of HSE/CSE. The protective effects of CDS were tested with its pulmonary 
administration at two doses of 5 or 30 µg/kg at 2 h before the HSE/CSE instillation. The 
HSE/CSE instillation successfully induced the lung oxidative stress of decreased rGSH levels by 
43.3 % 1 h post-HSE/CSE instillation. This HSE/CSE-induced lung oxidative stress was 
significantly inhibited by 92.9 % with CDS at 30 µg/kg (p<0.05), but not at 5 µg/kg. By 48 h, 
HSE/CSE also induced the airway luminal infiltration of inflammatory neutrophils by 104.8-
fold. Nevertheless, this HSE/CSE-induced airway neutrophilia was significantly (76.6 %) 
inhibited by CDS at 30 µg/kg. Finally, again by 48 h, HSE/CSE induced the BALF elastase 
activity and lung hemorrhage by 2.8- and 9.3-fold, respectively (p<0.05). CDS, however, was 
able to inhibit both at 30 µg/kg by 59.7 and 70.4 %, respectively (p<0.05). When this rat model 
was assessed on 28 days, the airspace enlargement by the HSE/CSE instillation was evident, 
yielding a 1.5-fold greater MLI value of the alveolar airspace (53.0 → 79.1 µm, p<0.05). CDS at 
30 µg/kg, but not at 5 µg/kg, almost completely inhibited such emphysematous changes of the 
airspace enlargement, resulting in the near normal MLI value of 53.8 µm. These results clearly 
suggested that CDS at 30 µg/kg, when administered to the lung at 2 h prior to the HSE/CSE 
instillation, exerted significant in vivo protective effects against induced lung tissue oxidative 
stress, airway luminal neutrophilia and elastase activity, and lung hemorrhage, thereby 
preventing the airspace enlargement in this rat model of experimental pulmonary emphysema. 
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CHAPTER 5 
 
 
SUMMARY AND GENERAL CONCLUSIONS 
 
 
 
 
 
In this dissertation project, the therapeutic potential of cinnamic acid-based 
dehydropolymers (DHPs) was assessed in vitro and in vivo as novel chemical entities for 
pulmonary delivery in the treatment of pulmonary emphysema. Unsulfated or sulfated DHPs 
were tested in three in vitro systems to assess their inhibitory potencies against oxidation, 
inflammation and neutrophil elastase, such that the most potent triple inhibitor yielding the 
lowest half-maximal inhibitory concentrations could be identified and characterized. The most 
potent triple inhibitor was then tested with pulmonary administration in the rat model of 
experimental emphysema induced by human sputum elastase/cigarette smoke extract 
(HSE/CSE). Its dose-dependent “prophylactic” triple in vivo inhibitory actions against induced 
tissue oxidative stress, airway inflammatory neutrophilia, lung luminal elastase activity and 
hemorrhage were assessed, while its effects on the airspace enlargement were also sought. 
 
The in vitro assessment of anti-oxidative activity employed chromogenic free radical 
(ABTS.+) generation in chemical oxidation. Initial oxidation rate in the absence or presence of 
the test molecules at varying concentrations enabled determination of their concentration-
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dependent anti-oxidative activities. The half-maximal anti-oxidative concentration (AOC50) 
values were derived from nonlinear regression curve-fitting. Both unsulfated and sulfated DHPs 
along with the monomer caffeic acid (CA) exhibited potent concentration-dependent anti-
oxidative activities. Among them, the sulfated caffeic acid DHP, CDS was the most potent, 
yielding the AOC50 value of 3.52±0.14 µM. The other sulfated ferulic and sinapic acid DHPs, 
FDS and SDS, respectively, were slightly less potent (AOC50 = 5.05±0.34 and 5.53±0.22 µM, 
respectively). Sulfation led to a 1.8-fold increase in the potency, as the unsulfated caffeic acid 
DHP, CD resulted in the AOC50 value of 6.15±0.33 µM. Moreover, 4-15 unit oligomerization led 
to a 4.8-fold increase in the potency, as the monomer CA resulted in the AOC50 value of 
16.82±1.16 µM. Indeed, CDS was found to be more potent than a water soluble analogue of 
vitamin E, Trolox®. 
The in vitro assessment of anti-inflammatory activity employed lung epithelial repression 
of TNFα-induced nuclear factor kappa B (NFκB) in the plasmid (NFκB-luciferase; pNFκB-luc)-
transfected Calu-3 human bronchial epithelial cells. The NFκB-luc activity was assessed with a 
fold-induction relative to the transfection control in the presence of the test molecules at different 
concentrations. This enabled determination of their concentration-dependent anti-inflammatory 
activities. Both the unsulfated and sulfated DHPs exhibited anti-inflammatory activities, while 
CA failed to do so by 100 µM. CDS was again the most potent, yielding the half-maximal 
inhibitory concentration (IC50) value of ~10 µM; near complete 98.4 % repression was achieved 
at 50 µM. In contrast, neither CD nor FDS enabled such a complete repression at 50 µM, i.e., it 
remained to be lower 56.8 and 64.8 %, respectively. This anti-inflammatory activity of CDS was 
shown to be moderate, compared to the most potent inhaled corticosteroid, fluticasone 
propionate (FP) that was capable of 100 % repression at a lower 5 µM in this in vitro system. 
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The in vitro assessment of anti-elastase activity employed chromogenic substrate 
hydrolysis by human neutrophil elastase (HNE). Initial rate of p-nitroaniline (pNA) generation 
was assessed in the absence or presence of the test molecules at different concentrations, which 
enabled determination of concentration-dependent anti-HNE activity. The IC50 values were 
derived from non-linear regression curve-fitting. Both the unsulfated and sulfated DHPs 
demonstrated potent HNE inhibition. Among them, CDS was the most potent, yielding the IC50 
value of 0.43±0.04 µM. While the monomer CA failed to inhibit HNE by 100 µM, the other 
sulfated DHPs, FDS and SDS, were slightly less potent, yielding the IC50 values of 0.55±0.04 
and 0.72±0.07 µM, respectively. Sulfation led to a 6.6-fold increase in the potency, as the 
unsulfated DHP, CD resulted in the IC50 value of 2.82±0.20 µM. In addition to HNE, CDS also 
inhibited HSE, but not porcine pancreatic elastase (PPE), while exhibiting time-dependent HNE 
inhibitory profile.  
The in vivo rat model of experimental pulmonary emphysema was developed to assess 
the protective effects of the most potent triple inhibitor DHP, CDS, following pulmonary 
delivery. Pulmonary emphysema was induced by a single orotracheal instillation of HSE/CSE to 
assess several protective effects of CDS administered at 5 and 30 µg/kg at 2 h prior to the 
HSE/CSE instillation. The HSE/CSE instillation successfully caused lung tissue oxidative stress 
at 1 h airway inflammatory cell infiltration, luminal elastase activity and lung hemorrhage at 48 
h, and airspace enlargement at 28 days. CDS caused dose-dependent inhibition of the HSE/CSE-
induced 43.0 % decrease in the reduced lung tissue glutathione levels (rGSH). CDS at 30 µg/kg, 
but not at 5 µg/kg, was able to inhibit the HSE/CSE-induced rGSH decrease by 92.9 %. 
Likewise, CDS caused dose-dependent inhibition of the HSE/CSE-induced 104.8-fold increase 
in the airway inflammatory neutrophil infiltration, and at 30 µg/kg, enabled a significant 76.6 % 
103 
 
inhibition. In addition, CDS caused dose-dependent inhibition of the HSE/CSE-induced 2.8-fold 
increase in the airway luminal elastase activity, enabling 50.3 and 59.7 % inhibitions at 5 and 30 
µg/kg, respectively. CDS also caused dose-dependent inhibition of the HSE/CSE-induced 9.3-
fold (p<0.05) increase in the lung hemorrhage, enabling 59.9 and 70.4 % inhibitions at 5 and 30 
µg/kg, respectively. When this rat model was assessed on 28th days, HSE/CSE caused significant 
airspace enlargement, represented by a visual lack of alveolar walls and 1.5-fold increase in the 
MLI value (53.0 → 79.1 µm). In line with the triple inhibitory actions described above, CDS at 
30 µg/kg completely inhibited such emphysematous alveolar airspace enlargement, resulting in 
the normal MLI value of 53.8 µm. 
In summary, this dissertation project has successfully demonstrated that the cinnamic acid-
based DHPs are novel chemical entities with uniquely distinct pharmacophores that exhibit, for 
the first time, potent triple inhibitory activities to oxidative stress, inflammation and neutrophil 
elastase, the mechanisms suggested to be involved in development of emphysema. Among these 
DHPs, CDS was shown to be the most potent and promisingly effective in vitro, yielding the 
half-maximal inhibitory concentrations all in < 10 µM. As a result, CDS exerted significant triple 
protective actions against lung tissue oxidative stress, airway neutrophil infiltration and luminal 
elastase as well as lung hemorrhage following pulmonary administration at 30 µg/kg in the 
HSE/CSE-induced rat model of emphysema, successfully preventing the airspace enlargement. 
These data strongly supported the quite promising therapeutic potential of pulmonary delivery of 
CDS for the use in the treatment of emphysema.   
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In vitro anti-oxidative activity assessment 
    CDS - 0.0001 µM 
  
Time (min) 
ΔAbs R750 nm Mean 
Well 1 Well 2 
0 0.000 0.000 0.000 
1 0.129 0.127 0.128 
2 0.190 0.189 0.189 
3 0.244 0.242 0.243 
4 0.290 0.288 0.289 
5 0.330 0.329 0.329 
10 0.493 0.491 0.492 
15 0.606 0.604 0.605 
    
    CDS - 0.001 µM 
  
Time (min) 
ΔAbs R750 nm Mean 
Well 1 Well 2 
0 0.000 0.000 0.000 
1 0.127 0.126 0.126 
2 0.190 0.188 0.189 
3 0.245 0.244 0.244 
4 0.293 0.291 0.292 
5 0.334 0.332 0.333 
10 0.503 0.497 0.500 
15 0.620 0.610 0.615 
    
    CDS - 0.01 µM 
   
Time (min) 
ΔAbs R750 nm Mean 
Well 1 Well 2 
0 0.000 0.000 0.000 
1 0.125 0.131 0.128 
2 0.187 0.197 0.192 
3 0.242 0.253 0.248 
4 0.288 0.302 0.295 
5 0.329 0.344 0.337 
10 0.493 0.516 0.505 
15 0.606 0.633 0.620 
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CDS - 0.1 µM 
   
Time (min) 
ΔAbs R750 nm Mean 
Well 1 Well 2 
0 0.000 0.000 0.000 
1 0.121 0.123 0.122 
2 0.184 0.187 0.185 
3 0.239 0.244 0.241 
4 0.287 0.291 0.289 
5 0.328 0.333 0.330 
10 0.493 0.501 0.497 
15 0.609 0.616 0.612 
    
    CDS - 1 µM 
   
Time (min) 
ΔAbs R750 nm Mean 
Well 1 Well 2 
0 0.000 0.000 0.000 
1 0.098 0.093 0.096 
2 0.160 0.152 0.156 
3 0.217 0.207 0.212 
4 0.266 0.255 0.261 
5 0.310 0.297 0.304 
10 0.477 0.456 0.467 
15 0.595 0.568 0.582 
    
    CDS - 3 µM 
   
Time (min) 
ΔAbs R750 nm Mean 
Well 1 Well 2 
0 0.000 0.000 0.000 
1 0.037 0.040 0.038 
2 0.081 0.086 0.083 
3 0.132 0.138 0.135 
4 0.179 0.186 0.182 
5 0.222 0.230 0.226 
10 0.376 0.384 0.380 
15 0.479 0.488 0.483 
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CDS - 5 µM 
   
Time (min) 
ΔAbs R750 nm Mean 
Well 1 Well 2 
0 0.000 0.000 0.000 
1 0.007 0.008 0.007 
2 0.023 0.024 0.023 
3 0.051 0.052 0.051 
4 0.085 0.086 0.085 
5 0.121 0.122 0.121 
10 0.259 0.262 0.260 
15 0.335 0.340 0.337 
    
    CDS - 7 µM 
   
Time (min) 
ΔAbs R750 nm Mean 
Well 1 Well 2 
0 0.000 0.000 0.000 
1 0.004 0.003 0.004 
2 0.007 0.006 0.007 
3 0.015 0.014 0.015 
4 0.030 0.029 0.030 
5 0.049 0.048 0.049 
10 0.161 0.159 0.160 
15 0.225 0.223 0.224 
    
    CDS - 10 µM 
   
Time (min) 
ΔAbs R750 nm Mean 
Well 1 Well 2 
0 0.000 0.000 0.000 
1 0.001 0.001 0.001 
2 0.001 0.002 0.002 
3 0.002 0.003 0.003 
4 0.003 0.003 0.003 
5 0.004 0.004 0.004 
10 0.007 0.007 0.007 
15 0.009 0.010 0.010 
 
 
 
123 
 
CDS - 100 µM 
   
Time (min) 
ΔAbs R750 nm Mean 
Well 1 Well 2 
0 0.000 0.000 0.000 
1 0.014 0.024 0.019 
2 0.016 0.026 0.021 
3 0.017 0.027 0.022 
4 0.019 0.029 0.024 
5 0.020 0.030 0.025 
10 0.023 0.033 0.028 
15 0.024 0.034 0.029 
 
CD - 0.1 µM 
   
Time (min) 
ΔAbs R750 nm Mean 
Well 1 Well 2 
0 0.000 0.000 0.000 
1 0.124 0.126 0.125 
2 0.185 0.189 0.187 
3 0.238 0.242 0.240 
4 0.281 0.291 0.286 
5 0.321 0.333 0.327 
10 0.487 0.491 0.489 
15 0.598 0.604 0.601 
    
    CD - 1 µM 
   
Time (min) 
ΔAbs R750 nm Mean 
Well 1 Well 2 
0 0.000 0.000 0.000 
1 0.102 0.106 0.104 
2 0.161 3.164 1.663 
3 0.217 0.219 0.218 
4 0.260 0.270 0.265 
5 0.299 0.311 0.305 
10 0.461 0.465 0.463 
15 0.567 0.573 0.570 
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CDS - 3 µM 
   
Time (min) 
ΔAbs R750 nm Mean 
Well 1 Well 2 
0 0.000 0.000 0.000 
1 0.064 0.065 0.065 
2 0.120 0.126 0.123 
3 0.179 0.183 0.181 
4 0.229 0.239 0.234 
5 0.281 0.287 0.284 
10 0.474 0.478 0.476 
15 0.590 0.592 0.591 
    
    CD - 5 µM 
   
Time (min) 
ΔAbs R750 nm Mean 
Well 1 Well 2 
0 0.000 0.000 0.000 
1 0.056 0.058 0.057 
2 0.104 0.110 0.107 
3 0.153 0.163 0.158 
4 0.205 0.207 0.206 
5 0.247 0.253 0.250 
10 0.420 0.424 0.422 
15 0.518 0.532 0.525 
    
    CD - 7 µM 
   
Time (min) 
ΔAbs R750 nm Mean 
Well 1 Well 2 
0 0.000 0.000 0.000 
1 0.005 0.009 0.007 
2 0.013 3.016 1.515 
3 0.036 0.038 0.037 
4 0.060 0.070 0.065 
5 0.090 0.102 0.096 
10 0.230 0.234 0.232 
15 0.307 0.313 0.310 
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CD - 10 µM 
   
Time (min) 
ΔAbs R750 nm Mean 
Well 1 Well 2 
0 0.000 0.000 0.000 
1 0.001 0.002 0.002 
2 0.006 0.012 0.009 
3 0.024 0.028 0.026 
4 0.044 0.054 0.049 
5 0.072 0.078 0.075 
10 0.191 0.195 0.193 
15 0.260 0.262 0.261 
    
    CD - 30 µM 
   
Time (min) 
ΔAbs R750 nm Mean 
Well 1 Well 2 
0 0.000 0.000 0.000 
1 -0.002 -0.001 -0.001 
2 -0.004 0.002 -0.001 
3 -0.003 0.001 -0.001 
4 -0.005 0.005 0.000 
5 -0.003 0.003 0.000 
10 -0.001 0.003 0.001 
15 0.000 0.002 0.001 
    
    CD - 100 µM 
   
Time (min) 
ΔAbs R750 nm Mean 
Well 1 Well 2 
0 0.000 0.000 0.000 
1 0.004 0.005 0.004 
2 0.001 0.007 0.004 
3 0.003 0.007 0.005 
4 0.001 0.011 0.006 
5 0.003 0.009 0.006 
10 0.005 0.009 0.007 
15 0.006 0.008 0.007 
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FDS - 0.1 µM 
   
Time (min) 
ΔAbs R750 nm Mean 
Well 1 Well 2 
0 0.000 0.000 0.000 
1 0.103 0.107 0.105 
2 0.168 0.174 0.171 
3 0.23 0.236 0.233 
4 0.288 0.295 0.292 
5 0.343 0.35 0.347 
10 0.575 0.584 0.580 
15 0.753 0.764 0.759 
    
    FDS - 1 µM 
   
Time (min) 
ΔAbs R750 nm Mean 
Well 1 Well 2 
0 0.000 0.000 0.000 
1 0.081 0.077 0.079 
2 0.138 0.132 0.135 
3 0.194 0.186 0.190 
4 0.247 0.238 0.243 
5 0.299 0.289 0.294 
10 0.519 0.507 0.513 
15 0.689 0.677 0.683 
    
    FDS - 3 µM 
   
Time (min) 
ΔAbs R750 nm Mean 
Well 1 Well 2 
0 0.000 0.000 0.000 
1 0.056 0.049 0.053 
2 0.095 0.087 0.091 
3 0.136 0.126 0.131 
4 0.178 0.168 0.173 
5 0.214 0.210 0.212 
10 0.419 0.409 0.414 
15 0.581 0.571 0.576 
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FDS - 5 µM 
   
Time (min) 
ΔAbs R750 nm Mean 
Well 1 Well 2 
0 0.000 0.000 0.000 
1 0.043 0.043 0.043 
2 0.079 0.078 0.078 
3 0.116 0.115 0.115 
4 0.156 0.155 0.155 
5 0.196 0.194 0.195 
10 0.389 0.388 0.388 
15 0.548 0.550 0.549 
    
    FDS - 7 µM 
   
Time (min) 
ΔAbs R750 nm Mean 
Well 1 Well 2 
0 0.000 0.000 0.000 
1 0.025 0.025 0.025 
2 0.047 0.046 0.046 
3 0.071 0.069 0.070 
4 0.098 0.095 0.096 
5 0.126 0.123 0.124 
10 0.287 0.280 0.283 
15 0.431 0.424 0.427 
    
    FDS - 10 µM 
   
Time (min) 
ΔAbs R750 nm Mean 
Well 1 Well 2 
0 0.000 0.000 0.000 
1 0.013 0.013 0.013 
2 0.029 0.028 0.028 
3 0.045 0.042 0.043 
4 0.062 0.057 0.059 
5 0.081 0.075 0.078 
10 0.204 0.189 0.196 
15 0.326 0.306 0.316 
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FDS - 30 µM 
   
Time (min) 
ΔAbs R750 nm Mean 
Well 1 Well 2 
0 0.000 0.000 0.000 
1 0.001 0.002 0.002 
2 0.002 0.003 0.003 
3 0.004 0.004 0.004 
4 0.005 0.005 0.005 
5 0.007 0.007 0.007 
10 0.016 0.014 0.015 
15 0.021 0.019 0.020 
    
    FDS - 100 
µM 
   
Time (min) 
ΔAbs R750 nm Mean 
Well 1 Well 2 
0 0.000 0.000 0.000 
1 0.000 0.003 0.002 
2 0.001 0.004 0.003 
3 0.002 0.006 0.004 
4 0.003 0.006 0.005 
5 0.004 0.006 0.005 
10 0.005 0.008 0.007 
15 0.006 0.009 0.008 
 
SDS - 0.1 µM 
   
Time (min) 
ΔAbs R750 nm Mean 
Well 1 Well 2 
0 0.000 0.000 0.000 
1 0.082 0.080 0.081 
2 0.136 0.133 0.135 
3 0.188 0.184 0.186 
4 0.237 0.232 0.235 
5 0.284 0.278 0.281 
10 0.481 0.473 0.477 
15 0.633 0.625 0.629 
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SDS - 1 µM 
   
Time (min) 
ΔAbs R750 nm Mean 
Well 1 Well 2 
0 0.000 0.000 0.000 
1 0.067 0.065 0.066 
2 0.119 0.116 0.118 
3 0.168 0.165 0.167 
4 0.216 0.212 0.214 
5 0.260 0.256 0.258 
10 0.453 0.447 0.450 
15 0.602 0.594 0.598 
    
    SDS - 3 µM 
   
Time (min) 
ΔAbs R750 nm Mean 
Well 1 Well 2 
0 0.000 0.000 0.000 
1 0.039 0.039 0.039 
2 0.084 0.084 0.084 
3 0.129 0.128 0.129 
4 0.173 0.171 0.172 
5 0.216 0.215 0.216 
10 0.398 0.395 0.397 
15 0.540 0.537 0.539 
    
    SDS - 5 µM 
   
Time (min) 
ΔAbs R750 nm Mean 
Well 1 Well 2 
0 0.000 0.000 0.000 
1 0.013 0.014 0.013 
2 0.043 0.041 0.042 
3 0.080 0.077 0.078 
4 0.119 0.115 0.117 
5 0.157 0.152 0.154 
10 0.328 0.322 0.325 
15 0.461 0.455 0.458 
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SDS - 7 µM 
   
Time (min) 
ΔAbs R750 nm Mean 
Well 1 Well 2 
0 0.000 0.000 0.000 
1 0.015 0.011 0.013 
2 0.045 0.035 0.040 
3 0.084 0.072 0.078 
4 0.122 0.108 0.115 
5 0.162 0.146 0.154 
10 0.332 0.312 0.322 
15 0.468 0.440 0.454 
    
    SDS - 10 µM 
   
Time (min) 
ΔAbs R750 nm Mean 
Well 1 Well 2 
0 0.000 0.000 0.000 
1 0.005 0.007 0.006 
2 0.021 0.022 0.022 
3 0.050 0.049 0.050 
4 0.083 0.082 0.083 
5 0.118 0.117 0.118 
10 0.278 0.276 0.277 
15 0.403 0.401 0.402 
 
CA - 1 µM 
   
Time (min) 
ΔAbs R750 nm 
Mean 
Well 1 Well 2 
0 0.000 0.000 0.000 
1 0.081 0.085 0.083 
2 0.138 0.144 0.141 
3 0.191 0.199 0.195 
4 0.240 0.250 0.245 
5 0.287 0.299 0.293 
10 0.486 0.502 0.494 
15 0.640 0.656 0.648 
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CA - 10 µM 
   
Time (min) 
ΔAbs R750 nm 
Mean 
Well 1 Well 2 
0 0.000 0.000 0.000 
1 0.028 0.032 0.030 
2 0.087 0.093 0.090 
3 0.144 0.150 0.147 
4 0.196 0.204 0.200 
5 0.247 0.255 0.251 
10 0.453 0.465 0.459 
15 0.609 0.625 0.617 
    
    CA - 20 µM 
   
Time (min) 
ΔAbs R750 nm 
Mean 
Well 1 Well 2 
0 0.000 0.000 0.000 
1 0.010 0.010 0.010 
2 0.010 0.010 0.010 
3 0.020 0.022 0.021 
4 0.081 0.085 0.083 
5 0.142 0.144 0.143 
10 0.379 0.385 0.382 
15 0.538 0.544 0.541 
    
    CA - 40 µM 
   
Time (min) 
ΔAbs R750 nm 
Mean 
Well 1 Well 2 
0 0.000 0.000 0.000 
1 0.005 -0.003 0.001 
2 0.007 -0.005 0.001 
3 0.009 -0.007 0.001 
4 0.010 -0.008 0.001 
5 0.011 -0.009 0.001 
10 0.157 0.133 0.145 
15 0.310 0.286 0.298 
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CA - 80 µM 
   
Time (min) 
ΔAbs R750 nm 
Mean 
Well 1 Well 2 
0 0.000 0.000 0.000 
1 0.000 0.004 0.002 
2 -0.001 0.005 0.002 
3 -0.002 0.006 0.002 
4 -0.003 0.007 0.002 
5 -0.004 0.008 0.002 
10 -0.005 0.011 0.003 
15 -0.004 0.012 0.004 
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In vitro anti-inflammatory activity assessment 
Treatment NF κB Fold Induction Average NF κB Fold Induction SD SE 
Vehicle+Vehicle 
0.974 
1.000 0.181 0.027 
0.989 
1.037 
1.124 
1.004 
0.872 
0.753 
1.069 
1.178 
0.484 
1.145 
1.371 
1.163 
0.649 
0.916 
1.272 
1.265 
0.745 
1.106 
0.884 
1.083 
0.917 
1.138 
1.037 
0.825 
0.974 
0.989 
1.037 
0.813 
0.972 
1.215 
0.785 
1.223 
0.992 
0.872 
1.105 
1.023 
1.130 
1.220 
0.650 
0.865 
1.135 
1.040 
1.004 
0.957 
134 
 
 
Treatment NF κB Fold Induction Average NF κB Fold Induction SD SE 
Vehicle+30 ng/ml TNFα 
1.985 
1.879 0.355 0.058 
1.773 
2.636 
2.277 
2.137 
1.606 
1.548 
1.850 
1.440 
2.313 
2.401 
1.942 
1.685 
1.512 
2.222 
1.606 
1.321 
2.179 
1.354 
1.733 
1.999 
2.092 
1.839 
1.985 
1.773 
2.229 
2.301 
2.150 
1.340 
1.228 
2.082 
2.131 
2.328 
1.936 
1.963 
1.666 
1.412 
1.442 
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Treatment NF κB Fold Induction Average NF κB Fold Induction SD SE 
CDS 1 µM+30 ng/ml TNFα  
1.745 
1.786 0.162 0.094 1.965 
1.648 
CDS 5 µM+30 ng/ml TNFα  
2.007 
1.745 0.252 0.146 1.723 
1.504 
CDS 10 µM+30 ng/ml TNFα  
1.405 
1.455 0.288 0.117 
1.964 
1.498 
1.170 
1.499 
1.196 
CDS 50 µM+30 ng/ml TNFα  
1.191 
1.002 0.262 0.151 0.703 
1.111 
CD 1 µM+30 ng/ml TNFα  
1.610 
1.713 0.127 0.073 1.673 
1.855 
CD 10 µM+30 ng/ml TNFα  
1.849 
1.665 0.437 0.219 
2.195 
1.260 
1.356 
CD 50 µM+30 ng/ml TNFα  
1.84 
1.380 0.340 0.170 
1.33 
1.02 
1.34 
FDS 1 µM+30 ng/ml TNFα  
1.577 
1.590 0.216 0.125 1.812 
1.381 
FDS 10 µM+30 ng/ml TNFα  
1.018 
1.514 0.439 0.196 
1.263 
2.021 
1.337 
1.931 
FDS 50 µM+30 ng/ml TNFα  
1.349 
1.307 0.060 0.034 1.334 
1.238 
CA 10 µM+30 ng/ml TNFα  
2.375 
2.072 0.324 0.187 1.730 
2.110 
CA 100 µM+30 ng/ml TNFα  
2.110 
1.936 0.292 0.169 2.100 
1.599 
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Treatment NF κB Fold Induction Average NF κB Fold Induction SD SE 
FP 2 µM+30 ng/ml TNFα  
1.792 
1.516 0.205 0.084 
1.703 
1.501 
1.501 
1.358 
1.244 
FP 5 µM+30 ng/ml TNFα  
0.848 
0.968 0.126 0.073 0.956 
1.099 
FP 10 µM+30 ng/ml TNFα  
1.009 
1.044 0.038 0.022 1.038 
1.085 
TA 2.3 µM+30 ng/ml TNFα  
1.435 
1.701 0.414 0.169 
1.421 
1.911 
2.012 
2.247 
1.182 
TA 4 µM+30 ng/ml TNFα  
1.855 
1.864 0.222 0.128 2.090 
1.647 
TA 11.5 µM+30 ng/ml TNFα  
0.878 
1.128 0.280 0.162 1.075 
1.430 
FP - Fluticasone propionate 
TA - Triamcinolone acetonide 
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In vitro anti-elastase activity assessment 
     
         CDS - 0.01 µM 
        
Time (min) 
ΔAbs R405 nm pNA (µg) generated Mean SD 
Well 1 Well 2 Well 3 Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
10 0.821 0.734 0.790 4.198 3.717 4.027 3.981 0.244 
20 1.335 1.287 1.323 7.042 6.776 6.975 6.931 0.138 
30 1.422 1.407 1.414 7.523 7.440 7.479 7.480 0.042 
40 1.428 1.410 1.411 7.556 7.456 7.462 7.491 0.056 
50 1.424 1.408 1.411 7.534 7.445 7.462 7.480 0.047 
60 1.424 1.411 1.414 7.534 7.462 7.479 7.491 0.038 
         
         CDS - 0.1 µM 
        
Time (min) 
ΔAbs R405 nm pNA (µg) generated Mean SD 
Well 1 Well 2 Well 3 Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
10 0.734 0.715 0.724 3.717 3.612 3.662 3.663 0.053 
20 1.267 1.248 1.265 6.665 6.560 6.654 6.627 0.058 
30 1.386 1.415 1.416 7.324 7.484 7.490 7.432 0.094 
40 1.393 1.427 1.414 7.362 7.550 7.479 7.464 0.095 
50 1.396 1.425 1.415 7.379 7.539 7.484 7.468 0.081 
60 1.394 1.426 1.414 7.368 7.545 7.479 7.464 0.089 
         
         CDS - 0.3 µM 
        
Time (min) 
ΔAbs R405 nm pNA (µg) generated Mean SD 
Well 1 Well 2 Well 3 Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
10 0.580 0.585 0.547 2.865 2.893 2.682 2.813 0.114 
20 1.097 1.115 1.063 5.725 5.825 5.537 5.695 0.146 
30 1.331 1.338 1.320 7.019 7.058 6.959 7.012 0.050 
40 1.376 1.384 1.368 7.268 7.313 7.224 7.268 0.044 
50 1.381 1.389 1.373 7.296 7.340 7.252 7.296 0.044 
60 1.380 1.390 1.373 7.290 7.346 7.252 7.296 0.047 
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CDS - 1 µM 
        
Time (min) 
ΔAbs R405 nm pNA (µg) generated Mean SD 
Well 1 Well 2 Well 3 Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
10 0.264 0.268 0.280 1.116 1.138 1.204 1.153 0.046 
20 0.549 0.549 0.568 2.692 2.692 2.797 2.727 0.061 
30 0.798 0.818 0.830 4.070 4.180 4.247 4.166 0.089 
40 0.989 1.027 1.044 5.126 5.337 5.431 5.298 0.156 
50 1.122 1.182 1.201 5.862 6.194 6.299 6.118 0.228 
60 1.199 1.280 1.300 6.288 6.736 6.847 6.624 0.296 
         
         CDS - 5 µM 
        
Time (min) 
ΔAbs R405 nm pNA (µg) generated Mean SD 
Well 1 Well 2 Well 3 Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
10 0.264 0.254 0.250 1.116 1.061 1.039 1.072 0.040 
20 0.533 0.521 0.513 2.604 2.538 2.494 2.545 0.056 
30 0.779 0.780 0.760 3.965 3.971 3.860 3.932 0.062 
40 0.989 0.980 0.963 5.127 5.077 4.983 5.062 0.073 
50 1.135 1.138 1.124 5.935 5.951 5.874 5.920 0.041 
60 1.243 1.250 1.234 6.532 6.571 6.482 6.528 0.044 
         
         CDS - 10 µM 
        
Time (min) 
ΔAbs R405 nm pNA (µg) generated Mean SD 
Well 1 Well 2 Well 3 Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
10 0.249 0.239 0.241 1.034 0.978 0.990 1.001 0.029 
20 0.515 0.498 0.501 2.505 2.411 2.428 2.448 0.050 
30 0.754 0.728 0.732 3.827 3.684 3.706 3.739 0.077 
40 0.952 0.924 0.934 4.923 4.768 4.823 4.838 0.078 
50 1.105 1.078 1.094 5.769 5.620 5.708 5.699 0.075 
60 1.215 1.192 1.211 6.378 6.250 6.355 6.328 0.068 
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CDS - 50 µM 
        
Time (min) 
ΔAbs R405 nm pNA (µg) generated Mean SD 
Well 1 Well 2 Well 3 Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
10 0.138 0.155 0.180 0.419 0.513 0.652 0.528 0.117 
20 0.299 0.318 0.346 1.310 1.415 1.570 1.432 0.131 
30 0.448 0.478 0.506 2.134 2.300 2.455 2.297 0.160 
40 0.593 0.624 0.652 2.936 3.108 3.263 3.102 0.163 
50 0.719 0.754 0.785 3.633 3.827 3.999 3.820 0.183 
60 0.828 0.869 0.902 4.236 4.463 4.646 4.448 0.205 
         
         CDS - 100 µM 
        
Time (min) 
ΔAbs R405 nm pNA (µg) generated Mean SD 
Well 1 Well 2 Well 3 Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
10 0.116 0.171 0.144 0.299 0.603 0.451 0.451 0.152 
20 0.256 0.316 0.286 1.073 1.405 1.239 1.239 0.166 
30 0.385 0.452 0.419 1.787 2.157 1.972 1.972 0.185 
40 0.507 0.577 0.542 2.462 2.849 2.655 2.655 0.194 
50 0.616 0.692 0.654 3.065 3.485 3.275 3.275 0.210 
60 0.713 0.793 0.753 3.601 4.044 3.823 3.823 0.221 
 
CD - 0.01 µM 
        
Time (min) 
ΔAbs R405 nm pNA (µg) generated Mean SD 
Well 1 Well 2 Well 3 Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
10 0.774 0.758 0.775 3.938 3.849 3.943 3.910 0.053 
20 1.317 1.302 1.311 6.942 6.859 6.908 6.903 0.042 
30 1.380 1.381 1.394 7.290 7.296 7.368 7.318 0.043 
40 1.378 1.372 1.394 7.279 7.246 7.368 7.297 0.063 
50 1.379 1.356 1.392 7.285 7.157 7.356 7.266 0.101 
60 1.379 1.357 1.392 7.285 7.163 7.356 7.268 0.098 
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CD - 0.1 µM 
        
Time (min) 
ΔAbs R405 nm pNA (µg) generated Mean SD 
Well 1 Well 2 Well 3 Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
10 0.773 0.772 0.713 3.935 3.930 3.603 3.823 0.190 
20 1.317 1.303 1.275 6.945 6.867 6.712 6.841 0.118 
30 1.399 1.387 1.405 7.398 7.332 7.431 7.387 0.051 
40 1.399 1.387 1.398 7.398 7.332 7.393 7.374 0.037 
50 1.399 1.389 1.390 7.398 7.343 7.349 7.363 0.030 
60 1.400 1.387 1.394 7.404 7.332 7.371 7.369 0.036 
         
         CDS - 1 µM 
        
Time (min) 
ΔAbs R405 nm pNA (µg) generated Mean SD 
Well 1 Well 2 Well 3 Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
10 0.674 0.660 0.628 3.383 3.305 3.128 3.272 0.130 
20 1.218 1.211 1.154 6.392 6.353 6.038 6.261 0.194 
30 1.356 1.381 1.363 7.156 7.294 7.194 7.215 0.071 
40 1.373 1.389 1.378 7.250 7.338 7.277 7.288 0.045 
50 1.372 1.381 1.374 7.244 7.294 7.255 7.264 0.026 
60 1.371 1.379 1.376 7.239 7.283 7.266 7.262 0.022 
         
         CDS - 3 µM 
        
Time (min) 
ΔAbs R405 nm pNA (µg) generated Mean SD 
Well 1 Well 2 Well 3 Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
10 0.518 0.493 0.501 2.524 2.386 2.430 2.447 0.071 
20 1.023 0.992 0.989 5.318 5.146 5.130 5.198 0.104 
30 1.287 1.293 1.286 6.778 6.811 6.773 6.788 0.021 
40 1.353 1.367 1.365 7.143 7.221 7.210 7.191 0.042 
50 1.365 1.377 1.377 7.210 7.276 7.276 7.254 0.038 
60 1.366 1.379 1.381 7.215 7.287 7.298 7.267 0.045 
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CDS - 30 µM 
        
Time (min) 
ΔAbs R405 nm pNA (µg) generated Mean SD 
Well 1 Well 2 Well 3 Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
10 0.312 0.295 0.302 1.382 1.288 1.326 1.332 0.047 
20 0.606 0.603 0.617 3.008 2.991 3.069 3.023 0.041 
30 0.871 0.881 0.883 4.474 4.529 4.540 4.514 0.036 
40 1.046 1.070 1.081 5.442 5.575 5.636 5.551 0.099 
50 1.157 1.199 1.214 6.056 6.288 6.371 6.239 0.163 
60 1.212 1.274 1.289 6.360 6.703 6.786 6.617 0.226 
         
         CDS - 100 µM 
        
Time (min) 
ΔAbs R405 nm pNA (µg) generated Mean SD 
Well 1 Well 2 Well 3 Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
10 0.242 0.246 0.244 0.997 1.019 1.008 1.008 0.011 
20 0.509 0.500 0.505 2.474 2.424 2.449 2.449 0.025 
30 0.757 0.743 0.750 3.846 3.768 3.807 3.807 0.039 
40 0.944 0.936 0.940 4.880 4.836 4.858 4.858 0.022 
50 1.082 1.074 1.078 5.643 5.599 5.621 5.621 0.022 
60 1.176 1.174 1.175 6.163 6.152 6.158 6.158 0.006 
 
FDS - 0.01 µM 
        
Time (min) 
ΔAbs R405 nm pNA (µg) generated Mean SD 
Well 1 Well 2 Well 3 Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
10 0.680 0.649 0.675 3.419 3.247 3.391 3.352 0.092 
20 1.172 1.117 1.152 6.140 5.836 6.030 6.002 0.154 
30 1.328 1.320 1.360 7.003 6.959 7.180 7.048 0.117 
40 1.356 1.372 1.382 7.158 7.247 7.302 7.236 0.073 
50 1.356 1.378 1.393 7.158 7.280 7.363 7.267 0.103 
60 1.354 1.376 1.391 7.147 7.269 7.352 7.256 0.103 
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FDS - 0.1 µM 
        
Time (min) 
ΔAbs R405 nm pNA (µg) generated Mean SD 
Well 1 Well 2 Well 3 Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
10 0.644 0.605 0.573 3.219 3.004 2.827 3.017 0.197 
20 1.099 1.025 1.010 5.736 5.327 5.244 5.436 0.264 
30 1.293 1.245 1.255 6.810 6.544 6.599 6.651 0.140 
40 1.340 1.321 1.341 7.070 6.965 7.075 7.036 0.062 
50 1.346 1.330 1.355 7.103 7.014 7.153 7.090 0.070 
60 1.348 1.329 1.357 7.114 7.009 7.164 7.095 0.079 
         
         FDS - 0.3 µM 
        
Time (min) 
ΔAbs R405 nm pNA (µg) generated Mean SD 
Well 1 Well 2 Well 3 Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
10 0.555 0.499 0.520 2.725 2.416 2.532 2.558 0.156 
20 0.925 0.907 0.937 4.772 4.673 4.839 4.761 0.084 
30 1.160 1.177 1.207 6.072 6.166 6.332 6.190 0.132 
40 1.296 1.288 1.328 6.825 6.780 7.002 6.869 0.117 
50 1.331 1.331 1.349 7.018 7.018 7.118 7.051 0.057 
60 1.342 1.341 1.355 7.079 7.073 7.151 7.101 0.043 
         
         FDS - 1 µM 
        
Time (min) 
ΔAbs R405 nm pNA (µg) generated Mean SD 
Well 1 Well 2 Well 3 Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
10 0.307 0.281 0.299 1.353 1.210 1.309 1.291 0.074 
20 0.620 0.542 0.600 3.085 2.653 2.974 2.904 0.224 
30 0.900 0.812 0.869 4.634 4.147 4.462 4.414 0.247 
40 1.088 1.009 1.063 5.674 5.237 5.536 5.482 0.223 
50 1.201 1.153 1.188 6.299 6.033 6.227 6.187 0.137 
60 1.264 1.234 1.254 6.648 6.482 6.592 6.574 0.085 
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FDS - 5 µM 
        
Time (min) 
ΔAbs R405 nm pNA (µg) generated Mean SD 
Well 1 Well 2 Well 3 Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
10 0.143 0.145 0.117 0.450 0.461 0.306 0.406 0.086 
20 0.282 0.278 0.230 1.219 1.197 0.931 1.115 0.160 
30 0.439 0.425 0.350 2.087 2.010 1.595 1.897 0.265 
40 0.565 0.554 0.483 2.784 2.723 2.331 2.613 0.246 
50 0.676 0.671 0.605 3.398 3.371 3.006 3.258 0.219 
60 0.775 0.776 0.713 3.946 3.951 3.603 3.833 0.200 
         
         FDS - 10 µM 
        
Time (min) 
ΔAbs R405 nm pNA (µg) generated Mean SD 
Well 1 Well 2 Well 3 Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
10 0.144 0.144 0.144 0.451 0.451 0.451 0.451 0.000 
20 0.298 0.291 0.294 1.303 1.264 1.283 1.283 0.019 
30 0.451 0.444 0.447 2.149 2.110 2.130 2.130 0.019 
40 0.580 0.573 0.576 2.863 2.824 2.843 2.843 0.019 
50 0.692 0.686 0.689 3.482 3.449 3.466 3.466 0.017 
60 0.788 0.789 0.788 4.013 4.019 4.016 4.016 0.003 
         
         FDS - 100 µM 
        
Time (min) 
ΔAbs R405 nm pNA (µg) generated Mean SD 
Well 1 Well 2 Well 3 Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
10 0.112 0.125 0.119 0.278 0.350 0.314 0.314 0.036 
20 0.223 0.229 0.226 0.892 0.925 0.909 0.909 0.017 
30 0.325 0.330 0.328 1.456 1.484 1.470 1.470 0.014 
40 0.421 0.426 0.424 1.987 2.015 2.001 2.001 0.014 
50 0.505 0.511 0.508 2.452 2.485 2.469 2.469 0.017 
60 0.583 0.588 0.586 2.883 2.911 2.897 2.897 0.014 
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SDS - 0.01 µM 
        
Time (min) 
ΔAbs R405 nm pNA (µg) generated Mean SD 
Well 1 Well 2 Well 3 Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
10 0.697 0.581 0.648 3.515 2.873 3.244 3.211 0.322 
20 1.158 1.049 1.132 6.065 5.462 5.921 5.816 0.315 
30 1.355 1.269 1.327 7.155 6.679 7.000 6.945 0.243 
40 1.390 1.370 1.371 7.349 7.238 7.243 7.277 0.062 
50 1.393 1.384 1.376 7.365 7.315 7.271 7.317 0.047 
60 1.393 1.386 1.375 7.365 7.326 7.266 7.319 0.050 
         
         SDS - 0.1 µM 
        
Time (min) 
ΔAbs R405 nm pNA (µg) generated Mean SD 
Well 1 Well 2 Well 3 Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
10 0.492 0.571 0.532 2.379 2.816 2.600 2.598 0.219 
20 0.828 0.990 0.963 4.237 5.134 4.984 4.785 0.480 
30 1.046 1.248 1.190 5.443 6.561 6.240 6.081 0.575 
40 1.183 1.321 1.303 6.201 6.965 6.865 6.677 0.415 
50 1.241 1.333 1.331 6.522 7.031 7.020 6.858 0.291 
60 1.250 1.335 1.338 6.572 7.042 7.059 6.891 0.276 
         
         SDS - 0.5 µM 
        
Time (min) 
ΔAbs R405 nm pNA (µg) generated Mean SD 
Well 1 Well 2 Well 3 Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
10 0.414 0.343 0.383 1.947 1.554 1.776 1.759 0.197 
20 0.807 0.730 0.753 4.121 3.695 3.823 3.880 0.219 
30 1.114 1.046 1.056 5.820 5.443 5.499 5.587 0.203 
40 1.264 1.228 1.244 6.649 6.450 6.539 6.546 0.100 
50 1.321 1.311 1.315 6.965 6.909 6.931 6.935 0.028 
60 1.338 1.335 1.335 7.059 7.042 7.042 7.048 0.010 
 
 
 
 
 
145 
 
SDS - 1 µM 
        
Time (min) 
ΔAbs R405 nm pNA (µg) generated Mean SD 
Well 1 Well 2 Well 3 Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
10 0.356 0.311 0.380 1.626 1.377 1.759 1.588 0.194 
20 0.707 0.636 0.744 3.568 3.175 3.773 3.505 0.304 
30 0.984 0.939 1.039 5.100 4.851 5.405 5.119 0.277 
40 1.192 1.169 1.227 6.251 6.124 6.445 6.273 0.162 
50 1.280 1.284 1.307 6.738 6.760 6.887 6.795 0.081 
60 1.320 1.330 1.338 6.959 7.014 7.059 7.011 0.050 
         
         SDS - 5 µM 
        
Time (min) 
ΔAbs R405 nm pNA (µg) generated Mean SD 
Well 1 Well 2 Well 3 Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
10 0.119 0.101 0.131 0.315 0.216 0.382 0.304 0.084 
20 0.255 0.226 0.301 1.068 0.907 1.322 1.099 0.209 
30 0.426 0.419 0.500 2.014 1.975 2.423 2.137 0.248 
40 0.598 0.611 0.684 2.965 3.037 3.441 3.148 0.256 
50 0.749 0.765 0.842 3.800 3.889 4.315 4.001 0.275 
60 0.879 0.898 0.971 4.520 4.625 5.029 4.724 0.269 
         
         SDS - 7 µM 
        
Time (min) 
ΔAbs R405 nm pNA (µg) generated Mean SD 
Well 1 Well 2 Well 3 Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
10 0.124 0.097 0.112 0.343 0.194 0.277 0.271 0.075 
20 0.243 0.224 0.253 1.001 0.896 1.057 0.985 0.081 
30 0.391 0.404 0.432 1.820 1.892 2.047 1.920 0.116 
40 0.555 0.576 0.612 2.727 2.843 3.043 2.871 0.159 
50 0.690 0.740 0.764 3.474 3.751 3.883 3.703 0.209 
60 0.815 0.870 0.898 4.166 4.470 4.625 4.420 0.234 
 
 
 
 
 
146 
 
SDS - 10 µM 
        
Time (min) 
ΔAbs R405 nm pNA (µg) generated Mean SD 
Well 1 Well 2 Well 3 Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
10 0.092 0.104 0.095 0.166 0.232 0.182 0.193 0.035 
20 0.215 0.225 0.209 0.846 0.901 0.813 0.853 0.045 
30 0.364 0.375 0.358 1.670 1.731 1.637 1.679 0.048 
40 0.508 0.523 0.520 2.467 2.550 2.533 2.517 0.044 
50 0.670 0.676 0.663 3.363 3.396 3.324 3.361 0.036 
60 0.797 0.802 0.792 4.066 4.093 4.038 4.066 0.028 
         
         SDS - 100 µM 
        
Time (min) 
ΔAbs R405 nm pNA (µg) generated Mean SD 
Well 1 Well 2 Well 3 Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
10 0.122 0.062 0.092 0.331 0.000 0.166 0.166 0.166 
20 0.235 0.035 0.135 0.957 0.000 0.403 0.453 0.480 
30 0.249 0.149 0.199 1.034 0.481 0.757 0.757 0.277 
40 0.264 0.244 0.254 1.117 1.006 1.062 1.062 0.055 
50 0.396 0.296 0.346 1.847 1.294 1.571 1.571 0.277 
60 0.493 0.293 0.393 2.384 1.277 1.831 1.831 0.553 
 
CA - 1 µM 
        
Time (min) 
ΔAbs R405 nm pNA (µg) generated Mean SD 
Well 1 Well 2 Well 3 Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
10 0.704 0.679 0.668 3.551 3.413 3.352 3.439 0.102 
20 1.117 1.110 1.114 5.836 5.797 5.820 5.818 0.019 
30 1.249 1.361 1.261 6.566 7.186 6.633 6.795 0.340 
40 1.264 1.414 1.286 6.649 7.479 6.771 6.967 0.448 
50 1.262 1.358 1.288 6.638 7.169 6.782 6.863 0.275 
60 1.260 1.372 1.287 6.627 7.247 6.777 6.884 0.323 
 
 
 
 
 
147 
 
CA - 10 µM 
        
Time (min) 
ΔAbs R405 nm pNA (µg) generated Mean SD 
Well 1 Well 2 Well 3 Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
10 0.727 0.692 0.678 3.679 3.486 3.408 3.525 0.140 
20 1.162 1.159 1.160 6.086 6.069 6.075 6.077 0.008 
30 1.326 1.326 1.332 6.993 6.993 7.026 7.004 0.019 
40 1.347 1.355 1.349 7.109 7.153 7.120 7.128 0.023 
50 1.348 1.356 1.349 7.115 7.159 7.120 7.131 0.024 
60 1.347 1.355 1.348 7.109 7.153 7.115 7.126 0.024 
         
         CA - 100 µM 
        
Time (min) 
ΔAbs R405 nm pNA (µg) generated Mean SD 
Well 1 Well 2 Well 3 Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
10 0.723 0.680 0.705 3.655 3.417 3.556 3.543 0.119 
20 1.172 1.136 1.182 6.139 5.940 6.194 6.091 0.134 
30 1.323 1.232 1.313 6.974 6.471 6.919 6.788 0.276 
40 1.340 1.263 1.361 7.068 6.642 7.185 6.965 0.285 
50 1.339 1.263 1.363 7.063 6.642 7.196 6.967 0.289 
60 1.337 1.261 1.362 7.052 6.631 7.190 6.958 0.291 
         
         CA - 1 mM 
        
Time (min) 
ΔAbs R405 nm pNA (µg) generated Mean SD 
Well 1 Well 2 Well 3 Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
10 0.772 0.707 0.747 3.926 3.566 3.787 3.760 0.181 
20 1.226 1.167 1.240 6.437 6.111 6.514 6.354 0.214 
30 1.301 1.253 1.361 6.852 6.586 7.184 6.874 0.299 
40 1.309 1.278 1.391 6.896 6.725 7.350 6.990 0.323 
50 1.298 1.280 1.393 6.835 6.736 7.361 6.977 0.336 
60 1.293 1.280 1.393 6.808 6.736 7.361 6.968 0.342 
 
 
 
 
 
148 
 
CA - 5 mM 
        
Time (min) 
ΔAbs R405 nm pNA (µg) generated Mean SD 
Well 1 Well 2 Well 3 Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
10 0.755 0.699 0.708 3.835 3.526 3.575 3.645 0.166 
20 1.236 1.216 1.227 6.496 6.386 6.446 6.443 0.055 
30 1.347 1.362 1.378 7.110 7.193 7.282 7.195 0.086 
40 1.379 1.400 1.419 7.287 7.403 7.509 7.400 0.111 
50 1.383 1.406 1.426 7.309 7.437 7.547 7.431 0.119 
60 1.383 1.407 1.428 7.309 7.442 7.558 7.437 0.125 
         
         CA - 10 mM 
        
Time (min) 
ΔAbs R405 nm pNA (µg) generated Mean SD 
Well 1 Well 2 Well 3 Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
10 0.637 0.607 0.585 3.181 3.015 2.894 3.030 0.144 
20 1.075 1.094 1.052 5.604 5.709 5.477 5.597 0.116 
30 1.292 1.284 1.274 6.805 6.760 6.705 6.757 0.050 
40 1.354 1.368 1.379 7.148 7.225 7.286 7.220 0.069 
50 1.373 1.394 1.408 7.253 7.369 7.446 7.356 0.097 
60 1.380 1.402 1.419 7.291 7.413 7.507 7.404 0.108 
 
 
 
 
 
 
 
 
 
 
 
 
149 
 
Porcine Pancreatic Elastase  
      
         CDS - 0.1 µM 
       
Time (min) 
ΔAbs R405 nm pNA (µg) generated Mean SD 
Well 1 Well 2 Well 3 Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
10 0.374 0.359 0.349 1.727 1.644 1.589 1.653 0.070 
20 0.689 0.664 0.648 3.469 3.331 3.243 3.348 0.114 
30 0.925 0.887 0.880 4.775 4.565 4.526 4.622 0.134 
40 1.082 1.064 1.012 5.643 5.544 5.256 5.481 0.201 
50 1.190 1.167 1.100 6.241 6.114 5.743 6.032 0.259 
60 1.250 1.228 1.155 6.573 6.451 6.047 6.357 0.275 
         
         CDS - 1 µM 
        
Time (min) 
ΔAbs R405 nm pNA (µg) generated Mean SD 
Well 1 Well 2 Well 3 Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
10 0.394 0.366 0.375 1.839 1.684 1.734 1.752 0.079 
20 0.711 0.676 0.688 3.592 3.399 3.465 3.485 0.098 
30 0.944 0.918 0.908 4.881 4.737 4.682 4.767 0.103 
40 1.095 1.074 1.086 5.717 5.600 5.667 5.661 0.058 
50 1.198 1.178 1.170 6.286 6.176 6.131 6.198 0.080 
60 1.256 1.242 1.245 6.607 6.530 6.546 6.561 0.041 
         
         CDS - 10 µM 
        
Time (min) 
ΔAbs R405 nm pNA (µg) generated Mean SD 
Well 1 Well 2 Well 3 Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
10 0.377 0.390 0.397 1.742 1.814 1.853 1.803 0.056 
20 0.686 0.714 0.726 3.451 3.606 3.673 3.577 0.114 
30 0.908 0.936 0.974 4.680 4.834 5.045 4.853 0.183 
40 1.048 1.102 1.095 5.454 5.753 5.714 5.640 0.162 
50 1.134 1.194 1.201 5.930 6.262 6.300 6.164 0.204 
60 1.184 1.251 1.265 6.206 6.577 6.654 6.479 0.239 
 
 
 
 
150 
 
CD - 0.1 µM 
        
Time (min) 
ΔAbs R405 nm pNA (µg) generated Mean SD 
Well 1 Well 2 Well 3 Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
10 0.366 0.338 0.341 1.681 1.526 1.543 1.583 0.085 
20 0.681 0.645 0.644 3.423 3.224 3.219 3.289 0.117 
30 0.931 0.892 0.885 4.806 4.591 4.552 4.650 0.137 
40 1.078 1.058 1.039 5.620 5.509 5.404 5.511 0.108 
50 1.175 1.155 1.128 6.156 6.046 5.896 6.033 0.130 
60 1.245 1.228 1.200 6.543 6.449 6.294 6.429 0.126 
         
         CD - 1 µM 
        
Time (min) 
ΔAbs R405 nm pNA (µg) generated Mean SD 
Well 1 Well 2 Well 3 Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
10 0.348 0.366 0.355 1.583 1.683 1.622 1.630 0.050 
20 0.648 0.678 0.656 3.243 3.409 3.287 3.313 0.086 
30 0.873 0.922 0.883 4.488 4.759 4.543 4.596 0.143 
40 1.043 1.077 1.051 5.428 5.616 5.472 5.506 0.098 
50 1.162 1.179 1.160 6.086 6.180 6.075 6.114 0.058 
60 1.228 1.252 1.225 6.451 6.584 6.435 6.490 0.082 
         
         CD - 10 µM 
        
Time (min) 
ΔAbs R405 nm pNA (µg) generated Mean SD 
Well 1 Well 2 Well 3 Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
10 0.358 0.354 0.365 1.640 1.617 1.678 1.645 0.031 
20 0.665 0.659 0.684 3.338 3.305 3.443 3.362 0.072 
30 0.912 0.908 0.943 4.704 4.682 4.876 4.754 0.106 
40 1.066 1.075 1.087 5.556 5.606 5.672 5.611 0.058 
50 1.156 1.164 1.182 6.054 6.098 6.198 6.117 0.074 
60 1.218 1.225 1.249 6.397 6.436 6.569 6.467 0.090 
 
 
 
 
 
151 
 
Control 
        
Time (min) 
ΔAbs R405 nm pNA (µg) generated Mean SD 
Well 1 Well 2 Well 3 Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
10 0.357 0.333 0.352 1.632 1.499 1.604 1.578 0.070 
20 0.678 0.647 0.678 3.408 3.236 3.408 3.350 0.099 
30 0.904 0.886 0.886 4.658 4.558 4.558 4.591 0.057 
40 1.036 1.044 1.038 5.388 5.432 5.399 5.407 0.023 
50 1.165 1.151 1.159 6.102 6.024 6.069 6.065 0.039 
60 1.228 1.225 1.221 6.450 6.434 6.411 6.432 0.019 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
152 
 
Human Sputum Elastase 
       
         CDS - 0.01 µM 
        
Time (min) 
ΔAbs R405 nm pNA (µg) generated 
Mean SD Well 
1 Well 2 Well 3 Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
1 0.037 0.035 0.035 0.000 0.000 0.000 0.000 0.000 
2 0.075 0.072 0.070 0.072 0.055 0.044 0.057 0.014 
3 0.114 0.108 0.109 0.288 0.254 0.260 0.267 0.018 
4 0.154 0.147 0.149 0.509 0.470 0.481 0.487 0.020 
5 0.196 0.186 0.190 0.741 0.686 0.708 0.712 0.028 
6 0.242 0.224 0.231 0.996 0.896 0.935 0.942 0.050 
7 0.287 0.264 0.274 1.245 1.117 1.173 1.178 0.064 
8 0.332 0.304 0.316 1.494 1.339 1.405 1.412 0.078 
9 0.377 0.344 0.358 1.743 1.560 1.637 1.647 0.092 
10 0.422 0.386 0.401 1.991 1.792 1.875 1.886 0.100 
20 0.836 0.773 0.790 4.282 3.933 4.027 4.081 0.180 
30 1.093 1.034 1.057 5.703 5.377 5.504 5.528 0.165 
40 1.205 1.170 1.191 6.323 6.129 6.246 6.233 0.097 
50 1.242 1.226 1.243 6.528 6.439 6.533 6.500 0.053 
60 1.251 1.248 1.261 6.577 6.561 6.633 6.590 0.038 
 
 
 
 
 
 
 
 
 
 
 
 
153 
 
CDS - 0.1 µM 
        
Time (min) 
ΔAbs R405 nm pNA (µg) generated Mean SD 
Well 1 Well 2 Well 3 Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
1 0.024 0.025 0.025 0.000 0.000 0.000 0.000 0.000 
2 0.052 0.050 0.051 0.000 0.000 0.000 0.000 0.000 
3 0.080 0.075 0.077 0.100 0.072 0.083 0.085 0.014 
4 0.109 0.103 0.106 0.260 0.227 0.243 0.243 0.017 
5 0.139 0.133 0.137 0.426 0.393 0.415 0.411 0.017 
6 0.172 0.164 0.169 0.609 0.564 0.592 0.588 0.022 
7 0.206 0.196 0.201 0.797 0.741 0.769 0.769 0.028 
8 0.239 0.228 0.235 0.979 0.918 0.957 0.951 0.031 
9 0.270 0.262 0.268 1.151 1.106 1.140 1.132 0.023 
10 0.301 0.296 0.300 1.322 1.294 1.317 1.311 0.015 
20 0.608 0.603 0.615 3.020 2.993 3.059 3.024 0.033 
30 0.857 0.857 0.869 4.398 4.398 4.464 4.420 0.038 
40 1.035 1.031 1.042 5.383 5.360 5.421 5.388 0.031 
50 1.142 1.139 1.142 5.974 5.958 5.974 5.969 0.010 
60 1.200 1.197 1.193 6.295 6.279 6.257 6.277 0.019 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
154 
 
CDS - 0.3 µM 
        
Time (min) 
ΔAbs R405 nm pNA (µg) generated Mean SD 
Well 1 Well 2 Well 3 Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
1 0.014 0.013 0.013 0.000 0.000 0.000 0.000 0.000 
2 0.027 0.025 0.026 0.000 0.000 0.000 0.000 0.000 
3 0.041 0.038 0.039 0.000 0.000 0.000 0.000 0.000 
4 0.055 0.052 0.054 0.000 0.000 0.000 0.000 0.000 
5 0.072 0.068 0.070 0.055 0.033 0.044 0.044 0.011 
6 0.090 0.083 0.087 0.155 0.116 0.138 0.136 0.019 
7 0.107 0.101 0.105 0.249 0.216 0.238 0.234 0.017 
8 0.124 0.119 0.125 0.343 0.315 0.349 0.336 0.018 
9 0.143 0.139 0.143 0.448 0.426 0.448 0.441 0.013 
10 0.163 0.157 0.161 0.559 0.526 0.548 0.544 0.017 
20 0.360 0.366 0.363 1.649 1.682 1.665 1.665 0.017 
30 0.544 0.555 0.551 2.666 2.727 2.705 2.700 0.031 
40 0.705 0.722 0.718 3.557 3.651 3.629 3.612 0.049 
50 0.842 0.862 0.854 4.315 4.426 4.381 4.374 0.056 
60 0.953 0.975 0.966 4.929 5.051 5.001 4.993 0.061 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
155 
 
CDS - 0.5 µM 
        
Time (min) 
ΔAbs R405 nm pNA (µg) generated Mean SD 
Well 1 Well 2 Well 3 Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
1 0.013 0.013 0.013 0.000 0.000 0.000 0.000 0.000 
2 0.025 0.025 0.026 0.000 0.000 0.000 0.000 0.000 
3 0.038 0.036 0.038 0.000 0.000 0.000 0.000 0.000 
4 0.050 0.049 0.051 0.000 0.000 0.000 0.000 0.000 
5 0.063 0.062 0.063 0.006 0.000 0.006 0.004 0.003 
6 0.076 0.076 0.076 0.077 0.077 0.077 0.077 0.000 
7 0.091 0.090 0.093 0.160 0.155 0.171 0.162 0.008 
8 0.106 0.104 0.107 0.243 0.232 0.249 0.242 0.008 
9 0.119 0.118 0.122 0.315 0.310 0.332 0.319 0.012 
10 0.134 0.133 0.138 0.398 0.393 0.420 0.404 0.015 
20 0.303 0.303 0.315 1.333 1.333 1.400 1.355 0.038 
30 0.471 0.473 0.486 2.263 2.274 2.346 2.294 0.045 
40 0.627 0.634 0.643 3.126 3.164 3.214 3.168 0.044 
50 0.766 0.775 0.784 3.894 3.944 3.994 3.944 0.050 
60 0.886 0.899 0.904 4.558 4.630 4.658 4.615 0.051 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
156 
 
CDS - 1 µM 
        
Time (min) 
ΔAbs R405 nm pNA (µg) generated Mean SD 
Well 1 Well 2 Well 3 Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
1 0.012 0.009 0.010 0.000 0.000 0.000 0.000 0.000 
2 0.021 0.019 0.019 0.000 0.000 0.000 0.000 0.000 
3 0.031 0.030 0.030 0.000 0.000 0.000 0.000 0.000 
4 0.043 0.042 0.041 0.000 0.000 0.000 0.000 0.000 
5 0.057 0.054 0.053 0.000 0.000 0.000 0.000 0.000 
6 0.070 0.066 0.066 0.044 0.022 0.022 0.030 0.013 
7 0.084 0.084 0.080 0.122 0.122 0.100 0.114 0.013 
8 0.098 0.095 0.094 0.199 0.183 0.177 0.186 0.012 
9 0.112 0.108 0.108 0.277 0.254 0.254 0.262 0.013 
10 0.127 0.125 0.125 0.360 0.349 0.349 0.352 0.006 
20 0.290 0.283 0.284 1.261 1.223 1.228 1.237 0.021 
30 0.452 0.446 0.443 2.157 2.124 2.108 2.130 0.025 
40 0.600 0.598 0.591 2.976 2.965 2.926 2.956 0.026 
50 0.729 0.723 0.719 3.690 3.657 3.634 3.660 0.028 
60 0.836 0.832 0.828 4.282 4.260 4.237 4.260 0.022 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
157 
 
CDS - 5 µM 
        
Time (min) 
ΔAbs R405 nm pNA (µg) generated Mean SD 
Well 1 Well 2 Well 3 Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
1 0.008 0.009 0.008 0.000 0.000 0.000 0.000 0.000 
2 0.016 0.017 0.016 0.000 0.000 0.000 0.000 0.000 
3 0.026 0.026 0.025 0.000 0.000 0.000 0.000 0.000 
4 0.036 0.035 0.035 0.000 0.000 0.000 0.000 0.000 
5 0.046 0.045 0.046 0.000 0.000 0.000 0.000 0.000 
6 0.056 0.055 0.056 0.000 0.000 0.000 0.000 0.000 
7 0.068 0.067 0.067 0.033 0.028 0.028 0.030 0.003 
8 0.079 0.078 0.078 0.094 0.089 0.089 0.090 0.003 
9 0.091 0.090 0.090 0.160 0.155 0.155 0.157 0.003 
10 0.104 0.102 0.102 0.232 0.221 0.221 0.225 0.006 
20 0.243 0.231 0.233 1.001 0.935 0.946 0.961 0.036 
30 0.384 0.368 0.370 1.781 1.693 1.704 1.726 0.048 
40 0.516 0.498 0.500 2.511 2.412 2.423 2.449 0.055 
50 0.636 0.614 0.617 3.175 3.054 3.070 3.100 0.066 
60 0.741 0.716 0.721 3.756 3.618 3.646 3.673 0.073 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
158 
 
CDS - 10 µM 
        
Time (min) 
ΔAbs R405 nm pNA (µg) generated Mean SD 
Well 1 Well 2 Well 3 Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
1 0.008 0.005 0.006 0.000 0.000 0.000 0.000 0.000 
2 0.016 0.013 0.013 0.000 0.000 0.000 0.000 0.000 
3 0.025 0.021 0.022 0.000 0.000 0.000 0.000 0.000 
4 0.034 0.030 0.030 0.000 0.000 0.000 0.000 0.000 
5 0.043 0.038 0.039 0.000 0.000 0.000 0.000 0.000 
6 0.053 0.049 0.049 0.000 0.000 0.000 0.000 0.000 
7 0.063 0.059 0.059 0.006 0.000 0.000 0.002 0.003 
8 0.075 0.070 0.070 0.072 0.044 0.044 0.053 0.016 
9 0.085 0.081 0.080 0.127 0.105 0.100 0.111 0.015 
10 0.096 0.091 0.091 0.188 0.160 0.160 0.170 0.016 
20 0.217 0.208 0.209 0.857 0.808 0.813 0.826 0.027 
30 0.345 0.332 0.333 1.566 1.494 1.499 1.519 0.040 
40 0.465 0.452 0.451 2.229 2.157 2.152 2.180 0.043 
50 0.575 0.560 0.561 2.838 2.755 2.760 2.784 0.046 
60 0.674 0.658 0.659 3.386 3.297 3.303 3.328 0.050 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
159 
 
CDS - 20 µM 
        
Time (min) 
ΔAbs R405 nm pNA (µg) generated Mean SD 
Well 1 Well 2 Well 3 Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
1 0.005 0.005 0.002 0.000 0.000 0.000 0.000 0.000 
2 0.012 0.012 0.008 0.000 0.000 0.000 0.000 0.000 
3 0.020 0.019 0.015 0.000 0.000 0.000 0.000 0.000 
4 0.028 0.026 0.022 0.000 0.000 0.000 0.000 0.000 
5 0.037 0.034 0.030 0.000 0.000 0.000 0.000 0.000 
6 0.048 0.043 0.037 0.000 0.000 0.000 0.000 0.000 
7 0.058 0.052 0.045 0.000 0.000 0.000 0.000 0.000 
8 0.067 0.061 0.054 0.028 0.000 0.000 0.009 0.016 
9 0.078 0.071 0.062 0.089 0.050 0.000 0.046 0.044 
10 0.087 0.082 0.072 0.138 0.111 0.055 0.101 0.042 
20 0.200 0.188 0.174 0.763 0.697 0.620 0.693 0.072 
30 0.315 0.299 0.282 1.400 1.311 1.217 1.309 0.091 
40 0.425 0.406 0.387 2.008 1.903 1.798 1.903 0.105 
50 0.526 0.505 0.485 2.567 2.451 2.340 2.452 0.113 
60 0.619 0.595 0.574 3.081 2.949 2.832 2.954 0.125 
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CDS - 100 µM 
        
Time (min) 
ΔAbs R405 nm pNA (µg) generated Mean SD 
Well 1 Well 2 Well 3 Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
1 0.003 -0.008 -0.006 0.000 0.000 0.000 0.000 0.000 
2 0.004 -0.007 -0.005 0.000 0.000 0.000 0.000 0.000 
3 0.008 -0.001 -0.002 0.000 0.000 0.000 0.000 0.000 
4 0.015 0.005 0.003 0.000 0.000 0.000 0.000 0.000 
5 0.024 0.012 0.010 0.000 0.000 0.000 0.000 0.000 
6 0.031 0.022 0.018 0.000 0.000 0.000 0.000 0.000 
7 0.041 0.029 0.028 0.000 0.000 0.000 0.000 0.000 
8 0.051 0.037 0.039 0.000 0.000 0.000 0.000 0.000 
9 0.060 0.045 0.048 0.000 0.000 0.000 0.000 0.000 
10 0.070 0.056 0.057 0.044 0.000 0.000 0.015 0.026 
20 0.165 0.161 0.159 0.570 0.548 0.537 0.551 0.017 
30 0.239 0.226 0.223 0.979 0.907 0.891 0.926 0.047 
40 0.323 0.308 0.308 1.444 1.361 1.361 1.389 0.048 
50 0.397 0.385 0.381 1.853 1.787 1.765 1.802 0.046 
60 0.471 0.453 0.446 2.263 2.163 2.124 2.183 0.071 
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Control 
        
Time (min) 
ΔAbs R405 nm pNA (µg) generated Mean SD 
Well 1 Well 2 Well 3 Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
1 0.039 0.040 0.040 0.000 0.000 0.000 0.000 0.000 
2 0.079 0.079 0.080 0.094 0.094 0.100 0.096 0.003 
3 0.120 0.120 0.121 0.321 0.321 0.326 0.323 0.003 
4 0.163 0.163 0.166 0.559 0.559 0.575 0.564 0.010 
5 0.209 0.208 0.212 0.813 0.808 0.830 0.817 0.012 
6 0.260 0.253 0.257 1.095 1.057 1.079 1.077 0.019 
7 0.311 0.301 0.305 1.377 1.322 1.344 1.348 0.028 
8 0.359 0.349 0.356 1.643 1.588 1.626 1.619 0.028 
9 0.405 0.401 0.402 1.897 1.875 1.881 1.885 0.012 
10 0.450 0.451 0.451 2.146 2.152 2.152 2.150 0.003 
20 0.844 0.853 0.865 4.326 4.376 4.442 4.381 0.058 
30 1.061 1.068 1.092 5.526 5.565 5.698 5.596 0.090 
40 1.136 1.139 1.173 5.941 5.958 6.146 6.015 0.114 
50 1.161 1.158 1.201 6.080 6.063 6.301 6.148 0.133 
60 1.170 1.163 1.214 6.129 6.091 6.373 6.198 0.153 
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Time-dependent inhibition 
   
      Pre-incubation time - 0 min 
   
      Control 
     
Time (min) 
ΔAbs R405 nm Mean SD 
Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 
1 0.115 0.107 0.112 0.111 0.004 
2 0.225 0.211 0.221 0.219 0.007 
3 0.329 0.312 0.327 0.323 0.009 
4 0.432 0.409 0.432 0.424 0.013 
5 0.531 0.505 0.531 0.522 0.015 
6 0.629 0.596 0.624 0.616 0.018 
7 0.724 0.684 0.714 0.707 0.021 
8 0.809 0.768 0.801 0.793 0.022 
9 0.889 0.847 0.883 0.873 0.023 
10 0.956 0.922 0.958 0.945 0.020 
      
      CDS - 0.3 µM 
     
Time (min) 
ΔAbs R405 nm Mean SD 
Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 
1 0.107 0.110 0.110 0.109 0.002 
2 0.208 0.214 0.218 0.213 0.005 
3 0.302 0.311 0.320 0.311 0.009 
4 0.394 0.405 0.418 0.406 0.012 
5 0.485 0.497 0.510 0.497 0.013 
6 0.572 0.587 0.598 0.586 0.013 
7 0.657 0.674 0.685 0.672 0.014 
8 0.737 0.756 0.771 0.755 0.017 
9 0.813 0.832 0.850 0.832 0.019 
10 0.883 0.898 0.919 0.900 0.018 
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CDS - 0.7 µM 
     
Time (min) 
ΔAbs R405 nm Mean SD 
Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 
1 0.089 0.085 0.082 0.085 0.004 
2 0.170 0.164 0.160 0.165 0.005 
3 0.245 0.239 0.233 0.239 0.006 
4 0.321 0.309 0.300 0.310 0.011 
5 0.395 0.376 0.365 0.379 0.015 
6 0.453 0.437 0.429 0.440 0.012 
7 0.514 0.492 0.489 0.498 0.014 
8 0.576 0.553 0.543 0.557 0.017 
9 0.639 0.612 0.592 0.614 0.024 
10 0.697 0.669 0.645 0.670 0.026 
      
      CDS - 1 µM 
     
Time (min) 
ΔAbs R405 nm Mean SD 
Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 
1 0.071 0.069 0.061 0.067 0.005 
2 0.139 0.135 0.120 0.131 0.010 
3 0.195 0.193 0.176 0.188 0.010 
4 0.255 0.250 0.231 0.245 0.013 
5 0.310 0.302 0.278 0.297 0.017 
6 0.365 0.356 0.326 0.349 0.020 
7 0.418 0.408 0.376 0.401 0.022 
8 0.469 0.459 0.423 0.450 0.024 
9 0.518 0.508 0.468 0.498 0.026 
10 0.563 0.555 0.512 0.543 0.027 
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Pre-incubation time - 1 min 
   
      Control 
     
Time (min) 
ΔAbs R405 nm Mean SD 
Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 
1 0.106 0.101 0.104 0.104 0.003 
2 0.208 0.199 0.206 0.204 0.005 
3 0.309 0.295 0.304 0.303 0.007 
4 0.408 0.388 0.402 0.399 0.010 
5 0.504 0.480 0.494 0.493 0.012 
6 0.598 0.570 0.583 0.584 0.014 
7 0.687 0.659 0.669 0.672 0.014 
8 0.771 0.744 0.755 0.757 0.014 
9 0.851 0.825 0.834 0.837 0.013 
10 0.926 0.898 0.910 0.911 0.014 
      
      CDS - 0.3 µM 
     
Time (min) 
ΔAbs R405 nm Mean SD 
Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 
1 0.105 0.100 0.102 0.102 0.003 
2 0.206 0.195 0.203 0.201 0.006 
3 0.302 0.288 0.301 0.297 0.008 
4 0.396 0.380 0.396 0.391 0.009 
5 0.488 0.467 0.486 0.480 0.012 
6 0.575 0.549 0.572 0.565 0.014 
7 0.653 0.629 0.659 0.647 0.016 
8 0.729 0.706 0.741 0.725 0.018 
9 0.803 0.781 0.817 0.800 0.018 
10 0.871 0.851 0.886 0.869 0.018 
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CDS - 0.7 µM 
     
Time (min) 
ΔAbs R405 nm Mean SD 
Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 
1 0.071 0.068 0.065 0.068 0.003 
2 0.141 0.136 0.130 0.136 0.006 
3 0.207 0.202 0.195 0.201 0.006 
4 0.269 0.268 0.258 0.265 0.006 
5 0.327 0.330 0.317 0.325 0.007 
6 0.387 0.391 0.374 0.384 0.009 
7 0.445 0.447 0.429 0.440 0.010 
8 0.500 0.500 0.483 0.494 0.010 
9 0.554 0.552 0.536 0.547 0.010 
10 0.608 0.604 0.589 0.600 0.010 
      
      CDS - 1 µM 
     
Time (min) 
ΔAbs R405 nm Mean SD 
Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 
1 0.048 0.044 0.043 0.045 0.003 
2 0.098 0.089 0.088 0.092 0.006 
3 0.143 0.133 0.131 0.136 0.006 
4 0.186 0.175 0.173 0.178 0.007 
5 0.229 0.217 0.216 0.221 0.007 
6 0.274 0.257 0.254 0.262 0.011 
7 0.319 0.296 0.295 0.303 0.014 
8 0.362 0.333 0.336 0.344 0.016 
9 0.404 0.373 0.376 0.384 0.017 
10 0.442 0.413 0.413 0.423 0.017 
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Pre-incubation time - 5 min 
   
      Control 
     
Time (min) 
ΔAbs R405 nm Mean SD 
Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 
1 0.099 0.091 0.095 0.095 0.004 
2 0.197 0.180 0.186 0.188 0.009 
3 0.293 0.268 0.276 0.279 0.013 
4 0.388 0.357 0.366 0.370 0.016 
5 0.474 0.445 0.450 0.456 0.016 
6 0.562 0.533 0.535 0.543 0.016 
7 0.647 0.617 0.620 0.628 0.017 
8 0.730 0.699 0.703 0.711 0.017 
9 0.809 0.779 0.783 0.790 0.016 
10 0.882 0.855 0.856 0.864 0.015 
      
      CDS - 0.3 µM 
     
Time (min) 
ΔAbs R405 nm Mean SD 
Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 
1 0.083 0.086 0.096 0.088 0.007 
2 0.166 0.171 0.189 0.175 0.012 
3 0.249 0.254 0.272 0.258 0.012 
4 0.330 0.336 0.355 0.340 0.013 
5 0.409 0.417 0.441 0.422 0.017 
6 0.482 0.497 0.525 0.501 0.022 
7 0.552 0.571 0.606 0.576 0.027 
8 0.622 0.641 0.683 0.649 0.031 
9 0.691 0.709 0.757 0.719 0.034 
10 0.759 0.775 0.825 0.786 0.034 
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CDS - 0.7 µM 
     
Time (min) 
ΔAbs R405 nm Mean SD 
Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 
1 0.042 0.043 0.041 0.042 0.001 
2 0.086 0.087 0.085 0.086 0.001 
3 0.130 0.132 0.129 0.130 0.002 
4 0.175 0.178 0.174 0.176 0.002 
5 0.217 0.223 0.222 0.221 0.003 
6 0.259 0.267 0.269 0.265 0.005 
7 0.304 0.310 0.311 0.308 0.004 
8 0.343 0.352 0.353 0.349 0.006 
9 0.392 0.395 0.395 0.394 0.002 
10 0.435 0.437 0.438 0.437 0.002 
      
      CDS - 1 µM 
     
Time (min) 
ΔAbs R405 nm Mean SD 
Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 
1 0.028 0.027 0.027 0.027 0.001 
2 0.060 0.056 0.055 0.057 0.003 
3 0.088 0.086 0.085 0.086 0.002 
4 0.121 0.117 0.117 0.118 0.002 
5 0.154 0.148 0.148 0.150 0.003 
6 0.187 0.180 0.177 0.181 0.005 
7 0.222 0.210 0.210 0.214 0.007 
8 0.255 0.240 0.244 0.246 0.008 
9 0.286 0.272 0.277 0.278 0.007 
10 0.318 0.303 0.309 0.310 0.008 
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Pre-incubation time - 7 min 
   
      Control 
     
Time (min) 
ΔAbs R405 nm Mean SD 
Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 
1 0.091 0.087 0.089 0.089 0.002 
2 0.180 0.172 0.175 0.176 0.004 
3 0.271 0.256 0.262 0.263 0.008 
4 0.361 0.342 0.349 0.351 0.010 
5 0.449 0.427 0.433 0.436 0.011 
6 0.536 0.512 0.511 0.520 0.014 
7 0.619 0.593 0.593 0.602 0.015 
8 0.698 0.671 0.677 0.682 0.014 
9 0.774 0.747 0.753 0.758 0.014 
10 0.845 0.821 0.825 0.830 0.013 
      
      CDS - 0.3 µM 
     
Time (min) 
ΔAbs R405 nm Mean SD 
Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 
1 0.077 0.076 0.082 0.078 0.003 
2 0.154 0.154 0.164 0.157 0.006 
3 0.232 0.230 0.245 0.236 0.008 
4 0.309 0.304 0.323 0.312 0.010 
5 0.381 0.376 0.399 0.385 0.012 
6 0.449 0.449 0.477 0.458 0.016 
7 0.516 0.520 0.552 0.529 0.020 
8 0.583 0.589 0.623 0.598 0.022 
9 0.651 0.656 0.691 0.666 0.022 
10 0.717 0.720 0.757 0.731 0.022 
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CDS - 0.7 µM 
     
Time (min) 
ΔAbs R405 nm Mean SD 
Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 
1 0.035 0.036 0.037 0.036 0.001 
2 0.073 0.075 0.076 0.075 0.002 
3 0.115 0.115 0.116 0.115 0.001 
4 0.156 0.156 0.156 0.156 0.000 
5 0.198 0.198 0.197 0.198 0.001 
6 0.240 0.238 0.240 0.239 0.001 
7 0.279 0.279 0.281 0.280 0.001 
8 0.320 0.318 0.321 0.320 0.002 
9 0.361 0.358 0.359 0.359 0.002 
10 0.401 0.397 0.399 0.399 0.002 
      
      CDS - 1 µM 
     
Time (min) 
ΔAbs R405 nm Mean SD 
Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 
1 0.025 0.026 0.024 0.025 0.001 
2 0.051 0.052 0.050 0.051 0.001 
3 0.080 0.079 0.077 0.079 0.002 
4 0.107 0.107 0.106 0.107 0.001 
5 0.134 0.135 0.136 0.135 0.001 
6 0.163 0.163 0.164 0.163 0.001 
7 0.193 0.191 0.192 0.192 0.001 
8 0.223 0.218 0.221 0.221 0.003 
9 0.253 0.246 0.253 0.251 0.004 
10 0.282 0.275 0.284 0.280 0.005 
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Pre-incubation time - 10 min 
   
      Control 
     
Time (min) 
ΔAbs R405 nm Mean SD 
Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 
1 0.091 0.088 0.095 0.091 0.004 
2 0.181 0.175 0.188 0.181 0.007 
3 0.270 0.262 0.282 0.271 0.010 
4 0.360 0.348 0.374 0.361 0.013 
5 0.449 0.431 0.464 0.448 0.017 
6 0.532 0.517 0.554 0.534 0.019 
7 0.613 0.602 0.643 0.619 0.021 
8 0.691 0.684 0.729 0.701 0.024 
9 0.764 0.763 0.810 0.779 0.027 
10 0.832 0.837 0.886 0.852 0.030 
      
      CDS - 0.3 µM 
     
Time (min) 
ΔAbs R405 nm Mean SD 
Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 
1 0.062 0.063 0.072 0.066 0.006 
2 0.125 0.127 0.143 0.132 0.010 
3 0.187 0.189 0.216 0.197 0.016 
4 0.250 0.250 0.285 0.262 0.020 
5 0.314 0.313 0.353 0.327 0.023 
6 0.375 0.379 0.421 0.392 0.025 
7 0.436 0.442 0.488 0.455 0.028 
8 0.492 0.505 0.556 0.518 0.034 
9 0.553 0.563 0.621 0.579 0.037 
10 0.605 0.616 0.684 0.635 0.043 
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CDS - 0.7 µM 
     
Time (min) 
ΔAbs R405 nm Mean SD 
Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 
1 0.027 0.027 0.028 0.027 0.001 
2 0.057 0.056 0.057 0.057 0.001 
3 0.087 0.087 0.088 0.087 0.001 
4 0.116 0.119 0.119 0.118 0.002 
5 0.147 0.150 0.151 0.149 0.002 
6 0.177 0.182 0.184 0.181 0.004 
7 0.207 0.214 0.216 0.212 0.005 
8 0.236 0.246 0.248 0.243 0.006 
9 0.267 0.279 0.280 0.275 0.007 
10 0.296 0.310 0.312 0.306 0.009 
      
      CDS - 1 µM 
     
Time (min) 
ΔAbs R405 nm Mean SD 
Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 
1 0.023 0.021 0.021 0.022 0.001 
2 0.048 0.044 0.044 0.045 0.002 
3 0.073 0.068 0.070 0.070 0.003 
4 0.100 0.093 0.095 0.096 0.004 
5 0.125 0.120 0.121 0.122 0.003 
6 0.153 0.148 0.150 0.150 0.003 
7 0.181 0.174 0.179 0.178 0.004 
8 0.211 0.201 0.207 0.206 0.005 
9 0.240 0.228 0.236 0.235 0.006 
10 0.268 0.256 0.264 0.263 0.006 
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Pre-incubation time - 30 min 
   
      Control 
     
Time (min) 
ΔAbs R405 nm Mean SD 
Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 
1 0.066 0.067 0.066 0.066 0.001 
2 0.132 0.135 0.135 0.134 0.002 
3 0.201 0.206 0.206 0.204 0.003 
4 0.281 0.280 0.281 0.281 0.001 
5 0.358 0.354 0.358 0.357 0.002 
6 0.426 0.423 0.433 0.427 0.005 
7 0.500 0.494 0.503 0.499 0.005 
8 0.576 0.566 0.571 0.571 0.005 
9 0.650 0.639 0.641 0.643 0.006 
10 0.724 0.714 0.709 0.716 0.008 
      
      CDS - 0.3 µM 
     
Time (min) 
ΔAbs R405 nm Mean SD 
Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 
1 0.017 0.033 0.019 0.023 0.009 
2 0.040 0.056 0.039 0.045 0.010 
3 0.070 0.076 0.062 0.069 0.007 
4 0.096 0.098 0.084 0.093 0.008 
5 0.122 0.124 0.111 0.119 0.007 
6 0.147 0.140 0.136 0.141 0.006 
7 0.174 0.192 0.165 0.177 0.014 
8 0.201 0.214 0.192 0.202 0.011 
9 0.230 0.234 0.219 0.228 0.008 
10 0.261 0.287 0.250 0.266 0.019 
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CDS - 0.7 µM 
     
Time (min) 
ΔAbs R405 nm Mean SD 
Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 
1 0.013 0.015 0.015 0.014 0.001 
2 0.029 0.031 0.031 0.030 0.001 
3 0.045 0.048 0.047 0.047 0.002 
4 0.062 0.065 0.064 0.064 0.002 
5 0.078 0.083 0.081 0.081 0.003 
6 0.099 0.100 0.101 0.100 0.001 
7 0.116 0.122 0.121 0.120 0.003 
8 0.135 0.143 0.141 0.140 0.004 
9 0.155 0.164 0.161 0.160 0.005 
10 0.176 0.186 0.181 0.181 0.005 
      
      CDS - 1 µM 
     
Time (min) 
ΔAbs R405 nm Mean SD 
Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 
1 0.015 0.014 0.015 0.015 0.001 
2 0.032 0.031 0.032 0.032 0.001 
3 0.050 0.050 0.050 0.050 0.000 
4 0.066 0.066 0.068 0.067 0.001 
5 0.085 0.085 0.088 0.086 0.002 
6 0.106 0.106 0.108 0.107 0.001 
7 0.126 0.126 0.128 0.127 0.001 
8 0.147 0.147 0.150 0.148 0.002 
9 0.168 0.168 0.171 0.169 0.002 
10 0.190 0.190 0.194 0.191 0.002 
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Pre-incubation time - 90 min 
   
      Control 
     
Time (min) 
ΔAbs R405 nm Mean SD 
Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 
1 0.039 0.044 0.039 0.041 0.003 
2 0.080 0.087 0.079 0.082 0.004 
3 0.123 0.133 0.121 0.126 0.006 
4 0.167 0.179 0.164 0.170 0.008 
5 0.212 0.226 0.208 0.215 0.009 
6 0.258 0.273 0.253 0.261 0.010 
7 0.303 0.321 0.302 0.309 0.011 
8 0.349 0.371 0.352 0.357 0.012 
9 0.394 0.422 0.400 0.405 0.015 
10 0.441 0.472 0.447 0.453 0.016 
      
      CDS - 0.3 µM 
     
Time (min) 
ΔAbs R405 nm Mean SD 
Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 
1 0.018 0.017 0.019 0.018 0.001 
2 0.035 0.033 0.036 0.035 0.002 
3 0.051 0.050 0.053 0.051 0.002 
4 0.069 0.067 0.070 0.069 0.002 
5 0.089 0.085 0.087 0.087 0.002 
6 0.109 0.103 0.105 0.106 0.003 
7 0.129 0.122 0.123 0.125 0.004 
8 0.149 0.141 0.141 0.144 0.005 
9 0.170 0.161 0.159 0.163 0.006 
10 0.190 0.181 0.179 0.183 0.006 
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CDS - 0.7 µM 
     
Time (min) 
ΔAbs R405 nm Mean SD 
Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 
1 0.011 0.014 0.014 0.013 0.002 
2 0.021 0.027 0.027 0.025 0.003 
3 0.033 0.041 0.041 0.038 0.005 
4 0.045 0.055 0.055 0.052 0.006 
5 0.058 0.070 0.069 0.066 0.007 
6 0.070 0.086 0.084 0.080 0.009 
7 0.083 0.102 0.100 0.095 0.010 
8 0.096 0.117 0.115 0.109 0.012 
9 0.110 0.133 0.130 0.124 0.013 
10 0.123 0.149 0.146 0.139 0.014 
      
      CDS - 1 µM 
     
Time (min) 
ΔAbs R405 nm Mean SD 
Well 1 Well 2 Well 3 
0 0.000 0.000 0.000 0.000 0.000 
1 0.012 0.013 0.013 0.013 0.001 
2 0.024 0.026 0.025 0.025 0.001 
3 0.038 0.039 0.037 0.038 0.001 
4 0.052 0.053 0.050 0.052 0.002 
5 0.066 0.068 0.064 0.066 0.002 
6 0.081 0.082 0.079 0.081 0.002 
7 0.096 0.097 0.092 0.095 0.003 
8 0.111 0.112 0.107 0.110 0.003 
9 0.127 0.128 0.124 0.126 0.002 
10 0.141 0.143 0.141 0.142 0.001 
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In vivo data sheets 
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tGSH, GSSG and rGSH levels 
<Negative Control> 
PBS + PBS 
Rat Protocol tGSH GSSG rGSH 
  Dose 1 Dose 2 
Interval between 
doses nmoles/g lung tissue 
Animal 1 PBS PBS 2 h 1053.21 238.00 577.21 
Animal 2 PBS PBS 2 h 909.52 193.27 522.98 
Animal 3 PBS PBS 2 h 995.82 273.72 448.38 
Animal 4 PBS PBS 2 h 898.01 223.16 451.69 
Animal 5 PBS PBS 2 h 867.55 140.36 586.83 
Mean 944.82 213.70 517.42 
SD 77.07 50.19 66.16 
SE 34.46 22.45 29.59 
   
<Positive Control> 
PBS + HSE/CSE     
Rat Protocol tGSH GSSG rGSH 
  Dose 1 Dose 2 
Interval between 
doses nmoles/g lung tissue 
Animal 1 PBS HSE-100+CSE 2 h 785.43 211.49 362.45 
Animal 2 PBS HSE-100+CSE 2 h 760.41 227.17 306.07 
Animal 3 PBS HSE-100+CSE 2 h 625.71 187.68 250.35 
Animal 4 PBS HSE-100+CSE 2 h 659.39 190.20 278.99 
Animal 5 PBS HSE-100+CSE 2 h 698.26 211.04 276.18 
Mean 705.84 205.52 294.81 
SD 66.99 16.49 42.65 
SE 29.96 7.37 19.07 
   <Test #1> 
   CDS 5 µg/kg + HSE/CSE     
Rat  Protocol tGSH GSSG rGSH 
  Dose 1 Dose 2 
Interval between 
doses nmoles/g lung tissue 
Animal 1 CDS-5 HSE-100+CSE 2 h 797.70 123.75 550.20 
Animal 2 CDS-5 HSE-100+CSE 2 h 859.44 157.87 543.70 
Animal 3 CDS-5 HSE-100+CSE 2 h 659.64 139.54 380.57 
Animal 4 CDS-5 HSE-100+CSE 2 h 953.85 207.52 538.82 
Animal 5 CDS-5 HSE-100+CSE 2 h 802.49 186.83 428.84 
Mean 814.63 163.10 488.43 
SD 107.06 34.16 78.41 
SE 47.88 15.28 35.07 
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<Test #2> 
CDS 30 µg/kg + HSE/CSE   
Rat Protocol tGSH GSSG rGSH 
  Dose 1 Dose 2 
Interval between 
doses nmoles/g lung tissue 
Animal 1 CDS-30 HSE-100+CSE 2 h 938.26 203.58 531.10 
Animal 2 CDS-30 HSE-100+CSE 2 h 985.94 273.84 438.26 
Animal 3 CDS-30 HSE-100+CSE 2 h 913.92 170.66 572.60 
Animal 4 CDS-30 HSE-100+CSE 2 h 822.70 162.49 497.72 
Animal 5 CDS-30 HSE-100+CSE 2 h 806.09 169.04 468.01 
Mean 893.38 195.92 501.54 
SD 76.84 46.39 52.60 
SE 34.36 20.75 23.52 
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Total and differential cell count in BALF 
N:Neutrophil M:Macrophage 
<Negative Control> 
PBS + PBS                             
Rat 
Protocol BALF [ml] 
Total cell  Differential  % Differential Differential cell  
count 
[x10P
6
P] cell counts cell counts count in 8 ml [x10P
4
P] 
Dose 1 Dose 2 Interval Vol 
Rec 
Vol in 8 ml N M Other N M Other N M Other 
Animal 1 PBS PBS 2 h 8.0 7.5 0.73 4 325 3 1.20 97.89 0.90 0.88 71.46 0.66 
Animal 2 PBS PBS 2 h 8.0 7.4 0.90 4 330 4 1.18 97.63 1.18 1.07 87.87 1.07 
Animal 3 PBS PBS 2 h 8.0 7.5 0.64 2 334 1 0.59 99.11 0.30 0.38 63.43 0.19 
Animal 4 PBS PBS 2 h 8.0 7.5 0.77 4 324 4 1.20 97.59 1.20 0.93 75.14 0.93 
Animal 5 PBS PBS 2 h 8.0 7.4 0.78 4 334 2 1.18 98.24 0.59 0.92 76.62 0.46 
Mean 0.76 Mean 0.83 74.91 0.66 
SD 0.09 SD 0.26 8.87 0.35 
SE 0.05 SE 0.12 3.97 0.16 
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<Positive Control> 
PBS + HSE/CSE                             
Rat 
Protocol BALF [ml] 
Total cell  Differential  % Differential Differential cell  
count 
[x10P
6
P] cell counts cell counts count in 8 ml [x10P
4
P] 
Dose 
1 Dose 2 Interval Vol 
Rec 
Vol in 8 ml N M Other N M Other N M Other 
Animal 1 PBS HSE-100+CSE 2 h 10.0 8.0 2.12 146 173 11 44.24 52.42 3.33 93.62 110.94 7.05 
Animal 2 PBS HSE-100+CSE 2 h 8 7.5 2.21 135 238 3 35.90 63.30 0.80 79.24 139.69 1.76 
Animal 3 PBS HSE-100+CSE 2 h 8.0 7.5 2.27 157 221 5 40.99 57.70 1.31 93.05 130.98 2.96 
Animal 4 PBS HSE-100+CSE 2 h 8.0 7.5 2.50 124 196 4 38.27 60.49 1.23 95.68 151.23 3.09 
Animal 5 PBS HSE-100+CSE 2 h 8.0 7.5 2.13 124 231 5 34.44 64.17 1.39 73.37 136.68 2.96 
Mean 2.24 Mean 86.99 133.90 3.56 
SD 0.16 SD 10.02 14.81 2.02 
SE 0.08 SE 4.48 6.62 0.91 
 
<Test #1> 
    CDS 5 µg/kg + HSE/CSE                           
Rat 
Protocol BALF [ml] 
Total cell  Differential  % Differential Differential cell  
count 
[x10P
6
P] cell counts cell counts count in 8 ml [x10P
4
P] 
Dose 1 Dose 2 Interval Vol 
Rec 
Vol in 8 ml N M Other N M Other N M Other 
Animal 1 CDS-5 HSE-100+CSE 2 h 8.0 7.5 2.51 87 302 5 22.08 76.65 1.27 55.43 192.42 3.19 
Animal 2 CDS-5 HSE-100+CSE 2 h 8.0 7.5 1.51 50 318 3 13.48 85.71 0.81 20.30 129.10 1.22 
Animal 3 CDS-5 HSE-100+CSE 2 h 8.0 7.5 2.57 142 365 4 27.79 71.43 0.78 71.29 183.25 2.01 
Animal 4 CDS-5 HSE-100+CSE 2 h 8.0 6.5 2.68 116 211 5 34.94 63.55 1.51 93.47 170.02 4.03 
Animal 5 CDS-5 HSE-100+CSE 2 h 8.0 6.5 2.46 99 197 4 33.00 65.67 1.33 81.10 161.38 3.28 
Mean 2.34 Mean 64.32 167.23 2.74 
SD 0.47 SD 28.27 24.43 1.12 
SE 0.24 SE 12.64 10.92 0.50 
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<Test #2> 
CDS 30 µg/kg + HSE/CSE                           
Rat 
Protocol BALF [ml] 
Total cell  Differential  % Differential Differential cell  
count 
[x10P
6
P] cell counts cell counts count in 8 ml [x10P
4
P] 
Dose 1 Dose 2 Interval Vol 
Rec 
Vol in 8 ml N M Other N M Other N M Other 
Animal 1 CDS-30 HSE-100+CSE 2 h 8.0 7.5 1.13 26 311 3 7.65 91.47 0.88 8.64 103.36 1.00 
Animal 2 CDS-30 HSE-100+CSE 2 h 8.0 7.5 1.41 93 336 6 21.38 77.24 1.38 30.14 108.91 1.94 
Animal 3 CDS-30 HSE-100+CSE 2 h 8.0 7.5 1.59 63 243 4 20.32 78.39 1.29 32.31 124.64 2.05 
Animal 4 CDS-30 HSE-100+CSE 2 h 8.0 7.4 1.12 9 310 3 2.80 96.27 0.93 3.13 107.83 1.04 
Animal 5 CDS-30 HSE-100+CSE 2 h 8.0 5.6 1.14 85 264 5 24.01 74.58 1.41 27.37 85.02 1.61 
Mean 1.28 Mean 20.32 105.95 1.53 
SD 0.21 SD 13.43 14.20 0.49 
SE 0.11 SE 6.01 6.35 0.22 
<Test #3> 
CDS 30 µg/kg + PBS                           
Rat 
Protocol BALF [ml] 
Total cell  Differential  % Differential Differential cell  
count 
[x10P
6
P] cell counts cell counts count in 8 ml [x10P
4
P] 
Dose 1 Dose 2 Interval Vol 
Rec 
Vol in 8 ml N M Other N M Other N M Other 
Animal 1 CDS-30 PBS 2 h 8.0 7.0 0.97 0 388 3 0.00 99.23 0.77 0.00 96.44 0.75 
Animal 2 CDS-30 PBS 2 h 8.0 5.6 1.06 2 312 3 0.63 98.42 0.95 0.67 104.33 1.00 
Animal 3 CDS-30 PBS 2 h 8.0 5.5 0.82 0 301 4 0.00 98.69 1.31 0.00 80.92 1.08 
Mean 0.95 Mean 0.22 93.90 0.94 
SD 0.12 SD 0.39 11.91 0.17 
SE 0.06 SE 0.22 6.87 0.10 
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BALF elastase 
activity 
      
        
        <Negative Control> 
      PBS + PBS 
       
        Time 
(min) 
Animal 
1 
Animal 
2 
Animal 
3 
Animal 
4 
Animal 
5 
Average SD 
0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
5 0.034 0.077 0.046 0.015 0.037 0.042 0.023 
10 0.034 0.077 0.047 0.021 0.037 0.043 0.021 
20 0.034 0.078 0.046 0.031 0.035 0.045 0.020 
30 0.033 0.074 0.045 0.037 0.032 0.044 0.017 
40 0.031 0.070 0.043 0.039 0.028 0.042 0.017 
60 0.026 0.066 0.041 0.039 0.022 0.038 0.017 
        
        <Positive Control> 
      PBS + HSE/CSE 
      
        Time 
(min) 
Animal 
1 
Animal 
2 
Animal 
3 
Animal 
4 
Animal 
5 
Average SD 
0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
5 0.101 0.044 0.052 0.111 0.097 0.081 0.031 
10 0.127 0.073 0.073 0.111 0.124 0.101 0.027 
20 0.129 0.097 0.087 0.109 0.139 0.112 0.022 
30 0.135 0.101 0.092 0.111 0.144 0.117 0.022 
40 0.126 0.102 0.095 0.109 0.147 0.116 0.021 
60 0.123 0.101 0.095 0.104 0.148 0.114 0.021 
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<Test #1> 
       CDS 5 µg/kg + HSE/CSE 
     
Time (min) 
Animal 
1 
Animal 
2 
Animal 
3 
Animal 
4 
Animal 
5 
Average SD 
0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
5 0.045 0.050 0.039 0.049 0.060 0.048 0.008 
10 0.073 0.074 0.067 0.056 0.068 0.067 0.007 
20 0.079 0.089 0.070 0.063 0.068 0.074 0.010 
30 0.088 0.089 0.073 0.062 0.071 0.076 0.011 
40 0.088 0.075 0.075 0.064 0.070 0.074 0.009 
60 0.091 0.084 0.074 0.062 0.070 0.076 0.011 
        
        <Test #2> 
       CDS 30 µg/kg + HSE/CSE 
     
Time (min) 
Animal 
1 
Animal 
2 
Animal 
3 
Animal 
4 
Animal 
5 
Average SD 
0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
5 0.088 0.043 0.049 0.076 0.050 0.061 0.020 
10 0.091 0.066 0.068 0.094 0.049 0.074 0.019 
20 0.095 0.074 0.075 0.093 0.046 0.076 0.020 
30 0.092 0.073 0.073 0.091 0.043 0.074 0.020 
40 0.092 0.084 0.074 0.089 0.039 0.076 0.022 
60 0.089 0.067 0.074 0.083 0.033 0.069 0.022 
        
        <Test #3> 
       CDS 30 µg/kg + PBS 
       
Time (min) 
Animal 
1 
Animal 
2 
Animal 
3 
Average SD   
 
0 0.000 0.000 0.000 0.000 0.000   
 5 0.004 0.039 0.066 0.036 0.031   
 10 0.004 0.039 0.067 0.037 0.032   
 20 0.003 0.040 0.067 0.037 0.032   
 30 0.004 0.041 0.067 0.037 0.032   
 40 0.003 0.042 0.068 0.038 0.032   
 60 0.000 0.039 0.064 0.034 0.032   
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<Negative Control> 
PBS + PBS 
Rat Protocol ΔAbsR412 nm 
  Dose 1 Dose 2 
Interval between 
doses   
Animal 1 PBS PBS 2 h 0.026 
Animal 2 PBS PBS 2 h 0.066 
Animal 3 PBS PBS 2 h 0.041 
Animal 4 PBS PBS 2 h 0.039 
Animal 5 PBS PBS 2 h 0.022 
Mean 0.038 
SD 0.017 
SE 0.008 
 
<Positive Control> 
PBS + HSE/CSE       
Rat Protocol ΔAbsR412 nm 
  Dose 1 Dose 2 
Interval between 
doses   
Animal 1 PBS HSE-100+CSE 2 h 0.123 
Animal 2 PBS HSE-100+CSE 2 h 0.101 
Animal 3 PBS HSE-100+CSE 2 h 0.095 
Animal 4 PBS HSE-100+CSE 2 h 0.104 
Animal 5 PBS HSE-100+CSE 2 h 0.148 
Mean 0.114 
SD 0.021 
SE 0.010 
 <Test #1> 
 CDS 5 µg/kg + HSE/CSE       
Rat Protocol ΔAbsR412 nm 
  Dose 1 Dose 2 
Interval between 
doses   
Animal 1 CDS-5 HSE-100+CSE 2 h 0.091 
Animal 2 CDS-5 HSE-100+CSE 2 h 0.084 
Animal 3 CDS-5 HSE-100+CSE 2 h 0.074 
Animal 4 CDS-5 HSE-100+CSE 2 h 0.062 
Animal 5 CDS-5 HSE-100+CSE 2 h 0.070 
Mean 0.076 
SD 0.011 
SE 0.005 
 
 
185 
 
<Test #2> 
CDS 30 µg/kg + HSE/CSE       
Rat Protocol ΔAbsR412 nm 
  Dose 1 Dose 2 
Interval between 
doses   
Animal 1 CDS-30 HSE-100+CSE 2 h 0.089 
Animal 2 CDS-30 HSE-100+CSE 2 h 0.067 
Animal 3 CDS-30 HSE-100+CSE 2 h 0.074 
Animal 4 CDS-30 HSE-100+CSE 2 h 0.083 
Animal 5 CDS-30 HSE-100+CSE 2 h 0.033 
Mean 0.069 
SD 0.022 
SE 0.010 
<Test #3> 
CDS 30 µg/kg + PBS       
Rat Protocol ΔAbsR412 nm 
  Dose 1 Dose 2 
Interval between 
doses   
Animal 1 CDS-30 PBS 2 h 0.000 
Animal 2 CDS-30 PBS 2 h 0.039 
Animal 3 CDS-30 PBS 2 h 0.064 
Mean 0.034 
SD 0.032 
SE 0.014 
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Lung Hemorrhage Data 
<Negative Control> 
PBS + PBS 
Rat ID Protocol Blank Abs  Corrected  
  Dose 1 Dose 2 
Interval between 
doses   value value 
Animal 1 PBS PBS 2 h 0.045 0.056 0.011 
Animal 2 PBS PBS 2 h 0.045 0.059 0.014 
Animal 3 PBS PBS 2 h 0.045 0.048 0.003 
Animal 4 PBS PBS 2 h 0.045 0.057 0.012 
Animal 5 PBS PBS 2 h 0.045 0.042 -0.003 
Mean 
  
0.007 
SD 
  
0.007 
SE 
  
0.003 
   
<Positive Control> 
PBS + HSE/CSE     
Rat ID Protocol Blank Abs  Corrected  
  Dose 1 Dose 2 
Interval between 
doses   value value 
Animal 1 PBS HSE-100+CSE 2 h 0.045 0.132 0.087 
Animal 2 PBS HSE-100+CSE 2 h 0.045 0.153 0.108 
Animal 3 PBS HSE-100+CSE 2 h 0.045 0.095 0.050 
Animal 4 PBS HSE-100+CSE 2 h 0.045 0.082 0.037 
Animal 5 PBS HSE-100+CSE 2 h 0.045 0.087 0.042 
Mean 
  
0.065 
SD 
  
0.031 
SE 
  
0.014 
   <Test #1> 
   CDS 5 µg/kg + HSE/CSE   
Rat ID Protocol Blank Abs  Corrected  
  Dose 1 Dose 2 
Interval between 
doses   value value 
Animal 1 CDS-5 HSE-100+CSE 2 h 0.045 0.088 0.043 
Animal 2 CDS-5 HSE-100+CSE 2 h 0.045 0.065 0.020 
Animal 3 CDS-5 HSE-100+CSE 2 h 0.045 0.067 0.022 
Animal 4 CDS-5 HSE-100+CSE 2 h 0.045 0.074 0.029 
Animal 5 CDS-5 HSE-100+CSE 2 h 0.045 0.081 0.036 
Mean 
  
0.030 
SD 
  
0.010 
SE 
  
0.004 
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<Test #2> 
CDS 30 µg/kg + HSE/CSE   
Rat ID Protocol Blank Abs  Corrected  
  Dose 1 Dose 2 
Interval between 
doses   value value 
Animal 1 CDS-30 HSE-100+CSE 2 h 0.045 0.065 0.020 
Animal 2 CDS-30 HSE-100+CSE 2 h 0.045 0.070 0.025 
Animal 3 CDS-30 HSE-100+CSE 2 h 0.045 0.091 0.046 
Animal 4 CDS-30 HSE-100+CSE 2 h 0.045 0.061 0.016 
Animal 5 CDS-30 HSE-100+CSE 2 h 0.045 0.059 0.014 
Mean 
  
0.024 
SD 
  
0.013 
SE 
  
0.006 
<Test #3> 
CDS 30 µg/kg + PBS     
Rat ID Protocol Blank Abs  Corrected  
  Dose 1 Dose 2 
Interval between 
doses   value value 
Animal 1 CDS-30 PBS 2 h 0.045 0.045 0.000 
Animal 2 CDS-30 PBS 2 h 0.045 0.056 0.011 
Animal 3 CDS-30 PBS 2 h 0.045 0.052 0.007 
Mean 
  
0.006 
SD 
  
0.006 
SE 
  
0.003 
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Mean Linear Intercept Data 
Lung lobar section -  Left Lung 
<Negative Control> 
PBS + PBS 
Rat ID Protocol Left Lung 
  Dose 1 Dose 2 
Interval between 
doses (µm) 
Animal 1 PBS PBS 2 h 48.86 
Animal 2 PBS PBS 2 h 54.82 
Animal 3 PBS PBS 2 h 57.30 
Animal 4 PBS PBS 2 h 52.41 
Animal 5 PBS PBS 2 h 51.67 
Mean 53.01 
SD 3.20 
SE 1.43 
 
<Positive Control> 
PBS + HSE/CSE     
Rat ID Protocol Left Lung 
  Dose 1 Dose 2 
Interval between 
doses (µm) 
Animal 1 PBS HSE-100+CSE 2 h 74.74 
Animal 2 PBS HSE-100+CSE 2 h 75.83 
Animal 3 PBS HSE-100+CSE 2 h 79.98 
Animal 4 PBS HSE-100+CSE 2 h 79.47 
Animal 5 PBS HSE-100+CSE 2 h 85.59 
Mean 79.12 
SD 4.26 
SE 1.91 
 <Test #1> 
 CDS 5 µg/kg + HSE/CSE   
Rat ID Protocol Left Lung 
  Dose 1 Dose 2 
Interval between 
doses (µm) 
Animal 1 CDS-5 HSE-100+CSE 2 h 83.91 
Animal 2 CDS-5 HSE-100+CSE 2 h 94.73 
Animal 3 CDS-5 HSE-100+CSE 2 h 78.11 
Animal 4 CDS-5 HSE-100+CSE 2 h 81.28 
Animal 5 CDS-5 HSE-100+CSE 2 h 89.53 
Mean 85.51 
SD 6.64 
SE 2.97 
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<Test #2> 
CDS 30 µg/kg + HSE/CSE   
Rat ID Protocol Left Lung 
  Dose 1 Dose 2 
Interval between 
doses (µm) 
Animal 1 CDS-30 HSE-100+CSE 2 h 56.44 
Animal 2 CDS-30 HSE-100+CSE 2 h 53.49 
Animal 3 CDS-30 HSE-100+CSE 2 h 53.93 
Animal 4 CDS-30 HSE-100+CSE 2 h 48.99 
Animal 5 CDS-30 HSE-100+CSE 2 h 56.09 
Mean 53.79 
SD 2.98 
SE 1.33 
 
